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I. Enantioselective Rhodium-Catalysed Arylation of Electron-Deficient 
Alkenylarenes 
-substituted alkenyl-para-nitroarenes, an unexplored substrate class for catalytic 
asymmetric addition reactions, undergo highly enantioselective rhodium-catalysed 
arylations with arylboronic acids in the presence of a dibenzylamide-containing 
chiral diene ligand. One example of the asymmetric arylation of an alkenyl-p-cyano-
m-(trifluoromethyl)benzene is also reported. The scope of this process is broad with 
variation in the -position of the alkene, additional substituents on the electron-
deficient arene, and sterically and electronically unique arylboronic acids all 
tolerated. The synthetic utility of the developed methodology is demonstrated by 
smoothly converting one arylated product into its corresponding indole via the 
Bartoli reaction. 
 
II. Enantioselective Copper-Catalysed Reductive Coupling of Alkenylazaarenes 
with Ketones 
Catalytic enantioselective methods for the preparation of chiral azarene-containing 
compounds are of high value. By combining the utility of copper hydride catalysis 
with the ability of C=N-containing azaarenes to activate adjacent alkenes toward 
nucleophilic additions, the enantioselective reductive coupling of alkenylazaarenes 
with ketones has been developed. The process is tolerant of a wide variety of 
azaarenes and ketones, and provides aromatic heterocycles bearing tertiary-alcohol-
containing sidechains with high levels of diastereo- and enantioselection. 
 1 





In 1987, the FDA (Food and Drug Administration, U.S.) published guidelines, followed 
by a policy statement in 1992, discouraging the development of racemic drugs.
1
 
Consequently, there has been dramatic growth in the field of transition metal-catalysed 
asymmetric reactions for important organic transformations.
2-9
 While approximately 
one-third of all new molecular entity approvals by the FDA were racemic during the 
1980’s, this figure dropped to a mere 6% between 2001 and 2007. 
 
1,4-Nucleophilic additions are a well-established methodology in modern organic 
chemistry. The mechanism of a typical 1,4-addition involves the attack of a nucleophile 
to the electron-deficient center of an alkene conjugated to an electron-withdrawing 
group, such as a carbonyl (Scheme 1.1). 
 
 
Scheme 1.1: 1,4-Nucleophilic Addition 
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Through this reaction method it is possible to create a stereogenic center at the -
position. Although conjugate additions are well-studied, their application in single 
enantiomer production through the development of new, cheap, catalytic and 




Scheme 1.2: Simplistic Representation of Rhodium-Catalysed Hydroarylation 
 
The enantioselective rhodium-catalysed 1,4-addition of arylboron compounds to β-
substituted electron-deficient alkenes grants access to enantiomerically enriched 
compounds through the formation of a new C–C bond (Scheme 1.2).
5, 10-15
 Since the 
initial discovery of enones as substrates for these reactions,
13-15
 subsequent efforts have 
extended the scope of the acceptor
16-23
 to alkenes conjugated to a range of electron-
withdrawing groups.
24-43
 As shown in Equation 1.1, our group recently demonstrated the 
ability of heteroarenes containing a suitably placed C=N moiety to activate adjacent 





Equation 1.1: RCAA of Alkenylheteroarenes 
 
Our interest turned towards extending the scope of this process to include arenes 
containing electron-withdrawing substituents, which might provide sufficient activation 
 3 
to an adjacent alkene to promote the aforementioned RCAA (Scheme 1.3). Given the 
ubiquitous nature of arenes in compounds for applications ranging from biology to 
materials science, the successful realisation of such a process would grant access to the 
preparation of useful molecular building blocks. A survey of related reports on conjugate 
addition processes are presented below. 
 
 
Scheme 1.3: RCAA of Electron-Deficient Alkenylarenes 
 
1.1. Base-Catalysed 1,4-Nucleophilic Additions to Alkenylarenes 
 
Several base-catalysed additions to alkenylarenes have been reported previously.
44-51
 For 
example, in 1970, Pines and co-workers described the base-catalysed addition of N-






Scheme 1.4: Base-Catalysed Addition of N-Methyl-2-pyrrolidone or N-Methyl-2-piperidone to 
Styrene 
 




Scheme 1.5: Mechanism for Base-Catalysed Addition of N-Methyl-2-Pyrrolidone to Styrene 
 
This methodology has been applied more recently by Knochel’s group in the non-
enantioselective addition of various alkylnitriles, alkylketones, and alkylimines to 





Scheme 1.6: Base-Catalysed Addition of Alkylnitriles, Alkylketones, and Alkylimines to 
Vinylarenes 
 
Numerous reports of strongly activated alkenylarenes undergoing similar conjugate 
additions exist in literature also. For example, Strobel and co-workers reported the 
 5 
addition of various active methylene compounds to o- and p-nitrostyrene (Scheme 1.7).
47
 
m-Nitrostyrene 9d failed to react. This result is not unexpected since the nitro group on 
the arene, in this case, is not conjugated to the adjacent alkene. 
 
 
Scheme 1.7: Base-Catalysed Addition of Active Methylene Compounds to o- and p-Nitrostyrene 
 
A similar study conducted by Bose and co-workers in 1965 demonstrated the 
intramolecular addition of stabilised carbon nucleophiles to alkenes conjugated to 
nitroarenes using piperidine as the basic solvent (Scheme 1.8).
49
 The importance of the 
nitro group at the o- and p-positions, thus in conjugation with the adjacent alkene, is 
again highlighted in this report where substrates 11c and 11d failed to react. 
 
 
Scheme 1.8: Intramolecular Addition of Carbon Nucleophiles to Alkenyl-p-nitroarenes 
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1.2. Stoichiometric Enantioselective Carbolithiations of 
Alkenylarenes 
 
The base-catalysed conjugate additions discussed above proceed efficiently under mild 
conditions but do not deliver enantioenriched products. However, this has been achieved 
by employing highly reactive organolithium reagents.
52-56 
 
The asymmetric carbolithiation of cinnamyl derivatives has previously been reported by 
Normant and co-workers where a (–)-sparteine or (+)-sparteine surrogate was used as 
the chiral ligand (Scheme 1.9).
57-60
 Employing a trisubstituted alkene 13d led to the 
formation of product 15d possessing two stereocenters. 
 
 
Scheme 1.9: Asymmetric Carbolithiations of Cinnamyl Derivatives in the Presence of (–)-
Sparteine 
 
It was speculated that the high stereoselectivity observed may be arising from the ability 
of heteroatom X on the β-linkage to donate its lone pair of electrons to lithium (as shown 
in species 14). A subsequent report by the same group revealed that such an influence 






Scheme 1.10: Asymmetric Carbolithiations of β-Alkyl Styrenes in the Presence of (–)-Sparteine 
 
The described carbolithiations have also been applied to o-substituted alkenylarene 18, 
which can undergo further transformation to produce 2-alkylanilines, 3- and 2,3-






Scheme 1.11: Application of Asymmetric Carbolithiations 
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As discussed above, the enantioselective addition of various nucleophiles to 
alkenylarenes is made possible primarily through the use of highly reactive 
organolithium reagents that are known to exhibit low tolerance toward sensitive 
functional groups. Therefore, there exists a need to develop transition metal-catalysed 
asymmetric methodologies that are functional group-tolerant and capable of providing 
the desired products under mild conditions. 
 
1.3. Rhodium-Catalysed Asymmetric Hydroarylations 
 
Since Miyaura’s initial report on the non-enantioselective rhodium-catalysed addition of 
arylboronic acids to enones, numerous other RCAA have been reported to date.
5, 10-12, 14, 
65
 A typical rhodium-catalysed addition of an arylboron reagent 24 to an electron-
deficient acceptor 26 is believed to proceed as shown in Scheme 1.12. First, the 
transmetalation of an aryl group from 24 with the ligated rhodium species 23 produces 
the reactive aryl–rhodium species 25. Coordination of the alkene in compound 26 with 
25 and subsequent insertion into the Rh–Ar bond leads to the formation of adduct 27, 
which is readily protonated under protic conditions to liberate product 28 and regenerate 
the rhodium species 23. 
 
 
Scheme 1.12: Rhodium-Catalysed 1,4-Arylation 
 
The proposed mechanism for the formation of aryl–rhodium species 25 (Scheme 1.13) 
assumes that transmetalation from boron to rhodium proceeds through coordination of 
the Rh–OH complex 23 with an highly oxophilic arylboronic acid to give intermediate 
29 as a quaternised boron anion, from which the aryl fragment is transferred to rhodium 
in an intramolecular fashion to generate the aryl–rhodium species 25 and boric acid. 
This transmetalation occurs under neutral conditions, but can be greatly accelerated by 
 9 
the addition of a stoichiometric base. This is attributable to the quaternisation of 





Scheme 1.13: Proposed Mechanism for the Transmetalation of Arylboronic Acids to Rhodium 
 
The rhodium-catalysed addition of phenylboronic acid to 2-cyclohexenone, commonly 
known as the Hayashi-Miyaura reaction, is typically used as a model system to gauge 
catalytic activity of various ligands. As shown in Figure 1.1, numerous phosphine-, 
alkene-, nitrogen-, sulfur-, N-heterocyclic carbene (NHC)-based and their hybrid ligands 
containing two different coordinating centers have been reported to display excellent 
activity.
65
 Bissulfoxide and NHC ligands are two new and emerging classes of ligands in 
RCAA. For the purposes of this paper, reports employing well-documented 
bisphosphine and diene ligands will be discussed primarily. 
 
Regarding the rhodium precatalyst, [Rh(C2H4)2Cl]2 is the favourable choice because of 
its rapid and irreversible ligand exchange.
14
 1,5-Cyclooctadiene (cod)-based rhodium 
precursors, such as [Rh(cod)Cl]2 and [Rh(cod)OH]2, are usually avoided due to their 
slow and reversible ligand exchange step, which in turn allows them to compete with 
their corresponding chiral ligated rhodium complexes in solution, thereby diminishing 




Figure 1.1: Ligand Types for RCAA 
 
Early reports on RCAA have utilised arylboronic acids 30 as the source of the 
nucleophile (Figure 1.2). However, it is found that trace amounts of phenol existing in 
commercially available boronic acids can severely deactivate the ligated rhodium 
catalyst.
68
 The phenol impurity can be easily removed by dehydration of the boronic 
acid to form the cyclic trimeric anhydride (boroxine 31), followed by washing with 
hexane. The pure boroxine 31 can be readily hydrolysed back to the corresponding 
boronic acid 30 under basic aqueous conditions. Pinacol boronic esters 32 react slowly 
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in RCAA because of their sluggish hydrolysis. The additional coordination in N-
methyliminodiacetic acid (MIDA) boronates 33 greatly improves their stability, 
resulting in slow release of boronic acids from MIDA boronates to keep minimal 
amounts of free boronic acid throughout the RCAA. The reactive ArB(9-BBN) 
derivatives 34 are often applied in RCAA in aprotic solvents to afford a stable chiral 
boron enolate in the absence of base,
69
 which can be further trapped by other 
electrophiles to undergo tandem reactions. Other arylboron reagents include potassium 
aryltrifluoroborate salts 35, lithium trimethylarylborate salts 36, and sodium 
tetraarylborate salts 37. 
 
 
Figure 1.2: Arylboron Reagents for RCAA 
 
Boroxines 31 are becoming one of the preferred reagents for RCAA because of the 
convenient addition in accurate stoichiometry and their better stability toward 
protodeboration than boronic acids, particularly at high temperature. 
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1.3.1. RCAA of α,β-Unsaturated Ketones 
 
The first rhodium-catalysed addition of arylboronic acids to electron-deficient alkenes 
was described by Miyaura and co-workers in 1997.
13
 In this report, the combination of 
[Rh(acac)(CO)2] and 1,4-bis(diphenylphosphino)butane (dppb) ligand was shown to 
efficiently catalyse the conjugate addition of arylboronic acids to linear α,β-unsaturated 
ketones 38 in an aqueous co-solvent system (Scheme 1.14). The author observed no 
competing uncatalysed reaction of the arylboronic acids to the enones. More interesting 
to note is the exclusive production of the 1,4-addition product in preference to 1,2-
addition. Sensitive functional groups were tolerated on the organoboron reagent 
(products 39c and 39d), which is in contrast to conjugate addition reactions that employ 
highly reactive organolithium and Grignard reagents. Lastly, conducting the reaction 




Scheme 1.14: Rhodium-Catalysed Hydroarylation of Enones 
 
A year later, Hayashi and Miyaura developed the asymmetric variant to this process by 
employing a chiral bisphosphine-ligated rhodium catalyst (Scheme 1.15).
14
 The 
conjugate addition to cyclic and acyclic ketones proceeded with high conversion and 
excellent enantioselectivity. Addition of an alkenylboronic acid was also possible 




Scheme 1.15: RCAA of Enones 
 
In 2002, Hayashi and co-workers presented a detailed mechanism for the Hayashi-
Miyaura reaction (Scheme 1.16).
15
 According to the report, the reaction is initiated 
through the transmetalation of a phenyl group from boron to hydroxorhodium 42 to 
generate the phenyl–rhodium species 43. Subsequently, 2-cyclohexenone 40a inserts 
into the Rh–Ph bond of 43 to form the oxa-π-allylrhodium 44, which is unstable under 
protic conditions and readily hydrolysed to regenerate 42 and liberate the RCAA product 
41a. It is noteworthy that rhodium remains at a constant oxidation state of +1 throughout 
the catalytic cycle. Through detailed kinetic studies, Hayashi and co-workers were also 
able to reveal that the transmetalation from boron to rhodium was the rate-determining 





Scheme 1.16: Catalytic Cycle for the Hayashi-Miyaura Reaction 
 
Since Hayashi’s early report on the RCAA of enones, various electron-withdrawing 
groups other than a ketone have also been shown to activate adjacent alkenes toward 
RCAA. 
 
1.3.2. RCAA of α,β-Unsaturated Esters 
 






Scheme 1.17: RCAA of Enoates Using a Chiral Bisphosphine Ligand 
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In 2005, Carreira showed that a chiral diene-ligated rhodium catalyst could be used for 
the RCAA of β-aryl enoates (Scheme 1.18).
26
 A strongly electron-withdrawing nitro 
group at the sterically demanding o-position of the arene ring of substrate 47b did not 
hinder the reaction. The system could also tolerate heteroaromatic β-substituents as 
evidenced from the smooth arylation of substrates 47c and 47d. 
 
 
Scheme 1.18: RCAA of β-Aryl Enoates Using a Chiral Diene Ligand 
 
The RCAA of linear enoates was applied by Helmchen and co-workers toward the 
synthesis of (R)-Baclofen, which is an agonist for the GABAB receptors; and (R)-





Scheme 1.19: Synthesis of (R)-Baclofen and (R)-Rolipram 
 
1.3.3. RCAA of α,β-Unsaturated Amides 
 






Scheme 1.20: RCAA of Acyclic α,β-Unsaturated Amides 
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More recently, Lin and co-workers have described the highly enantioselective rhodium-






Scheme 1.21: RCAA of Cyclic α,β-Unsaturated Amides 
 
1.3.4. RCAA of α,β-Unsaturated Aldehydes 
 
In 2005, Carreira and co-workers successfully performed the RCAA of enals using a 
chiral diene ligand (Scheme 1.22).
32
 The RCAA of enals 55 presents a special challenge 
due to the high reactivity of aldehydes and their propensity to undergo 1,2-addition. 
Remarkably, the catalytic system developed by Carreira and co-workers was highly 
selective and solely produced the 1,4-addition products 56 while leaving the aldehyde 





Scheme 1.22: RCAA of β-Aryl Enals 
 
1.3.5. RCAA of α,β-Unsaturated Phosphonates 
 
α,β-Unsaturated phosphonates can also undergo RCAA, as demonstrated by Hayashi and 
co-workers by making use of a chiral bisphosphine-ligated rhodium complex (Scheme 
1.23).
33
 Arylboroxines were found to be better suited for these substrates than 
arylboronic acids, since product 58a was produced in a low 44% yield and an 84% ee 
when phenylboronic acid was employed under otherwise similar conditions. 
 
 
Scheme 1.23: RCAA of α,β-Unsaturated Phosphonates 
 
 19 
Consistent with the stereochemical model, the trans and cis geometries of 
alkenylphosphonate 57a afforded opposite enantiomers (Equation 1.2). 
 
 
Equation 1.2: Stereochemical Outcome for RCAA of α,β-Unsaturated Phosphonates 
 
1.3.6. RCAA of α,β-Unsaturated Pyridylsulfones 
 
Alkenyl-2-pyridylsulfones have also been shown to participate in RCAA (Scheme 
1.24).
34-36
 Interestingly, a range of α,β-unsaturated (hetero)arylsulfones were found to be 
poor candidates for RCAA. However, α,β-unsaturated o-pyridylsulfones underwent 
conjugate arylations to afford products 60 in high yields and enantioselectivities. 
 
 
Scheme 1.24: RCAA of α,β-Unsaturated Pyridylsulfones 
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The report suggested that the unique position of the nitrogen at the o-position of the 




Scheme 1.25: Importance of 2-Pyridyl Group in RCAA of α,β-Unsaturated Pyridylsulfones 
 
1.3.7. RCAA of Nitroalkenes 
 
Hayashi and co-workers have also demonstrated the use of nitroalkenes as strong 
acceptors in RCAA (Scheme 1.26).
37
 While the addition of arylboronic acids to 6-
membered cyclic nitroalkenes gave the arylated product in high diastereo- and 
enantioselectivity (product 63a), there was a significant loss in diastero- and/or 
enantioinduction when switching to alkenyl boronic acids (product 63b), to 5-membered 
cyclic nitroalkenes (product 63c) or to acyclic nitroalkenes (product 63d). 
 
 
Scheme 1.26: RCAA of Nitroalkenes 
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The cis-β-aryl substituted cyclic nitroalkanes could easily be converted to the more 
thermodynamically stable trans-isomer by treatment of the cis-rich mixture with sodium 
bicarbonate in refluxing ethanol (Equation 1.3). 
 
 
Equation 1.3: Conversion from cis- to trans- Isomer 
 
RCAA of electron-deficient α,α-disubstituted alkenes are rare in literature, presumably 
due to the high steric congestion at the α-position of such substrates. Notably, Hayashi’s 
report is one of the few examples where α,α-disubstituted alkenes underwent RCAA. 
 
1.3.8. RCAA of Arylmethylene Cyanoacetates 
 
In 2008, Hayashi and co-workers reported the RCAA of arylmethylene cyanoacetates 






Scheme 1.27: RCAA of Arylmethylene Cyanoacetates 
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The methodology was also applied toward the enantioselective synthesis of (R)-
tolterodine (Scheme 1.28), which involved the rhodium-catalysed asymmetric addition 
of phenylboronic acid to a methylene cyanoacetate 64e bearing a protected 2-hydroxy-5-
methylphenyl group to afford the arlyated product 65e. Removal of the carbomethoxy 
group by treatment with NaCN and LiI in DMF gave the nitrile 66 in high enantiopurity. 
The cyano group was then converted to the corresponding aldehyde 67, and subsequent 
reductive amination with diisopropylamine and sodium triacetoxyborohydride gave the 
protected tolterodine precursor 68. Deprotection of 68 via hydrogenolysis provided the 
desired product in quantitive yield. (R)-Tolterodine is an antimuscarinic drug that is used 




Scheme 1.28: Enantioselective Synthesis of (R)-Tolterodine 
 
1.3.9. RCAA of Borylalkenes 
 
More recently, Hayashi and co-workers have employed borylalkenes in RCAA to give 
chiral β-arylalkylboranes with high enantioselectivities (Scheme 1.29).
41-42
 The utility of 
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this process was demonstrated by converting the arylated boranes 70 into their 




Scheme 1.29: RCAA of Borylalkenes 
 
1.3.10. RCAA of Strained Alkenes 
 
In 2002, Lautens and co-workers reported the rhodium-catalysed asymmetric ring 
opening of oxabicyclic alkenes with arylboronic acids (Scheme 1.30).
17
 Unlike typical 
RCAA where alkenes are activated through conjugation with an electron-withdrawing 
group, Lautens’ work relied on the placement of an alkene in a strained ring system, 
which provided the driving force for rhodium-catalysed asymmetric arylations. Also, in 
a typical RCAA the carbo-rhodation step is followed by hydrolysis, whereas in this 
report the carbo-rhodated species underwent β-elimination instead, providing secondary 




Scheme 1.30: Rh-Catalysed Asymmetric Arylation of Oxabicyclic Alkenes 
 
 
Scheme 1.31: Catalytic Cycle for the Asymmetric Ring Opening of Oxabicyclic Alkenes 
 
The first step in the proposed mechanism for the asymmetric ring opening of oxabicyclic 
alkenes involves transmetalation of the arylboronic acid to ligated rhodium(I) hydroxide 
74 generating intermediate 75 (Scheme 1.31). This species then undergoes an exo-
selective asymmetric carbo-rhodation at the oxabicycle olefin 72 to generate 
intermediate 76. Chelation of the olefin and the oxygen atom of the oxabicycle may help 
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to contribute to the high exo selectivity. β-Elimination of oxygen to give the ring-opened 
intermediate 77 then occurs, followed by hydrolysis to liberate the ring-opened product 
73 and regenerating the ligated rhodium(I) hydroxide 74. 
 
1.3.11. RCAA of Alkenylheteroarenes 
 
In 2010, our group demonstrated the use of C=N-containing heteroarenes for activating 
adjacent alkenes toward RCAA (Scheme 1.32).
43
 In this report, the parent 2-
alkenylpyridine failed to participate in RCAA; however, 2-alkenylazaarenes containing 
more electron-withdrawing azines (products 79a and 79b) and azoles (products 79c and 
79d) successfully participated in RCAA. 
 
 
Scheme 1.32: RCAA of 2-Alkenylheteroarenes 
 
1.3.12. RCAA of Alkenylarenes 
 
Lautens and co-workers have also shown that various vinylarenes, where activation of 
the adjacent alkene is minimal, can undergo rhodium-catalysed Heck-type reactions 






Scheme 1.33: Rh-Catalysed Heck-Type Reaction to Vinylarenes 
 
Drawing from past knowledge of 2-alkenylazaarenes that effectively underwent RCAA, 
it occurred to us that placement of a strong electron-withdrawing group (such as a nitro 
group) on the arene might lead to sufficient polarisation of the adjacent alkene to the 





Scheme 1.34: RCAA to Electron-Deficient Alkenylarenes 
 
Although nitroalkenes have been successfully employed in a myriad of additions of 
carbon nucleophiles,
37-39, 72-74
 the analogus reactions of their phenylogous counterparts 
82 are extremely rare,
18c-h
 and no asymmetric reactions have been reported. Therefore, 
the successful realisation of the RCAA of electron-deficient alkenylarenes was an 
attractive goal and would set the stage for the use of this underexploited class of 




2. Results and Discussion 
 
In order to test our hypothesis illustrated in Scheme 1.34, synthesis of the appropriate 
substrates was necessary (Scheme 1.35). In most cases, our approach comprised of a 
two-step strategy involving the zirconium-catalysed hydroboration of terminal alkynes 
84 leading to the stereoselective production of E-alkenylboronic esters 85, which were 
then subjected to Suzuki-Miyaura coupling conditions with aryl halides 86 containing 
various electron-withdrawing substituents to afford the desired substrates 82 available 
for RCAA chemistry. 
 
 
Scheme 1.35: Strategy for the Synthesis of Alkenylarene Substrates 
 
2.1. Step 1: Zirconium-Catalysed Preparation of E-Alkenylboronic 
Acid Pinacol Esters 
 
For the preparation of alkenylboronic acid pinacol esters 85, a stereoselective zirconium-
catalysed procedure developed previously by Wang and co-workers was followed 
(Scheme 1.36).
75
 The preparation of 85a-85d proved to be fairly straightforward and the 





Reagent was purchased from commercial sources. 
Scheme 1.36: Preparation of E-Alkenylboronic Esters 
 
2.2. Step 2: Preparation of Alkenylarenes via Suzuki-Miyaura Cross-
Couplings 
 
Compounds 85a-85d and other commercially available alkenylboronic acid pinacol 
esters were then coupled with a range of aryl halides 86 following standard Suzuki-
Miyaura cross-coupling methodology. First, alkenylarenes containing various electron-






Reaction was conducted using aryl iodide 86. 
b 
Reaction was conducted using aryl bromide 86. 
Scheme 1.37A: Preparation of Alkenylarenes 
 
Next, strongly electron-withdrawing groups were placed at the m- or o-position of the 




Reaction was conducted using aryl iodide 86. 
b 
Reaction was conducted using aryl bromide 86. 
Scheme 1.37B: Preparation of Alkenylarenes 
 
Alkenylarenes containing various β-substituents such as linear or bulky aliphatic groups 
(products 82j and 82k, respectively), an allyl ether (product 82l), a silyl ether (product 





Reaction was conducted using aryl iodide 86. 
b 
Reaction was conducted using aryl bromide 86. 
c 
Reagent 
was purchased from commercial sources. 
Scheme 1.37C: Preparation of Alkenylarenes 
 
Alkenylarenes possessing p- and m-substituents (82p-u) or p- and o-substituents (82v-x) 
on the arene were synthesised as well (Scheme 1.37D). Generally, the desired 
alkenylarenes were produced in good yield. In certain cases where the arene contained 
more than one electron-withdrawing group, decomposition of starting material was 
observed. This was attributed to a side nucleophilic aromatic substitution (SNAr) 
reaction that may be occurring during the coupling reaction (Equation 1.4). This was 
overcome by making use of a milder base such as caesium fluoride, which allowed 





Reaction was conducted using aryl iodide 86. 
b 
Reaction was conducted using aryl bromide 86. 
c 
Reaction 
was conducted using aryl chloride 86.
 d 
Reaction was conducted using aryl triflate 86. 
e
 Reaction was 
conducted using NaOH. 
f
 Reaction was conducted using CsF. 
Scheme 1.37D: Preparation of Alkenylarenes 
 
 
Equation 1.4: SNAr Mechanism 
 
α,α-Disubstitued alkenyl-p-nitroarene 82y was prepared by coupling 4-





Equation 1.5: Preparation of α,α-Disubstitued Alkenylarenes 
 
Lastly, alkenyl-p-nitroarene 82z containing an allyl amine β-substituent was also 
prepared through a reductive amination (Equation 1.6). 
 
 
Equation 1.6: Preparation of Alkenylarenes Containing an Allyl Amine  
 
The alkenylarenes thus prepared were then subjected to RCAA conditions. 
 
2.3. RCAA of Alkenylarenes 
 
To maximise the chances of productive reactions taking place, alkenylarene 82a 
containing the strongly electron-withdrawing nitro group at the p-position was selected 
as a test substrate (Table 1.1). As a preliminary gauge of reactivity, the addition of 
PhB(OH)2 to 82a was performed using [Rh(cod)Cl]2 (2.5 mol%) and KOH (2.5 equiv.) 
in dioxane/H2O at 80 °C under microwave (μw) irradiation for 30 min. This experiment 
resulted in 42% conversion into rac-83a (entry 1). Next, the use of chiral ligands was 
evaluated in combination with [Rh(C2H4)2Cl]2 as a precatalyst to assess whether 83a 
could be obtained with improved conversions and in high enantioselectivity. Chiral 
diene ligands have been shown to provide excellent results in RCAA
76-91
 and, in view of 
the success obtained with secondary amide-containing ligand L1
92-93
 in our group’s 
previous study of the RCAA of alkenylheteroarenes
43











d 42 n/a 
2 L1 35 97 
  3
 e 
L1 70 95 
4 L2 24 95 
5 L3 76 70 







9 L7 66 97 
a 





H NMR analysis of the unpurified reaction mixtures. 
c
 Determined by HPLC analysis on a chiral 
stationary phase. 
d
 [Rh(cod)Cl]2 was used in place of [Rh(C2H4)2Cl]2, without an additional chiral ligand. 
e
 
Reaction conducted at 120 °C for 30 min. 
f
 Product 83a was isolated in 92% yield. 
Table 1.1: Ligand Optimisation for the RCAA of 82a 
 
Although L1 did lead to 83a in 97% ee, the conversion was only 35% (entry 2). 
Increasing the temperature to 120 °C did increase the conversion with only a slight 
impact upon enantioselection (95% ee), but appreciable starting material remained (entry 
3). Additional amide-containing chiral dienes were then investigated. The 
enantioselectivity remained high with ligand L2 that lacks the pyrrole on the cyclohexyl 
ring, but the conversion was low (entry 4). Ligand L3 containing a morpholine amide 
provided improved conversion (76%) at 80 °C, but the product was formed in only 70% 
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ee (entry 5). Ligands L4 and L5 containing tertiary amides gave further improved results 
(entries 6 and 7), with dibenzylamide-containing ligand L5 giving the product in >95% 
conversion, 92% isolated yield, and 95% ee (entry 7). In contrast, ligand L6 containing 
only one benzyl group on the amide nitrogen atom afforded inferior results (entry 8), 
further suggesting that under these conditions, a tertiary amide in the ligand is beneficial 
for high conversion. Finally, (R)-Binap (L7) was tested for comparison and although the 
enantioselectivity was high, the reaction did not go to completion (entry 9). On the basis 
of these results, ligand L5 was selected for further study. Using ligand L5, other reaction 
parameters such as catalyst loading, solvent and reaction time were also optimised. 
 
Having identified the optimum set of conditions, substrates containing an electron-
withdrawing group other than a p-nitrophenyl group were tested (Scheme 1.38A). 
Unfortunately, attempts to arylate substrates 82b-82e led to poor conversion to the 
desired product, which were too low to warrant further purification. Attempts to activate 
these substrates by changing reaction parameters proved to be unfruitful, leading either 
to recovery of starting material or the formation of various undesired products. These 
results highlight the strong electron-withdrawing influence of a nitro group and the 
ability of a p-nitrophenyl group to activate adjacent alkenes toward RCAA. 
 
 
Scheme 1.38A: RCAA of Alkenylarenes 
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Next, substrates containing an electron-withdrawing group at various positions of the 
electron-deficient arene were subjected to our RCAA conditions (Scheme 1.38B). Not 
surprisingly, substrate 82f did not participate in rhodium-catalysed arylation. In this 
case, the alkene is not conjugated to the nitro group of the adjacent m-nitrobenzene 




Scheme 1.38B: RCAA of Alkenylarenes 
 
More intriguing was the failure of substrate 82g to undergo conjugate arylation. We 
believed that the nitro group at the o-position of the arene in substrate 82g would be 
conjugated to the adjacent alkene and impart a stronger electron-withdrawing influence 
in comparison to the p-nitrobenzene-containing substrate 82a. Although the true reason 
for the inactivity displayed by substrates 82g and 82h toward RCAA remains unclear, it 
is possible that several factors may be inhibiting one or more key steps in the catalytic 
cycle for the rhodium-catalysed arylation of these particular o-substituted substrates. A 
likely explanation may be that due to the size and close proximity of the nitro and cyano 
group to the alkene in substrates 82g and 82h respectively, the p-orbitals on the alkene 
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and the adjacent arene may twist out of plane, thus breaking the conjugation needed for 
RCAA. 
 
We also considered the possibility that o-substituted substrates such as 82g and 82h may 
be poisoning the catalyst by binding to it too strongly and thus preventing it from re-
entering the catalytic cycle. To test this theory, one reaction using 82g was conducted 
using stoichiometric quantities of the rhodium precatalyst and the chiral diene ligand L5 
(Equation 1.7). As before, no arylated product was observed. 
 
 
Equation 1.7: Catalyst-Poisoning Test in RCAA of Alkenylarenes 
 
Equipped with the knowledge that placement of a nitro group at the p-position of the 
alkenylarene ring is crucial for success, the addition of arylboronic acids to various β-
substituted alkenyl-p-nitroarenes was investigated (Scheme 1.38C). The range of 
tolerated substituents at the β-position of the alkene include simple linear alkyl groups 
(products 83a, and 83b), a cyclopropyl group (product 83c), an allyl amine (product 
83d), an allyl ether (product 83e) and a trimethylsilyl (product 83f) substituent.  The 
modest yield of product 83f may be attributed to the steric hindrance provided by the 
bulkier trimethylsilyl group. Thermal heating was found to be as effective as microwave 








Unless otherwise stated, reactions were conducted using 0.20 mmol of 82. Cited yields are of isolated 
material. Enantiomeric excesses were determined by chiral HPLC analysis. 
b
 Reaction conducted under 
thermal heating under otherwise identical conditions. 
c 
Reaction performed using 1.0 mmol of 82j at 80 °C 
under thermal heating for 1 h, using 1.25 mol% of Rh and 3 mol% of L5. 
Scheme 1.38C: Scope of β-substituents in RCAA of Alkenyl-p-Nitroarenes 
 
Furthermore, to test the practical applicability of this process, thermal heating was 
employed in the addition of phenylboronic acid to 82m on a 5.0 mmol scale with 1.25 
mol% of [Rh(C2H4)2Cl]2  and 3 mol% of L5 at 80 °C for 1.5 h, which provided 83g in 
88% yield and 93% ee, thus demonstrating the reaction to proceed smoothly on a 
preparative scale and at a reduced catalyst loading (Equation 1.8). 
 
 
Equation 1.8: Preparative-Scale RCAA of 2-Alkenyl-p-Nitroarene 
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Substrate 82n containing a β-aryl substituent did not undergo RCAA (Equation 1.9). 
 
 
Equation 1.9: RCAA of β-Aryl Alkenyl-p-Nitroarene 
 
Regarding the scope of the nucleophile (Scheme 1.38D); p-, m- and o-tolyl boronic acid 
were competent reaction partners in this process (products 83h-83j, respectively). The 
reaction of sterically demanding o-tolylboronic acid with substrate 82j required a 
reaction time of 1 h to afford 83j. Arylboronic acids containing electron-withdrawing or 




Unless otherwise stated, reactions were conducted using 0.20 mmol of 82. Cited yields are of isolated 
material. Enantiomeric excesses were determined by chiral HPLC analysis. 
b
 Reaction time was 1 h. 
Scheme 1.38D: Scope of Arylboronic Acids in RCAA of Alkenyl-p-Nitroarenes 
 39 
 
In addition to a p-nitrophenyl group, the process is also tolerant of multisubstituted 
arenes (Scheme 1.38E). Other arenes that provide effective activation include m-
carbomethoxy-p-nitrophenyl (product 83o), p-nitro-m-(trifluoromethyl)phenyl (product 
83p), m-methyl-p-nitrophenyl (product 83q), p-nitronaphthyl (product 83r), o-fluoro-p-




Unless otherwise stated, reactions were conducted using 0.20 mmol of 82. Cited yields are of isolated 
material. Enantiomeric excesses were determined by chiral HPLC analysis. 
Scheme 1.38E: Scope of Substitution on Arene in RCAA of Alkenyl-p-Nitroarenes 
 
The powerful effect of a p-nitrophenyl group allowed us to address a problem 
discovered during our group’s recent study of enantioselective rhodium-catalysed 
addition of arylboronic acids to alkenylheteroarenes, which identified a 2-pyridyl group 
as providing insufficient activation of an adjacent alkene for arylation to proceed 
efficiently.
43
 Gratifyingly, 2-alkenylpyridine 82v containing a 5-nitro group underwent 
arylation to give product 83t in high yield and enantioselectivity (Scheme 1.38E). 
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Surprisingly, substrate 82s containing a m-cyano-p-nitrophenyl group failed to arylate 




Equation 1.10: RCAA of Substrate Containing a m-Cyano-p-Nitrophenyl Group 
 
As noted previously, examples of RCAA of electron-deficient α,α-disubstituted alkenes 
are rare in literature. Nevertheless, arylation of an α,α-disubstituted alkenyl-p-nitroarene 
82y was attempted in our study (Equation 1.11). Disappointingly, none of the arylated 
product was observed. 
 
 
Equation 1.11: RCAA of α,α-Disubstituted Alkenyl-p-Nitroarene 
 
We have previously discussed our efforts to employ alkenylbenzene substrates 
containing a p-electron-withdrawing substituent other than a nitro group, which led to 
poor conversion into mixtures of identified undesired products (Scheme 1.38A). We 
rationalised that the placement of an electron-withdrawing group other than a nitro 
group at the p-position along with another electron-withdrawing substituent would help 
to further activate the adjacent alkene toward RCAA. Pleasingly, substrate 82t 
containing a p-cyano-m-(trifluoromethyl)phenyl group did undergo arylation in 59% 
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yield and 84% ee in the presence of 10 mol% of the rhodium–chiral diene complex after 
1.5 hours (Equation 1.12A). Substrate 82u containing a p-carbomethoxy-m-nitrophenyl 
group was also subjected to similar RCAA conditions. Unfortunately, only trace 
amounts of the arylated product was observed (Equation 1.12B). 
 
 
Equation 1.12: RCAA of p-Cyano-m-(trifluoromethyl)phenyl Group-Containing Alkenylarene 
 
A possible mechanism for the RCAA of electron-deficient alkenyl-p-nitroarenes is 
illustrated in Scheme 1.39. Treatment of [Rh(C2H4)2Cl]2 and L5 with KOH results in 
formation of chiral diene-ligated rhodium hydroxide 87. Transmetalation of 87 with the 
arylboronic acid leads to the formation of rhodium–aryl species 88, where the rhodium–
aryl linkage is positioned trans to the more electron-deficient alkene. Coordination of 
the alkenylarene 82 to the remaining binding site of 88 then occurs as depicted in 89 to 
minimise unfavourable nonbonding interactions between the arene and the amide 
substituent of the ligand. Arylrhodation of the bound substrate results in the formation of 
intermediate 90, which then undergoes hydrolysis to regenerate the rhodium hydroxide 




Scheme 1.39: Possible Mechanism for RCAA of Electron-Deficient Alkenyl-p-Nitroarenes 
 
Nitroarenes are well-known to undergo a range of transformations, making them 
versatile intermediates in the preparation of dyes, pharmaceuticals and other functional 
compounds.
94
 In order to demonstrate the synthetic utility of the arylation products 
described herein, 83q was smoothly converted into indole 91 in 67% yield by treatment 






Equation 1.13: Indole Synthesis 
 
Finally, in order to determine the absolute stereochemistry of the arylated products, the 
nitro group in 83g was reduced to the corresponding amine and then tosylated to give 92 
as a white crystalline solid (Scheme 1.40). 
 
 
Scheme 1.40: Manipulation of Nitro Group 
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The absolute stereochemistry of compound 92 was then determined by single crystal X-








In summary, a new dibenzylamide-containing chiral diene ligand L5 has been prepared, 
which enables highly enantioselective rhodium-catalysed additions of arylboronic acids 
to alkenyl-p-nitroarenes and an alkenyl-p-cyano-m-(trifluoromethyl)arene to take place 
under mild conditions (Scheme 1.41).
97
 These reactions represent, to the best of our 
knowledge, the first examples of catalytic asymmetric addition of air- and moisture-




Scheme 1.41: RCAA of Electron-Deficient Alkenylarenes 
 
The powerful electron-withdrawing influence of a nitro group was demonstrated by the 
placement of other electron-withdrawing groups on the arene (such as carbonyls, nitrile 




Equation 1.14: Electron-Withdrawing Influence of a Nitro Group in RCAA of Electron-
Deficient Alkenylarenes 
 
Work was also carried out to better understand the structural requisites necessary for this 
process. Alkenylarenes containg a m- or o-nitrobenzene moeity failed to participate in 




Equation 1.15: Structural Requirements for RCAA of Electron-Deficient Alkenyl-p-Nitroarenes 
 
Extension of this concept to other classes of reactions may present exciting new 
opportunities for asymmetric catalysis. Studies in this area are currently underway in our 
group. 
 
4. Future Work 
 
As shown in Equation 1.14B, electron-withdrawing groups other than a nitro group, 
when placed at the p-position of an arene, failed to provide sufficient activation of the 
adjacent alkene toward RCAA. However, substrate 64t containing a p-cyano-m-
(trifluoromethyl)phenyl underwent arylation, albeit in low yield (Equation 1.12A). This 
result suggests that there is scope to increase the range of electron-deficient arenes that 
can be used as activating groups. Future developments in this area may rest upon the 





Scheme 1.42: RCAA of Electron-Deficient Arenes not Containing a Nitro Group 
 
Lastly, chiral NHCs are an emerging class of ligands in RCAA. In 2011, T. Hayashi and 
co-workers reported the 1,4-addition of  various aryl, alkenyl, and alkyl organoborates to 
alkylidene cyanoacetates 93 catalysed by a NHC–copper complex (Scheme 1.43).
98
 The 
ability to perform 1,4-additions by replacing rhodium with a less-expensive metal, such 
as copper, helps make this process significantly more valuable. The report also suggests 
that the development of novel NHCs might spur a new wave of conjugate addition 
chemistry catalysed by copper and other cheaper metals. 
 
 
Scheme 1.43: Copper-Catalysed 1,4-Addition of Organoborates to Alkylidene Cyanoacetates
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II. Enantioselective Copper-Catalysed Reductive 




Nitrogen-containing aromatic heterocycles (azaarenes) are privileged structures that 
appear in numerous biologically active compounds such as natural products, 
pharmaceuticals, and agrochemicals (Figure 2.1). Therefore, the development of new 
methods for the incorporation of azaarenes into compounds, or to functionalise pre-
existing azaarenes, are of high value. 
 
 
Figure 2.1: Aromatic Heterocycles in Natural Products and Therapeutic Agents 
 
In this regard, recent efforts from our group have targeted the development of processes 
that exploit the ability of a suitably positioned C=N moiety within azaarenes to activate 
adjacent alkenes
99-101
 toward catalytic enantioselective 1,4-additions.
43, 102
 The first of 




disubstituted 2-alkenylazaarenes, which result in alkylazaarenes with a new stereogenic 





Equation 2.1: Catalytic Transformations of Alkenylazaarenes 
 
Since these reactions likely proceed via the intermediacy of organocopper species that 
undergo protonation with t-BuOH, we questioned whether these intermediates could be 
trapped in situ with an alternative electrophile such as a ketone (Equation 2.1B), thereby 
delivering synthetically valuable alcohol-containing products with stereochemistry at 
both α- and β-carbons. Reports on copper hydride-catalysed conjugate reductions and its 
extension to tandem processes such as reductive aldol reactions are present in literature 
and are discussed in the following sections. 
 
1.1. Copper Hydride (CuH)-Catalysed Conjugate Reductions 
 
Conjugate reduction of α,β-unsaturated carbonyl compounds by organosilanes mediated 
by complexes of rhodium, platinum, palladium, and molybdenum are well-established.
107-
109
 However, the use of copper, a less-expensive metal, for the analogous transformation 






Equation 2.2: CuH-Catalysed Reduction of Alkenes Conjugated to Common Electron-
Withdrawing Groups 
 
Modern usage of CuH reagents is well-recognised to have begun with Stryker’s 
reagent.
110-114
 In 1988, Stryker and co-workers reported the ability of this reagent, which 
exists as a phosphine-stabilised hexamer of the formula [(Ph3P)CuH]6, to effect conjugate 
reduction of carbonyl derivates 95 (Scheme 2.1). 
 
 
Scheme 2.1: 1,4-Reduction of Carbonyl Derivatives Catalysed by Stryker’s Reagent 
 
In this seminal report, highly regioselective 1,4-reduction, with near complete 
suppression of competing 1,2-reduction was observed. Mildness of reaction conditions 
and functional group compatibility adds to the merit of this process. For these reasons, 
Stryker’s reagent was awarded the status of “Reagent of the Year” in 1991. 
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Interestingly, a subsequent report by Stryker identified molecular hydrogen as a possible 
source of hydride for the conjugate reduction of enones, thus allowing the use of sub-
stoichiometric quantities of Stryker’s reagent.
115
 However, a major drawback 
encountered in this report was the delivery of H2 gas at very high pressures (>1000 psi), 
which in turn led to competing 1,2-reduction of enones to generate the corresponding 
alcohol. Hydrosilanes, which in general are inexpensive and environmentally friendly, 
have become the most frequent source of stoichiometric hydride (species 100, Scheme 
2.2) in modern CuH-catalysed reductions. Polymethylhydrosiloxane (PMHS), 
tetramethyldisiloxane (TMDS), Fleming’s silane (PhMe2SiH), triethoxysilane ((EtO)3SiH 
and phenylsilane (PhSiH3) are examples of commonly used organosilanes. 
 
An early protocol for the synthesis of ligated copper hydride reagents relied on the 
treatment of CuCl 97 with NaOt-Bu 98 producing CuOt-Bu 99. Addition of a hydride 
source 100 (such as a hydrosilane) to pre-formed 99 in the presence of a ligand (PPh3 in 
the case of Stryker’s reagent) leads to the generation of the ligated CuH species 101 
(Scheme 2.2). Since CuOt-Bu 99 is susceptible to oxidation, inert conditions are 
necessary for the in situ preparation of the CuH species 101. This problem can be 
circumvented by the use of air-stable, easy-to-handle and commercially available 
Cu(OAc)2H2O, which serves as a suitable substitute for CuOt-Bu. In the presence of a 
ligand and a hydrosilane reductant, Cu(OAc)2H2O (where Cu has an oxidation state of 
+2) is efficiently reduced to the CuH species 101 (where Cu has an oxidation state of +1). 
 
 
Scheme 2.2: Preparation of Ligated CuH Reagents 
 
Switching from PPh3 to chiral non-racemic ligands leads to the creation of a ligated CuH 
species capable of catalysing conjugate reductions in a diastero- and enantioselective 
fashion. Although myriad CuH-catalysed asymmetric reductions have been reported to 
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 bisphosphine ligands, such as those illustrated in Figure 2.2. 
 
 
Figure 2.2: Examples of Bisphosphine Ligands Used in CuH-Catalysed Conjugate Reductions 
 
More recently, NHC ligands have presented yet another possibility for the generation of 
isolable and air-stable copper–carbene complexes (Scheme 2.3).
119-121
 Besides their 
stability in air, NHCs are electronically distinct ligands from their bisphosphine 
counterpart due to their strong -donating and weak -accepting properties. They are 
structurally unique as well, possessing a likely linear array between the carbene carbon, 
copper and hydrogen atoms. However, chiral non-racemic carbene-based copper hydrides 




Scheme 2.3: Preparation of NHC–CuH Complex 
 
Enantioselective conjugate reductions catalysed by chiral phosphine-ligated CuH 
complexes and their application toward the synthesis of natural products and 
pharmaceutical drugs are well-documented.
103-106
 Detailed discussion of each report is 
beyond the scope of this thesis. Rather, only important breakthroughs and reports relevant 
to our study will be presented below. 
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One of the most significant breakthroughs was the first enantioselective conjugate 
reduction of α,β-unsaturated esters catalysed by the in situ formation of a chiral 
bisphosphine-ligated CuH species (Scheme 2.4).
122-125
 This report was published by 
Buchwald and co-workers in 1999.
122
 The reaction proceeded with high chemo- and 
enantioselectivity. E- and Z-isomers reacted to give opposite enantiomers (product ent-
103b). Isolated alkenes were left intact, highlighting the tolerance of the reactive copper 
species toward other sensitive functional groups (product 103d). 
 
 
Scheme 2.4: Enantioselective CuH-Catalysed Conjugate Reduction of Enoates 
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The mechanism for the conjugate reduction of enoate 102a as proposed by Buchwald is 
illustrated in Scheme 2.5. Upon combining (S)-p-tol-Binap, CuCl and NaOt-Bu, 
formation of (p-tol-Binap)CuOt-Bu 104 most likely occurs. Addition of PMHS then 
results in a σ-bond metathesis between (p-tol-Binap)CuOt-Bu 104 and PMHS to generate 
(p-tol-Binap)CuH 105. Asymmetric conjugate reduction of enoate 102a then occurs, 
resulting in formation of a copper enolate intermediate 106 that subsequently undergoes 
σ-bond metathesis with PMHS to make a silylketene acetal 107 and regenerate the copper 
hydride 105. The isolable product 107 when quenched with a proton source, such as 




Scheme 2.5: Catalytic Cycle of CuH-Catalysed Conjugate Reduction of Enoates 
 
In Buchwald’s report, EtOH was added in order to quench the reaction after ensuring 
complete consumption of the starting enoate. Advances in CuH chemistry since then have 
taken advantage of the tolerance of CuH complexes to alcohols and water. In fact, several 
methods rely on the presence of alcohols to enhance reaction rates. The role of this 
additive is usually ascribed to the more rapid quenching of the intermediate copper 
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enolate 108 generating a copper alkoxide, which is an ideal precursor to rapid 
reformation of copper hydride in the presence of excess silane (Scheme 2.6). 
 
 
Scheme 2.6: Role of Alcohol in CuH-Catalysed Conjugate Reductions 
 
Thus, the rate increase is presumably due to bypassing a slow metathesis step between 
Cu–O and Si–H bonds that is otherwise essential for regenerating CuH in the catalytic 






Equation 2.3: Deuteration Experiment: Effect of Alcohol in CuH-Catalysed Reductions 
 
Asymmetric hydrosilylation of unsaturated lactone 112 revealed that most of the 
deuterium was incorporated at the α-position, while only small amounts were found at the 
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β-position. Thus, since no exchange occurs between PMHS and t-BuOD, it would seem 
that the rate enhancement may well be due to more rapid quenching of the copper enolate 
by the alcohol than by the silane. It is likely that the ligated CuH species and t-BuOD 
undergo a facile H/D-exchange at room temperature, which may account for the 16% 




Since the discovery of enoates as suitable candidates for enantioselective CuH-catalysed 









 and nitro groups
141-142
 have been shown to 
successfully activate adjacent alkenes toward similar asymmetric reductions. The utility 
of this process has also been demonstrated by its application in the synthesis of various 
natural products and therapeutic drugs. For example, enantioselective CuH-catalysed 
reduction of compound 114 formed a key step in the synthesis of the tricyclic myrmicarin 
alkolid, myrmicarin-217 (Scheme 2.7).
132
 The myrmicarins are a family of alkaloids 






Scheme 2.7: Synthesis of Myrmicarin-217 by CuH-Catalysed Asymmetric 1,4-Reduction 
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CuH chemistry has also been applied toward the short asymmetric synthesis of the lignan 
eupomatilone-3 (Scheme 2.8).
133
 Remarkably, in the presence of excess NaOt-Bu as base, 
an efficient kinetic resolution of racemic enone 116 occured to afford the less reactive 
enantiomer with high diastero- and enantioselectivity.
124, 128
 Eupomatilones are a family 






Scheme 2.8: Synthesis of Eupomatilone-3 by CuH-Catalysed Asymmetric 1,4-Reduction 
 
Our group recently showed that azaarenes containing a suitably positioned C=N moiety 
could activate adjacent alkenes toward highly enantioselective CuH-catalysed conjugate 
reduction (Scheme 2.9).
102
 Given that heteroarenes such as oxazoles, thiazoles, pyridines, 
pyrazines, and others are ubiquitous in biologically active natural products, 
pharmaceuticals and agrochemicals, the ability to functionalise these privileged structures 




Scheme 2.9: CuH-Catalysed Asymmetric 1,4-Reduction of β,β-Disubstituted Alkenylazaarenes 
 
The proposed mechanism is illustrated in Scheme 2.10, which we believe follows a 
relatively similar pathway as the accepted mechanism for CuH-catalysed 1,4-reductions. 
 
 
Scheme 2.10: Proposed Catalytic Cycle of CuH-Catalysed 1,4-Reduction of β,β-Disubstituted 
Alkenylazaarenes 
 
Having proven that azaarenes could activate adjacent alkenes toward conjugate 
reductions, extension of this concept for tandem processes was sought. We questioned if 
the organocopper species 121 formed in the catalytic cycle could be trapped by an 
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electrophile other than a proton. Conjugate reduction-alkylation, conjugate reduction-
cyclisation and conjugate reduction-allylic substitution reactions were some of the 
avenues considered. Efforts eventually focused on the conjugate reduction-aldol reaction 
of alkenylazaarenes with various carbonyl derivatives. A discussion of existing reports on 
CuH-catalysed reductive aldol couplings is presented below. 
 
1.2. CuH-Catalysed Reductive Couplings 
 
Prior to the discovery of copper as an effective metal for catalysing reductive aldol 
reactions, early reports made use of expensive transition metals such as rhodium, 
palladium, iridium or cobalt.
145-155
 In 2001, Chiu and co-workers demonstrated the use of 
copper as a suitable metal for similar reductive aldol reactions.
156-157
 Not surprisingly, 
these seminal reports made use of stoichiometric quantities of Stryker’s reagent as the 





Scheme 2.11: Diastereoselective Cu-Mediated Aldol Cycloreduction Using Stryker’s Reagent 
 
At –40 °C, the formation of a new 5- or 6-membered carbocycle proceeded with high 
diastereoselectivity leading to the generation of products bearing all-cis stereochemistry 
(products 125a-125d). However, at an elevated temperature of 25 °C, the ester and the 
hydroxyl groups at the junction of the fused rings were found to be oriented trans to each 
other. These observations were attributed to the formation of the kinetically derived all-
cis product at low temperature, while at higher temperatures the copper aldolate 
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intermediate could undergo a retro-aldol reaction to give the thermodynamically more 
stable trans-oriented product. Interestingly, alkenes conjugated to electron-withdrawing 
groups other than a ketone also underwent copper-catalysed aldol cycloreductions 
(products 125c and 125d). The report also noted that while E- and Z-olefinic substrates 
delivered products with the same stereochemical outcome, the trans isomer reacted at a 
faster rate than its cis isomeric counterpart. 
 
In 2004, the same group also reported the reductive aldol cyclisation of alkynediones 
using sub-stoichiometric quantities of Stryker’s reagent and PMHS as the source of 
hydride (Scheme 2.12).
158
 Although these reactions may be viewed as a simple extension 
of Chiu’s previous report (Scheme 2.11), the ability to perform the reactions using sub-
stoichiometric quantities of Stryker’s reagent adds to the merit of this methodology. 
 
 
Scheme 2.12: Diastereoselective Cu-Catalysed Aldol Cycloreduction of Alkynediones Using 
Stryker’s Reagent 
 
The reductive aldol cyclisation of alkynediones provided β-hydroxycycloalkenones 
(products 127a-127d), which are complementary to those obtained from intramolecular 
Baylis-Hillman reactions. Whereas β-substituted enones and ketones make poor Michael 
acceptors and electrophiles respectively for the Baylis-Hillman reaction, the reductive 
aldol cyclisations of the related alkynones 126 mediated by Stryker’s reagent occured at 
low temperatures and under mild conditions. 
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The copper-catalysed reductive aldol reactions reported by Chiu employed Stryker’s 
reagent, which is achiral. Therefore, while the system may afford products with high 
levels of diastereoselectivity, generation of enantioenriched products was not possible. 
Enantioselective variants have been developed by making use of sub-stoichiometric 
quantities of metals such as rhodium, iridium and cobalt; however, the use of copper in 
transition metal-catalysed asymmetric reductive aldol reactions has only recently 
appeared in literature. 
 
In 2005, our group described the first enantioselective copper-catalysed aldol 
cycloreductions (Scheme 2.13).
159
 The β-Hydroxylactones 129a-129d were formed in 
excellent diastereoselectivity (>95:5 in all cases). However, the enantioselectivities 
observed were modest. 
 
 
Scheme 2.13: Diastereo- and Enantioselective Cu-Catalysed Aldol Cycloreduction for the 
Synthesis of β-Hydroxylactones 
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The report also noted the production of small quantities of uncyclised side products that 
had undergone reduction at the enoate and in some cases at the ketone. This observation 
indicates that the rate of σ-bond metathesis of the intermediate copper enolate with the 
siloxane is competitive with the rate of aldol cyclisation. A plausible catalytic cycle for 
the process was also presented (Scheme 2.14). 
 
 
Scheme 2.14: Catalytic Cycle of Cu-Catalysed Aldol Cycloreductions 
 
Presumably, in the presence of a bisphosphine ligand and TMDS, reduction of copper(II) 
occurs to generate a bisphosphine ligated copper(I)–hydride complex 130, which then 
engages in hydrometalation with substrate 128 to generate the copper enolate 131. 
Carbonyl addition results in the copper aldolate 132, which then undergoes -bond 
metathesis with the siloxane to liberate the silylated product 133 (which is deprotected 
upon work-up to give product 129), regenerating the copper(I) complex 130. The report 
also suggests that alternative mechanisms that invoke the participation of copper species 
such as silyl hydrido cuprates 134 may also be operative. Furthermore, the role played by 
 62 
the acetate counterion is unclear. The observed stereochemistry of the products 
presumably arises from preferential formation of the Z-copper enolate, coupled with 
chelation in the carbonyl addition step (as in 131). 
 
Later that year, our group reported related copper(I)-catalysed reductive aldol 
cyclisations for the generation of 4-hydroxypiperidin-2-ones 135 (Scheme 2.15).
160
 In 





 = H), smoothly underwent copper-catalysed reductive aldol cyclisation. 
Enantioenriched substrates 134b-134d containing pre-existing stereocenters also cyclised 
to give the corresponding piperidinones 135b-135d, respectively. 
 
 
Scheme 2.15: Diastereoselective Cu-Catalysed Aldol Cycloreduction for the Synthesis of 4-
Hydroxypiperidin-2-ones 
 
The moderate to excellent levels of 1,2- and 1,3-asymmetric induction in these reactions 
may be rationalised by invoking the chelated chair-like conformations 136-138 shown in 
Figure 2.3, with substituents in the tether linking the amide enolate and the ketone 






Figure 2.3: Possible Reactive Conformations for the Cyclisation of Substrates 134b-134d 
 
The synthetic utility of the piperidinone products was illustrated by a number of 
transformations (Scheme 2.16). Reductive removal of the carbonyl group by treatment of 
135 with borane at reflux allowed entry to the piperidine ring system 139, which is a 
ubiquitous structural feature of many natural products and biologically important 
compounds.
162-163
 139a was then converted into 140a by oxidative removal of the p-
methoxyphenyl (PMP) group followed by in situ treatment of the resulting amine with 
Boc2O. The amide reduction of piperidin-2-ones 135c and 135d with borane was 
accompanied by reduction of the ethyl esters to give piperidines 139b and 139c, 
respectively. Polyhydroxylated piperidines are of considerable biological interest due to 





Scheme 2.16: Conversion of Piperidinone Products into Piperidines 
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In 2008, Lipshutz and co-workers reported highly enantioselective CuH-catalysed 
reductive aldol cyclisations leading to the generation of chiral compounds containing 





Scheme 2.17: Highly Diastereo- and Enantioselective Cu-Catalysed Aldol Cycloreductions 
 
The copper-catalysed aldol cycloreduction was also performed using heterogenous Cu/C 
in the presence of 10 mol% NaOPh and 4.0 equiv. of DEMS (dimethoxymethylsilane) in 
toluene at –10 °C to afford the cyclised product 142a with high enantioselectivity 
(Equation 2.4A). Alternatively, the process could also be run entirely in water despite the 
water-insoluble nature of adduct Z-141a. Thus, in the presence of nanomicelle-forming 
PTS (a nonionic, vitamin E based surfactant; 2% by weight), 1,4-reduction/cyclisation in 





Equation 2.4: Heterogeneous and Aqueous Asymmetric Reductive Aldol Reactions 
 
Riant and co-workers have reported the efficient construction of polycyclic derivatives 
through the CuH-catalysed aldol cycloreduction of diketoesters (Scheme 2.18).
166-167
 The 
intramolecular reductive aldol reaction proceeded smoothly yielding 5- and 6-membered 
bicyclic products with high diastero- and enantioselectivities (products 144a-144d). 
However, substrates bearing a longer tether that could generate 7- or 8-membered rings 





Scheme 2.18: Enantioselective Cu-Catalysed Aldol Cycloreduction of Diketo-Esters 
 
Substitution at the quaternary carbon of the cyclised precursors was possible. This 
enabled the construction of new angular tricyclic compounds, such as 146, by using the 
allyl-substituted bicyclic adduct 144d (Scheme 2.19). The cross metathesis of t-butyl 
acrylate and the allyl group of adduct 144d was first carried out using sub-stoichiometric 
quantities of Hoveyda’s second generation catalyst, affording the cyclisation precursor 
145. A second reductive aldol cyclisation of 145 was performed to generate the angular 




Scheme 2.19: Enantioselective Cu-Catalysed Aldol Cycloreduction for the Formation of 
Tricyclic Compounds 
 
Marrubiin and marrubenol (Figure 2.4) are two natural diterpenes extracted from 
Marrubium vulgare L. (Horehound, Lamiaceae). The white horehound is a widespread 
Mediterranean plant used in traditional medicine, especially for its antinociceptive and 
expectorant effects. They have also been shown to exhibit potent relaxant activity.
168-170
 
Mangoni and co-workers have reported the racemic synthesis of marrubiin in 24 steps 
starting from the Wieland-Miescher ketone.
171
 However, Riant and co-workers applied 
their reductive aldol cyclisation methodology to the enantioselective synthesis of a key 






Figure 2.4: Structure of Marrubiin and Marrubenol 
 
 
Scheme 2.20: Synthesis of Key Intermediate ent-151a 
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In nature, the reduction of α,β-unsaturated thioester derivatives, such as crotonyl ACP 
(acyl carrier protein), is a transformation in the fatty acid biosynthesis pathway. Yet, only 
a handful of reports exist in literature even for simple reduction of α,β-unsaturated 
thioesters. One possible reason for this is that sulfur-rich compounds have been known to 
poison several metal catalysts. However, Chiu and co-workers successfully developed the 
CuH-catalysed reductive aldol cyclisation of α,β-unsaturated thioesters with a tethered 
ketone (Scheme 2.21).
173
 Disappointingly, only two cyclisations were reported (products 
153a and 153b). Also, a high catalyst loading was required to achieve good conversion 
into the desired cyclised product. 
 
 
Scheme 2.21: CuH-Catalysed Reductive Aldol Cyclisation of α,β-Unsaturated Thioesters 
 
A subsequent report by Chiu and co-workers transformed this into an asymmetric process 
by employing a chiral bisphosphine ligand (Scheme 2.22).
174
 In this report, products 
155a-155c were formed with excellent diastereo- and enantiocontrol. The catalyst 
loading was also reduced without affecting selectivity. The only obvious drawback was 
the long reaction times needed, which ranged from 40 to 120 hours. Nevertheless, the 
report successfully showed that diketo-enethioates could be used for CuH-catalysed 




Scheme 2.22: Diastereo- and Enantioselective CuH-Catalysed Reductive Aldol Cyclisation of 
α,β-Unsaturated Thioesters 
 
So far, enantioselective intramolecular reductive aldol cyclisations catalysed by chiral 
copper hydride species have been discussed, which proceed through the formation of 
entropically favoured medium-sized (5- or 6-membered) rings. The absence of this 
stabilising effect in analogous intermolecular reductive couplings can make such 
reactions less likely to occur. However, enantioselective CuH-catalysed intermolecular 
reductive aldol couplings using organosilanes as the source of hydride have also been 
reported previously. 
 
In 2006, Shibasaki and co-workers made initial attempts to reductively couple α,β-
unsaturated esters with ketones using a chiral bisphosphine-ligated CuH species (Scheme 
2.23).
175
 Initially, methyl acrylate 156a was reacted with a ketone possessing a prochiral 
carbonyl carbon such as acetophenone. Since high diastereo- and enantioselectivity was 
not observed (product 157a), asymmetric induction was solely examined at the α–
position using symmetrical ketones (products 157b-157d). However, only modest 
enantioselectivites were observed. The use of cyclic ketones afforded the coupled product 
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157d with diminished enantioselectivity. Nevertheless, the report successfully 




Scheme 2.23: Enantioselective Intermolecular Cu-Catalysed Reductive Aldol Coupling of 
Enoates with Ketones 
 
Soon after, the same group also reported the reductive coupling of allenic esters to 
ketones (Scheme 2.24A and 2.24B).
176
 The dramatic effect of the ligand was noted in this 
study whereby γ-cis- or α-selective products were formed depending on the ligand. In the 
presence of CuOAc (2.5 mol%), (R)-DTBM-Segphos (5 mol%), PCy3 (5 mol%) and 
pinacolborane (1.6 equiv.) in THF allenic esters 158a-158d reacted with various ketones 




Scheme 2.24A: γ-cis-Selective Cu-Catalysed Reductive Coupling of Allenic Esters with Ketones 
 
Interestingly, changing the reaction conditions to CuF(PPh3)3·2EtOH (2.5 mol%), 
Taniaphos ligand (5 mol%) and pinacolborane (1.6 equiv.) in THF led to the selective 
production of the α-products 161a-161d in modest to high enantioselectivity (Scheme 
2.24B). Although the product constitution (α- or γ-aldol) could be switched depending on 
the structure of the chiral bisphosphine ligand, no explanation of the reaction mechanism 





Scheme 2.24B: α-Selective Cu-Catalysed Reductive Coupling of Allenic Esters with Ketones 
 
The existence of a terminal olefin in products 161a-161d allowed further conversion to 
various α-substituted aldol products using a cross-metathesis reaction. For example, 161a 
was converted to 162 containing a longer alkyl chain at the α-position without 
epimerisation (Scheme 2.25). 
 
 
Scheme 2.25: Typical Conversion of α-Vinyl Aldol Product 
 
 74 
In the same year, Riant and co-workers also reported the reductive aldol coupling of α,β-
unsaturated esters with various aldehydes using sub-stoichiometric quantities of an 
achiral NHC-ligated copper catalyst (Scheme 2.26).
177
 The main drawback of (NHC)CuX 
complexes is the mandatory use of an activator such as NaOt-Bu. This permits a halide–
alkoxide exchange on the copper atom, which in turn can react with the hydrosilane to 
generate the copper–hydride active species. To avoid the use of an activator, air-stable 
(IMes)Cu(dibenzoylmethanoate) complex was synthesised and then used to catalyse 
reductive aldol reactions. The choice of the co-ligand on the metal center was made on 
the assumption that a weak Cu–O bond would allow direct activation of the complex to 
generate the desired copper–hydride catalyst. The diastereoselectivities observed were 
modest, but the chemoselective nature of the reaction was remarkable. 
 
 
Scheme 2.26: Intermolecular NHC-Ligated Cu-Catalysed Reductive Aldol Coupling of Enoates 
with Aldehydes 
 
The use of other functional groups such as a ketone (substrate 165) and a nitrile (substrate 
167) for activating the adjacent alkene toward CuH-catalysed reductive couplings 




Equation 2.5: Cu-Catalysed Reductive Coupling of Enones or Cyanoalkenes with Aldehydes 
 
Riant and co-workers also reported the enantioselective CuH-catalysed reductive 
coupling of α,β-unsaturated esters with various aldehydes by employing a chiral 
bisphosphine ligand (Scheme 2.27).
178-179
 Poor diastereoselectivity and modest 
enantioselectivities were observed. However, given the high reactivity of aldehydes 
toward CuH-catalysed 1,2-reduction, the ability to selectively reduce the α,β-unsaturated 
ester and then couple it with an aldehyde is appreciable. Oddly, the paper did not report 




Scheme 2.27: Cu-Catalysed Reductive Coupling of Enoates with Aldehydes 
 
The reductive aldol reactions previously described by Riant did not provide the coupled 
products in high diastero- and enantioselection. This was overcome in their subsequent 
publication, which reported the CuH-catalysed reductive coupling of α,β-unsaturated 






Scheme 2.28: Cu-Catalysed Reductive Coupling of Enoates with Ketones 
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Shibasaki and co-workers have also demonstrated the use of CuH catalysis in reductive 
Mannich-type reactions, thereby showing that the scope of the electrophile is not limited 
to aldehydes and ketones (Scheme 2.29).
182
 A high catalyst loading of 10 mol% and the 
addition of 2.8 equiv. of (EtO)3SiH were needed for this process. Diastero- and 
enantioselectivities were high in most cases (products 174a-174d). 
 
 
Scheme 2.29: Enantioselective Intermolecular Cu-Catalysed Reductive Mannich Reaction of 
Enoates with Ketimines 
 
The synthetic utility of the process was also demonstrated by the conversion of the 
reductive Mannich product 174c into enantioenriched β-amino acid derivative 175 in 
high yield without any epimerisation through cleavage of the diphenylphosphinoyl group 




Equation 2.6: Conversion to β-Amino Acid Derivative 
 
Examples of CuH-catalysed tandem processes, specifically those involving the 1,4-
reduction of polarised alkenes and their subsequent trapping with an electrophile, are 
present in literature and have been discussed so far. Our group set about to extend this 
methodology to include other important, yet underexploited electron-withdrawing groups 
on the acceptor. Drawing from past knowledge that azaarenes containing a suitably 
position C=N moiety could active adjacent alkenes toward CuH-catalysed conjugate 
reductions,
102
 we questioned whether the intermediate organocopper species formed 
could be trapped by an electrophile such as an aldehyde or a ketone to afford the 
reductively coupled product (Equation 2.7). 
 
To the best of our knowledge, the only report of catalytic reductive coupling of 
alkenylazaarenes has appeared from Krische’s group, who described a racemic rhodium-
catalysed hydrogenative coupling
153, 183-187






Scheme 2.30: Reductive Coupling of Vinylazines with Imines via Rh-Catalysed Hydrogenation 
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The ability to couple vinylazines with imines using molecular hydrogen delivered at 1 
atmospheric pressure at room temperature is remarkable. The addition of Na2SO4 was 
found to suppress imine hydrolysis. Whereas the parent 2-vinylpyridine did not 
participate in the coupling, presumably due to strong coordination at nitrogen, 6-
substituted-2-vinyl pyridines 176a-176c coupled efficiently to (hetero)aromatic and 
aliphatic imines. Products 177a-177c were obtained in good diastereoselectivity. 
However, the use of rhodium, which is an expensive metal, and the generation of 
optically inactive products were some of the limitations encountered in their report, 
which our group hoped to address. 
 
2. Results and Discussion 
 
Work in our group thus began in order to examine whether 2-alkenylazaarenes could be 
reductively coupled with ketones in an asymmetric fashion by employing a cheap metal 
such as copper (Equation 2.7). 
 
 
Equation 2.7: Cu-Catalysed Reductive Coupling of 2-Alkenylazaarenes with Ketones 
 
Prior to testing our theory, synthesis of the appropriate substrates was needed and is 
presented below. All work was done with the help of Bonnie Choi, who is a current 







2.1. Preparation of 2-Alkenylazaarenes 
 
Various 2-vinylazaarenes, β-substituted and β,β-disubstituted 2-alkenylazaarenes were 




Scheme 2.31: Strategy for the Synthesis of Alkenylazaarenes 
 
Despite being commercially available, potassium vinyltrifluoroborate 179 was 
conveniently prepared in our lab through addition of vinyl magnesium bromide 186 to 






Equation 2.8: Preparation of Potassium Vinyltrifluoroborate 
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Next, following standard Suzuki-Miyauara reaction conditions various azaaryl halides 
178 were coupled with potassium vinyltrifluoroborate 179 in the presence of a palladium 
catalyst and base (Scheme 2.32A). The 2-vinylazaarenes were obtained in high yields 




Reaction was conducted using azaaryl chloride 178. 
b 
Reaction was conducted using azaaryl bromide 178. 
c 
Reagent was purchased from commercial sources. 
Scheme 2.32A: Synthesis of 2-Vinylazaarenes 
 
Azaaryl halides 178l and 178m failed to couple with potassium vinyltrifluoroborate 




Scheme 2.32B: Synthesis of 2-Vinylazaarenes 
 
Similarly, 2-vinylarenes containing electron-withdrawing substituents were also prepared 
(Scheme 2.33). Drawing from our previous study on rhodium-catalysed conjugate 
arylations (Chapter 1), we hoped that arenes containing electron-withdrawing substituents 
may activate the adjacent alkene, thereby allowing such substrates to participate in 
transition metal-catalysed reductive aldol couplings. 
 
 
Scheme 2.33: Synthesis of 2-Vinylarenes 
 
For the preparation of β-substituted 2-alkenylazaarenes, the reaction of benzoin with 
crotonic acid 191 in the presence of DMAP and DCC afforded intermediate 192, which 
upon treatment with ammonium acetate in glacial acetic acid provided the desired 2-
alkenyloxazole 183a (Scheme 2.34). Product 183a was synthesised by Iain Roy, who is a 




Scheme 2.34: Synthesis of β-Substituted 2-Alkenyloxazole 
 
Other β-substituted 2-alkenylazaarenes were prepared by coupling alkenylboronic acid 
pinacol esters, prepared from our previous study (Chapter 1), with azaaryl halides 




Reaction was conducted using azaaryl chloride 178. 
b 
Reaction was conducted using azaaryl bromide 178. 
Scheme 2.35: Synthesis of β-Substituted 2-Alkenylazaarenes by Suzuki-Miyaura Coupling 
 
Lastly, two β,β-disubstituted 2-alkenylazaarenes were also synthesised. This was 
achieved by a cross-aldol condensation reaction of picolinaldehyde 184 with 3-
phenylpropanal to produce enal 185. Reduction of the aldehyde in compound 185 to the 
corresponding alcohol 186 and subsequent protection of the alcohol afforded the desired 




Scheme 2.36: Synthesis of β,β-Disubstituted 2-Alkenylazaarenes 
 
With the 2-alkenylazaarenes in hand, we began to investigate the possibility of our 
substrates undergoing CuH-catalysed reductive aldol couplings with ketones. 
 
2.2. Enantioselective Copper-Catalysed Reductive Coupling of 
Alkenylazaarenes with Ketones 
 
This study began with examination of the enantioselective reductive coupling of 2-
vinylquinoline 180a with commercially available acetophenone (1.1 equiv.) using PhSiH3 
(1.2 equiv.) as the hydride source, 5 mol% Cu(OAc)2·H2O and 5 mol% of various chiral 













1 L8 11:1 1:1 43/50 
2 L9 13:1 1:1 67/67 
3
 
L10 24:1 1:1 27/17 
4 L11 17:1 1:1 −60/−92 
5 L12 12:1 1:1 92/93 
6 L13 7:1 5:1 93/60 
a 




H NMR analysis of the unpurified 
reaction mixtures. 
c 
Determined by chiral HPLC analysis. 
Table 2.1: Evaluation of Chiral Bisphosphines 
 
Apart from high diastero- and enantioselection, good chemoselectivity (ratio of 
193a:194a) was also our goal. Pleasingly, proof of concept was quickly established, and 
all ligands evaluated led to complete consumption of 180a to provide the coupling 
product 193a as a mixture of diastereomers, along with traces of the simple reduction 
product 194a. Enantioselectivities were modest using ligands L8-L10 (entries 1-3), but 
high using (R,R)-Quinox-P* (L11) (entry 4), the Josiphos ligand L12 (entry 5), and the 
Taniaphos ligand L13 (entry 6). However, no diastereoselectivity was observed in most 
cases, with the notable exception being the reaction using L13 which provided 193a in 
5:1 dr and 93% ee for the major isomer while also displaying good chemoselectivity 
(entry 6). Accordingly, L13 was selected for further experimentation. 
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PhSiH3 was chosen as the stoichiometric source of hydride in our study. Using TMDS, 
PMHS, and Ph2MeSiH displayed comparable enantioinduction; however, slower reaction 
rates were observed with these hydrosilanes. In most cases significant quantities of the 
starting 2-vinylquinoline 180a was also recovered. The use of (EtO)3SiH led to 
decomposition of the starting material. 
 
With respect to the solvent; acetone, CH2Cl2, THF, Et2O and dioxane afforded product 
193a in diminished diastereoselectivity as compared to the 5:1 dr observed with the use 
of toluene. The use of a 1:1 mixture of THF in toluene did not improve 





 Reactions were conducted using 0.30-0.40 mmol of 180.
 
Cited yields are of pure isolated major 
diastereomers. Diastereomeric ratios were determined by 
1
H NMR analysis of the unpurified reaction 
mixtures. Enantiomeric excesses were determined by chiral HPLC analysis. 
Scheme 2.37A: Reductive Aldol Coupling of Vinylazaarenes with Acyclic Ketones 
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Next, the scope of our reaction was tested by subjecting our previously prepared 2-
alkenylazaarenes to the optimised conditions. Results of reductive coupling of various 2-
vinylazaarenes with a range of acyclic ketones are presented in Scheme 2.37A. Effective 
substrates included azines such as quinolone (products 193a and 193b), pyridine (product 
193c) and isoquinoline (products 193d-193g). With acyclic ketones, the 
diastereoselectivity of the reaction appears to be dependent on the steric properties of the 
azaarene, with diastereoselectivity increasing from pyridine to quinoline to isoquinoline 
(compare diastereomeric ratios for products 193c, 193a, and 193d). In the coupling of 2-
vinylpyridine with acetophenone, the two diastereomeric products 193ca and 193cb were 
isolated with high enantioselectivities (>99% and 92% ee, respectively). Regarding the 
electrophile, the process is tolerant of acyclic ketones containing various alkyl, aryl, or 
heteroaryl substituents (products 193a-193g). Ketones containing electron-withdrawing 
(193e) or electron-donating (193f) substituents on the aryl ring also readily coupled with 
vinylazaarenes under our reaction conditions. 
 
Azole-containing substrates 180g and 180h decomposed into a mixture of unidentifiable 
products under our reductive coupling conditions, as shown in Scheme 2.37B. 
 
 
Scheme 2.37B: Reductive Aldol Coupling of Vinylazaarenes with Acyclic Ketones 
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While 2-vinylazaarenes coupled smoothly with various acyclic ketones, 2-vinylquinoline 
180a failed to react with benzaldehyde (Equation 2.9). This was attributed to the 
preferential reduction of benzaldehyde to benzyl alcohol. 
 
 
Equation 2.9: Reductive Coupling of 2-Vinylquinoline with Benzaldehyde 
 
Interestingly, while substrate 180j failed to couple with acetophenone leading to the 
generation of a mixture of unidentifiable products (Equation 2.10A), the analogous 
substrate 180k did undergo an intermolecular reductive coupling with acetophenone 
followed by partial intramolecular cyclisation of 193h to form 195 (Equation 2.10B). 
Unfortunately, a 1:1 mixture of 193h to 195 was confirmed by 
1
H NMR spectroscopy. 
Running the reaction at an elevated temperature of 50 °C in the hope of biasing it toward 
the formation of a single product (either 193h or 195) proved to be unsuccessful and the 
reaction was eventually abandoned. 
 
 
Equation 2.10: Reductive Aldol Coupling of 3-Substituted Vinylazaarenes with Acetophenone 
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Apart from acyclic ketones, 5- and 6-membered cyclic ketones served as effective 
coupling partners for our reductive aldol process (Scheme 2.38), as exemplified by the 
successful use of two indanones (products 193i and 192j), 4-chromanone (product 193k), 
4-thiochromanone (product 193l), and tetralone (product 193m). These results also 
broadened the scope of the azaarene to include two isomeric forms of pyrimidine 





 Reactions were conducted using 0.30-0.40 mmol of 180.
 
Cited yields are of pure isolated major 
diastereomers. Diastereomeric ratios were determined by 
1
H NMR analysis of the unpurified reaction 
mixtures. Enantiomeric excesses were determined by chiral HPLC analysis. 
Scheme 2.38: Reductive Aldol Coupling of Vinylazaarenes with Cyclic Ketones 
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Although L13 provided the best results for products 193i and 193j, this ligand resulted in 
a low yield in the attempted synthesis of 193k, and poor diastereo- and 
enantioselectivities in the attempted syntheses of 193l and 193m. In these cases, (R,R)-
Quinox-P* (L11) was superior for 193k and 193l, and the Josiphos ligand L12 was 
optimal for 193m. 
 
The process was not limited to vinylazaarenes; β-substituted alkenylazaarenes were also 
effective coupling partners (Scheme 2.39). For example, alkenylazaarenes 183a-183c 
containing methyl, allylic ether, or phenethyl groups smoothly underwent reductive 
coupling to deliver products 196a-196c in high diastero- and enantioselectivities. 
Furthermore, these products contain additional examples of azaarenes such as a 





 Reactions were conducted using 0.30 mmol of 183. Cited yields are of pure isolated major diastereomers. 
Diastereomeric ratios were determined by 
1
H NMR analysis of the unpurified reaction mixtures. 
Enantiomeric excesses were determined by chiral HPLC analysis. 
Scheme 2.39: Reductive Aldol Coupling of β-Substituted 2-Alkenylazaarenes with Ketones 
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β,β-Disubstituted 2-alkenylazaarenes were also tested with the aim of generating three 
contiguous stereocenters through an intermolecular enantioselective CuH-catalysed 
reductive coupling. First, substrate 187a was reacted with acetophenone under our 
developed methodology (Equation 2.11). However, no coupled product was observed.  
The high steric congestion at the β-site may explain the failure of substrate 187a to 
reductively couple with acetophenone. 
 
 
Equation 2.11: Reductive Coupling of 187a with Acetophenone 
 
Interestingly, when substrate 187b was reacted with acetophenone under the same 
conditions, significant quantities of the reductive aldol cyclisation product 198 was 
observed without any evidence of the intermolecular reductive coupling product 197 
being formed (Equation 2.12A). 
 
 
Equation 2.12: Reductive Aldol Cyclisation of 187b 
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The formation of 198 shown in Equation 2.12A highlights the preference of substrate 
187b to undergo an entropically-favoured reductive cylisation with a tethered ester group 
instead of reductively coupling with the more electrophilic ketone. Conducting the 
reaction in the absence of acetophenone afforded the hemiketal 198 as the sole product, 
which was isolated in a moderate 50% yield (Equation 2.12B). The reaction to generate 
rac-198 by employing a variety of achiral ligands failed. Therefore, the ee of product 198 
could not be determined. 
 
Finally, the relative and absolute stereochemistries of products 193a, 193b, 193d, 193e, 
193k and 196c were determined by single crystal X-ray crystallography using a copper 
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Figure 2.5A: Stereochemical Determination of Reductive Aldol Products 
 
The stereochemistry of 193f and 193g were assigned by analogy with 193d and 193e (all 




Figure 2.5B: Stereochemical Determination of Reductive Aldol Products 
 
The stereochemistry of 193i, 193j, 196a, and 196b were assigned by analogy with 196c 
(all obtained using ligand L13) as illustrated in Figure 2.5C. 
 
 
Figure 2.5C: Stereochemical Determination of Reductive Aldol Products 
 
The stereochemistry of 193l was assigned by analogy with 193k (both obtained using 
ligand L11) as illustrated in Figure 2.5D. 
 
 
Figure 2.5D: Stereochemical Determination of Reductive Aldol Products 
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The stereochemistry of 193m (obtained using ligand L12) was assigned by analogy with 
the product obtained using ligand L13, which was the same enantiomer of 193m but in 
2:1 dr and 73% ee (Figure 2.5E). 
 
 
Figure 2.5E: Stereochemical Determination of Reductive Aldol Products 
 
Interestingly, the absolute stereochemistries of isoquinoline-containing products 193d-
193g are opposite to those of quinoline-containing products 193a and 193b, even though 
the same enantiomer of ligand L13 was employed throughout. In addition, the 
diastereochemical outcomes of the reactions producing 193i-193m are different from 
those resulting in 193a, 193b, and 193d-193g. Assuming that the reactions proceed via 
Zimmerman−Traxler-type transition states where the larger aryl group of the ketone 
occupies a pseudoequatorial position,
191
 Figure 2.6 depicts conformations that are 
consistent with these observations. 
 
 
Figure 2.6: Rationalisation of Stereochemical Outcomes 
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The stereochemical outcomes of the reactions producing 193a, 193b, and 193d-193g are 
consistent with the participation of Z-azaallylcopper species (TS 1 and TS 2), though the 
reasons for the opposite sense of enantioinduction in TS 2 compared with TS 1 are not 
clear at this time. Furthermore, while the preference for the Z-azaallylcopper species in 
TS 2 is readily explained by the severe A1,3-strain
192
 that would disfavour the 
corresponding E-azaallylcopper species, a similar argument cannot be used to explain the 
same preference in TS 1. For reactions producing 193i-193m, reaction through the E-
azaallylcopper species (or Z-azaallylcopper species in the case of 193k) appears to be 
favoured, as in TS 3 for the formation of 193j. The interplay between the steric and/or 
electronic properties of the alkenylazaarene and ligand, and the resulting effect on the 
stereochemical outcome, are clearly complex. In addition, while the preceding discussion 
has been based upon the assumption that chair-like transition states are operative, 
reaction through boat-like structures cannot be excluded. 
 
Pyridine isomers 3- and 4-vinylpyridine (substrates 199 and 200, respectively) failed to 
undergo similar reductive coupling reactions (Equation 2.13). These observations suggest 
that coordination of copper to the nitrogen atom on the azaarene is necessary for the 




Equation 2.13: Reductive Aldol Coupling of 3- and 4-Vinylpyridine 
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Potential application of our methodology toward the synthesis of various natural products 
and pharmaceutical drugs was also surveyed. Preliminary examination prompted 
Voriconazole as an ideal target candidate. Voriconazole is a triazole antifungal 
medication that is generally used to treat serious, invasive fungal infections. The drug is 
marketed by Pfizer. 
 
 
Scheme 2.40: Retrosynthetic Analysis of Voriconazole 
 
Retrosynthetic analysis revealed a short 2-step sequence toward the enantioselective 
synthesis of Voriconazole (Scheme 2.40). For a quick test of concept, CuH-catalysed 
reductive coupling of 2-vinylquinoline 180a with commercially available ketone 202 was 
attempted (Equation 2.14). Sadly, none of the coupled product was observed. We believe 
that the nitrogen atoms on the triazole ring of the ketone may be poisoning the system by 
strongly binding to the copper catalyst. Further experimentation is needed to address this 





Equation 2.14: Synthesis of Voriconazole Analog 
 
After the completion of this study, we questioned if arenes containing electron-
withdrawing substituents could activate an adjacent alkene toward reductive coupling 
chemisty (Scheme 2.41). Unfortunately, substrates 190a-190c failed to deliver our 








In summary, we have described the first examples of catalytic enantioselective reductive 
couplings of alkenylazaarenes (Scheme 2.42).
193
 The scope of this process is broad, with 
eleven different types of azaarenes and a range of acyclic and cyclic ketones having been 
shown to be effective coupling partners. β-Substitution on the alkene is tolerated, and the 
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reactions proceed under mild conditions to deliver products in good to high levels of 
diastereo- and enantioselection. 
 
 
Scheme 2.42: Reductive Aldol Coupling of Alkenylazaarenes with Ketones 
 
Failure of 3- and 4-vinylpyridine to react with a ketone under our developed set of 
conditions revealed essential structural requirements of our alkenylazaarene substrates 
necessary for the production of reductively coupled products. 
 
Finally, the synthesis of Voriconazole, an antifungal drug, was attempted. Despite its 
failure, we believe our developed methodology should be advantageous for its application 
in the preparation of other novel enantioenriched chiral azaarene-containing building 
blocks. 
 
4. Future Work 
 
The enantioselective CuH-catalysed reductive aldol coupling chemistry studied in our 
group opens two obvious avenues for further exploration: 
 
(a) Changing the nucleophile, resulting in the initial formation of a carbon–carbon or a 
carbon–heteroatom bond (Scheme 2.43B and 2.43C, respectively) instead of a 
carbon–hydrogen bond (Scheme 2.43A). The ability to initiate the reaction through 
the generation of a carbon–carbon or a carbon–boron bond would make the process 






Scheme 2.43: Domino Conjugate Addition/Aldol Coupling of Alkenylazaarenes 
 
(b) Changing the electrophile, resulting in the trapping of the organocopper intermediate 





Scheme 2.44: Domino Conjugate Addition/Mannich Reaction or Conjugate Addition/Allylic 
Substitution Reaction of Alkenylazaarenes 
 
After the successful completion of our reductive aldol chemistry where alkenylazaarenes 
were coupled with ketones, efforts were directed toward a similar reductive Mannich-
type coupling of alkenylazaarenes with imines (Scheme 2.44B). Proof of concept has 
been established through the enantioselective coupling of 2-vinyquinoline 180a with 
imine 204, affording our Mannich-type product 205 with high diastero- and 




Equation 2.15: CuH-Catalysed Reductive Mannich-Type Coupling of 2-Vinylquinoline with an 
Imine 
 
Due to this project being in its early stages of development, product 205 has not yet been 
isolated and fully characterised. The scope of this process is under investigation by 









CH2Cl2, MeCN, and THF were dried and purified by passage through activated alumina 
columns using a solvent purification system from 
http://www.glasscontoursolventsystems.com. All commercially available reagents were 
used as received. Thin layer chromatography (TLC) was performed on Merck DF-
Alufoilien 60F254 0.2 mm precoated plates. Product spots were visualized by UV light at 
254 nm, and subsequently developed using potassium permanganate or ceric ammonium 
molybdate solution as appropriate. Flash column chromatography was carried out using 
silica gel (Fisher Scientific 60Å particle size 35-70 micron) employing the method of 
Still and co-workers.
194
 Melting points were recorded on a Gallenkamp melting point 
apparatus and are uncorrected. Infra-red spectra were recorded on a Jasco FT/IR-460 Plus 
instrument as a thin film on sodium chloride plates or as a dilute solution in CHCl3. 
1
H 
NMR spectra were recorded on a Bruker AVA500 (500 MHz), a Bruker AVA400 (400 
MHz), or a Bruker DPX360 (360 MHz) spectrometer. Chemical shifts () are quoted in 
parts per million (ppm) downfield of tetramethylsilane, using residual protonated solvent 
as internal standard (CDCl3 at 7.27 ppm). Abbreviations used in the description of 
resonances are: s (singlet), d (doublet), t (triplet), q, (quartet), app (apparent), br (broad), 




NMR spectra were recorded on a Bruker AVA500 (125.8 MHz) spectrometer, a 
Bruker AVA400 (100.6 MHz), or a Bruker ARX250 (62.9 MHz) spectrometer. Chemical 
shifts () are quoted in parts per million (ppm) downfield of tetramethylsilane, using 
deuterated solvent as internal standard (CDCl3 at 77.0 ppm). Assignments were made 
using the DEPT sequence with secondary pulses at 90° and 135°. 
19
F NMR spectra were 
recorded on a Bruker AVA400 (376 MHz) spectrometer. Chemical shifts () are quoted 
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in parts per million (ppm) downfield of CFCl3 ( = 0 ppm), using fluorobenzene as 
internal standard (C6H5F at –113.5 ppm). High resolution mass spectra were recorded 
using electrospray ionization (ES), electron impact (EI), or atmospheric solids analysis 
probe (ASAP) techniques on a Finnigan MAT 900 XLT spectrometer, a Finnigan MAT 
95XP spectrometer, or a Thermofisher LTQ Orbitrap XL spectrometer at the EPSRC 
National Mass Spectrometry Service Centre, University of Wales, Swansea. Optical 
rotations were performed on an Optical Activity POLAAR 20 polarimeter. Chiral HPLC 
analysis was performed on an Agilent 1100 instrument using 4.6 x 250 mm columns. 
Authentic racemic samples of products for chiral HPLC assay determinations were 
obtained using [Rh(cod)Cl]2 (2.5 mol %) as an achiral precatalyst, using thermal heating. 
Reactions using microwave heating were carried out in a Biotage microwave synthesizer. 
 

























To a solution of carboxylic acid L15
43, 93
 (83 mg, 0.40 mmol), HBTU (167 mg, 0.44 
mmol), and Et3N (70 µL, 0.44 mmol) in MeCN (8 mL) at room temperature was added 
cyclohexylamine (55 µL, 0.48 mmol) in one portion, and the reaction was stirred at room 
temperature for 1 h. The reaction was diluted with brine (8 mL) and the mixture was 
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extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with 2 M 
HCl (30 mL), saturated aqueous NaHCO3 solution (30 mL), and brine (30 mL), and then 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (10% EtOAc/hexane) gave the amide L2 (95 mg, 83%) as a colorless 
solid. m.p. 32-34 °C; [α] 20
D
+23.5 (c 1.10, CHCl3); IR (film) 3312 (NH), 2930, 1628 




H NMR (500 MHz, CDCl3)  6.76 (1H, dd, J  
= 6.2, 1.8 Hz, =CH), 5.81 (1H, d, J = 6.0 Hz, =CH), 5.51 (1H, br d, J = 7.2 Hz, NH), 4.02 
(1H, dt, J = 6.0, 1.9 Hz, =CHCH), 3.86-3.76 (1H, m, NCH), 3.35-3.29 (1H, m, =CHCH), 
1.99-1.89 (2H, m), 1.82 (3H, d, J = 1.6 Hz, =CCH3), 1.75-1.66 (2H, m), 1.64-1.55 (2H, 
m), 1.42-1.34 (2H, m), 1.32-1.03 (5H, m), 1.00 (3H, d, J = 6.4 Hz, CH(CH3)2), 0.95 (1H, 
ddd, J = 11.5, 4.8, 2.4 Hz, CH), 0.82 (3H, d, J = 6.4 Hz, CH(CH3)2); 
13
C NMR 
(125.8 MHz, CDCl3)  165.1 (C), 145.3 (C), 143.9 (C), 137.1 (CH), 124.2 (CH), 48.0 
(CH), 47.8 (CH), 43.5 (CH), 40.0 (CH), 33.8 (CH), 33.3 (CH2), 33.2 (CH2), 31.8 (CH2), 
25.6 (CH2), 24.9 (CH2), 24.9 (CH2), 21.8 (CH3), 21.3 (CH3), 19.0 (CH3); HRMS (ES) 
Exact mass calculated for C19H30N1O1 [M+H]
+





To a solution of carboxylic acid L15
43, 93
 (70 mg, 0.34 mmol) and DMF (6 μL, 0.68 
mmol) in CH2Cl2 (0.6 mL) at 0 °C was added oxalyl chloride (32 μL, 0.37 mmol) 
dropwise over 1 min. The mixture was stirred at 0 °C for 1.5 h (until no more 
effervescence was observed) to give a solution of the corresponding acid chloride. To a 
separate mixture of diisopropylamine (50 μL, 0.35 mmol) in CH2Cl2 (1 mL) and 
saturated aqueous Na2CO3 solution (1 mL) at 0 °C was added the solution of the acid 
chloride dropwise via cannula. The mixture was then stirred at room temperature for 20 
h. The mixture was partitioned between saturated aqueous NaHCO3 solution (4 mL) and 
CH2Cl2 (4 mL). The aqueous layer was separated and extracted with CH2Cl2 (3 x 4 mL). 
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The combined organic layers were washed with 10% HCl solution (5 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (1% EtOAc/hexane→8% EtOAc/hexane) gave the diisopropyl amide L4 
(57 mg, 58%) as a colorless oil. [α] 20
D
 +28.6 (c 0.41, CHCl3); IR (film) 2963, 2870, 1609 




H NMR (360 MHz, CDCl3)  6.20 
(1H, dd, J = 6.1, 1.6 Hz, =CH), 5.77 (1H, d, J = 5.8 Hz, =CH), 3.73 (2H, br s, 2 x NCH) 
3.58 (1H, dt, J = 5.7, 1.8 Hz, =CHCH), 3.25 (1H, app dd, J = 5.8, 2.3 Hz, =CHCH), 1.80 
(3H, d, J = 1.6 Hz, =CCH3), 1.62 (1H, ddd, J = 11.6, 8.9, 2.9 Hz, CH), 1.50-1.32 (12H, 
m, 4 x CH3), 1.27-1.11 (2H, m, CH2), 0.94 (3H, d, J = 6.3 Hz, CH3), 0.89 (1H, ddd, J = 
11.6, 8.9, 2.9 Hz, CH), 0.79 (3H, d, J = 6.3 Hz, CH3); 
13
C NMR (62.9 MHz, CDCl3)  
170.7 (C), 146.1 (C), 144.3 (C), 131.2 (CH), 123.5 (CH), 48.1 (CH), 43.1 (CH), 42.7 
(CH), 34.0 (CH), 32.1 (CH2), 21.7 (CH3), 21.3 (CH3), 20.9 (2 x CH3), 20.8 (2 x CH3), 
19.1 (CH3) (2 x CH next to nitrogen were not observed); HRMS (ES) Exact mass calcd 
for C19H32N1O1 [M+H]
+





To a solution of carboxylic acid L15
43, 93
 (500 mg, 2.42 mmol) and DMF (42 μL, 0.55 
mmol) in CH2Cl2 (4.5 mL) at 0 °C was added oxalyl chloride (230 μL, 2.67 mmol) 
dropwise over 2 min. The mixture was stirred at 0 °C for 1.5 h (until no more 
effervescence was observed) to give a solution of the corresponding acid chloride. To a 
separate mixture of dibenzylamine (423 μL, 2.20 mmol) in CH2Cl2 (5 mL) and saturated 
aqueous Na2CO3 solution (5 mL) at 0 °C was added the solution of the acid chloride 
dropwise via cannula over 1 min. The mixture was then stirred at room temperature for 
21 h. The mixture was partitioned between saturated aqueous NaHCO3 solution (10 mL) 
and CH2Cl2 (10 mL). The aqueous layer was separated and extracted with CH2Cl2 (3 x 10 
mL). The combined organic layers were washed with 10% HCl solution (15 mL), dried 
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(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (3% EtOAc/hexane) gave the dibenzyl amide L5 (820 mg, 97%) as a 
colorless oil. [α] 20
D
 +14.1 (c 0.72, CHCl3); IR (film) 2958, 2862, 1608 (C=O), 1542, 




H NMR (360 MHz, CDCl3)  7.37-7.29 (6H, m, 
ArH), 7.20-7.18 (4H, m, ArH), 6.50 (1H, dd, J = 6.1, 1.6 Hz, =CH), 5.77 (1H, d, J = 5.8 
Hz, =CH), 4.60-4.41 (4H, m, 2 x NCH2), 3.83 (1H, dt, J = 5.8, 1.8 Hz, =CHCH), 3.28 
(1H, app dd, J = 5.8, 2.2 Hz, =CHCH), 1.79 (3H, d, J = 1.4 Hz, =CCH3), 1.64 (1H, ddd, J 
= 11.5, 8.9, 2.9 Hz, CH), 1.46-1.40 (1H, m, CH), 1.13-1.01 (1H, m, CH2), 0.96 (3H, d, J 
= 6.4 Hz, CH3), 0.95-0.90 (1H, m, CH2), 0.82 (3H, d, J = 6.4 Hz, CH3); 
13
C NMR 
(62.9 MHz, CDCl3)  171.2 (C), 144.4 (C), 143.8 (C), 137.2 (2 x C), 135.0 (CH), 128.6 
(6 x CH), 127.3 (4 x CH), 123.5 (CH), 48.1 (CH), 43.3 (CH), 42.8 (CH), 33.9 (CH), 32.0 
(CH2), 21.7 (CH3), 21.3 (CH3), 19.1 (CH3) (2 x CH2 next to nitrogen were not observed); 
HRMS (ES) Exact mass calcd for C27H32N1O1 [M+H]
+
: 386.2478, found: 386.2471. 
 
(1R,4R,7R)-7-Isopropyl-5-methyl-bicyclo[2.2.2]octa-2,5-diene-2-carboxylic acid 
benzylamide (L6)  
 
To a solution of carboxylic acid L15
43, 93
 (83 mg, 0.40 mmol), HBTU (167 mg, 0.44 
mmol), and Et3N (70 µL, 0.44 mmol) in MeCN (8 mL) at room temperature was added 
benzylamine (53 µL, 0.48 mmol) in one portion, and the reaction was stirred at room 
temperature for 1 h. The reaction was diluted with brine (8 mL) and the mixture was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with 2 M 
HCl (30 mL), saturated aqueous NaHCO3 solution (30 mL), and brine (30 mL), and then 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (10% EtOAc/hexane) gave the amide L6 (81 mg, 68%) as a white solid. 
Rf = 0.40 (20% EtOAc/hexane); m.p. 112-114 °C; [α]
20
D +25.4 (c 1.10, CHCl3);
 
IR (film) 




H NMR (500 
MHz, CDCl3)  7.34-7.21 (5H, m, ArH), 6.79 (1H, dd, J  = 6.2, 1.4 Hz, =CH), 5.90 (1H, 
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br s, NH), 5.77 (1H, d, J  = 5.7 Hz, =CH), 4.51-4.41 (2H, m, NCH2), 4.07-3.99 (1H, m, 
=CHCH), 3.34-3.26 (1H, m, =CHCH), 1.78 (3H, br s, =CCH3), 1.54 (1H, ddd, J = 11.5, 
9.1, 2.8 Hz, CH), 1.30-1.17 (1H, m, CH2), 1.11-1.01 (1H, m, CH2), 0.97 (3H, d, J = 6.4 
Hz, CH(CH3)2), 0.92 (1H, ddd, J = 11.5, 5.6, 2.5 Hz, CH), 0.79 (3H, d, J = 6.4 Hz, 
CH(CH3)2); 
13
C NMR (125.8 MHz, CDCl3)  165.8 (C), 144.8 (C), 143.8 (C), 138.5 (C), 
138.0 (CH), 128.7 (2 x CH), 127.9 (2 x CH), 127.4 (CH), 124.1 (CH), 47.8 (CH), 43.6 
(CH2), 43.6 (CH), 40.0 (CH), 33.8 (CH), 31.7 (CH2), 21.8 (CH3), 21.4 (CH3), 19.0 (CH3); 
HRMS (ES) Exact mass calculated for C20H26N1O1 [M+H]
+
: 296.2009, found: 296.2012. 
 
Preparation of Alkenylboronic Esters 
 




To a mixture of 4-phenylbut-1-yne (5.62 mL, 40.0 mmol), Cp2ZrHCl (292 mg, 1.00 
mmol), and Et3N (0.56 mL, 4.00 mmol) at room temperature was added pinacolborane 
(5.80 mL, 40.0 mmol) over 2 min, and the mixture was stirred for 16 h. The reaction was 
quenched carefully with H2O (75 mL) and after effervescence had ceased, the mixture 
was extracted with Et2O (2 x 100 mL). The combined organic extracts were dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the alkenylboronic ester 85a (7.86 g, 76%) as 








To a mixture of 1-hexyne (4.60 mL, 40.0 mmol), Cp2ZrHCl (292 mg, 1.00 mmol), and 
Et3N (0.56 mL, 4.00 mmol) at room temperature was added pinacolborane (5.80 mL, 
40.0 mmol) over 2 min, and the mixture was stirred for 16 h. The reaction was quenched 
carefully with H2O (75 mL) and after effervescence had ceased, the mixture was 
extracted with Et2O (2 x 100 mL). The combined organic extracts were dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the alkenylboronic ester 85b (6.75 g, 80%) as 








To a mixture of alkyne 206 (5.95 mL, 30.0 mmol), Cp2ZrHCl (219 mg, 0.75 mmol), and 
Et3N (0.42 mL, 3.00 mmol) at room temperature was added pinacolborane (4.35 mL, 
30.0 mmol) over 2 min, and the mixture was stirred for 16 h. The reaction was quenched 
carefully with H2O (75 mL) and after effervescence had ceased, the mixture was 
extracted with Et2O (2 x 100 mL). The combined organic extracts were dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the alkenylboronic ester 85c (8.01 g, 82%) as 








To a mixture of ethynyl(trimethyl)silane (2.83 mL, 20.0 mmol), Cp2ZrHCl (146 mg, 0.50 
mmol), and Et3N (0.28 mL, 2.00 mmol) at room temperature was added pinacolborane 
(2.90 mL, 20.0 mmol) over 2 min, and the mixture was stirred for 16 h. The reaction was 
quenched carefully with H2O (30 mL) and after effervescence had ceased, the mixture 
was extracted with Et2O (2 x 50 mL). The combined organic extracts were dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (30% CH2Cl2/hexane) gave the alkenylboronic ester 85d (716 mg, 16%) 





Preparation of Alkenylarenes 
 




A solution of 1-iodo-4-nitrobenzene (1.49 g, 6.00 mmol), alkenylboronic ester 85a
195
 
(1.70 g, 6.60 mmol), Pd(OAc)2 (67 mg, 0.30 mmol), PPh3 (315 mg, 1.20 mmol), and 
NaOH (720 mg, 18.0 mmol) in THF (60 mL) was heated to reflux for 16 h. The mixture 
was cooled to room temperature, and partitioned between Et2O (100 mL) and H2O (50 
mL). The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (80 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82a 
(1.11 g, 73%) as a yellow solid. m.p. 68-70 C; IR (film) 3028, 2937, 1595, 1514 (N-O), 
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H NMR (500 MHz, CDCl3) δ 8.18 (2H, d, J 
= 8.9 Hz, ArH), 7.46 (2H, d, J = 8.9 Hz, ArH), 7.41-7.35 (2H, m, ArH), 7.32-7.26 (3H, 
m, ArH), 6.53-6.49 (2H, m, CH=CH), 2.93-2.86 (2H, m, CH2Ph), 2.70-2.61 (2H, m, 
=CHCH2); 
13
C NMR (125.8 MHz, CDCl3)  146.3 (C), 144.0 (C), 141.0 (C), 135.1 (CH), 
128.5 (CH), 128.30 (2 x CH), 128.27 (2 x CH), 126.2 (2 x CH), 125.9 (CH), 123.7 (2 x 
CH), 35.2 (CH2), 34.8 (CH2); HRMS (EI) Exact mass calcd for C16H15N1O2 [M]
+
: 




A solution of 4-bromobenzonitrile (910 mg, 5.00 mmol), alkenylboronic ester 85b
75
 (1.16 
g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), and NaOH 
(600 mg, 15.0 mmol) in dry THF (50 mL) was heated to reflux for 16 h. The mixture was 
cooled to room temperature, and partitioned between Et2O (100 mL) and H2O (50 mL). 
The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and the combined 
organic layers were washed with saturated aqueous NH4Cl solution (80 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82b 
(830 mg, 90%) as a pale yellow oil. IR (film) 2958, 2929, 2871, 2225 (C≡N), 1649, 1604, 




H NMR (500 MHz, CDCl3) δ 7.57 (2H, d, J = 8.3 Hz, ArH), 
7.41 (2H, d, J = 8.3 Hz, ArH), 6.41-6.36 (2H, m, CH=CH), 2.30-2.21 (2H, m, =CHCH2), 
1.52-1.33 (4H, m, CH2CH2CH3), 0.94 (3H, t, J = 7.3 Hz, CH3); 
13
C NMR (125.8 MHz, 
CDCl3)  142.4 (C), 135.6 (CH), 132.3 (2 x CH), 128.4 (CH), 126.3 (2 x CH), 119.2 (C), 
109.9 (C), 32.8 (CH2), 31.1 (CH2), 22.2 (CH2), 13.9 (CH3); HRMS (ES) Exact mass calcd 
for C17H28N1O3Si1 [M+H]
+





A solution of 1-acetyl-4-bromobenzene (796 mg, 4.00 mmol), alkenylboronic ester 85a
195
 
(1.14 g, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 (210 mg, 0.80 mmol), and 
NaOH (480 mg, 12.0 mmol) in dry THF (40 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (50 mL) and H2O 
(30 mL). The aqueous layer was separated and extracted with Et2O (2 x 40 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (50 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82c 
(946 mg, 95%) as an off-white solid. m.p. 60-62 C; IR (film) 3030, 2931, 1676 (C=O), 




H NMR (500 MHz, CDCl3) δ 7.95 (2H, d, J 
= 8.4 Hz, ArH), 7.45 (2H, d, J = 8.4 Hz, ArH), 7.42-7.34 (2H, m, ArH), 7.33-7.26 (3H, 
m, ArH), 6.56-6.41 (2H, m, ArCH=CH), 2.92-2.83 (2H, m, CH2Ph), 2.67-2.57 (5H, m, 
CH2CH2Ph and CCH3); 
13
C NMR (125.8 MHz, CDCl3)  197.1 (C), 142.1 (C), 141.2 
(C), 135.3 (C), 132.9 (CH), 129.4 (CH), 128.5 (2 x CH), 128.2 (2 x CH), 128.2 (2 x CH), 
125.8 (2 x CH), 35.3 (CH2), 34.7 (CH2), 26.3 (CH3); HRMS (APCI) Exact mass calcd for 
C18H19O1 [M+H]
+




A solution of 1-bromo-4-(methylsulfonyl)benzene (940 mg, 4.00 mmol), alkenylboronic 
ester 85b
75
 (925 mg, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 (210 mg, 0.80 
mmol), and NaOH (480 mg, 12.0 mmol) in dry THF (40 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature, and partitioned between Et2O (50 mL) 
and H2O (30 mL). The aqueous layer was separated and extracted with Et2O (2 x 40 mL) 
and the combined organic layers were washed with saturated aqueous NH4Cl solution (50 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
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column chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the 
alkenylarene 82d (887 mg, 93%) as a yellow solid. m.p. 40-42 C; IR (film) 2956, 2925, 




H NMR (500 MHz, CDCl3) δ 
7.74 (2H, d, J = 8.5 Hz, ArH), 7.38 (2H, d, J = 8.5 Hz, ArH), 6.36-6.25 (2H, m, 
CH=CH), 2.93 (2H, s, SO2CH3), 2.20-2.09 (2H, m, =CHCH2), 1.45-1.20 (4H, m, 
CH2CH2CH3), 0.83 (3H, t, J = 7.3 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  142.8 
(C), 137.9 (C), 135.2 (CH), 127.8 (CH), 127.2 (2 x CH), 126.1 (2 x CH), 44.0 (CH3), 
32.3 (CH2), 30.7 (CH2), 21.8 (CH2), 13.5 (CH3); HRMS (ES) Exact mass calcd for 
C13H19O2S1 [M+H]
+




A solution of 3,5-bis(trifluoromethyl)iodobenzene (0.89 mL, 5.00 mmol), alkenylboronic 
ester 85a
195
 (1.42 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 
mmol), and NaOH (600 mg, 15.0 mmol) in dry THF (50 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature, and partitioned between Et2O (100 mL) 
and H2O (50 mL). The aqueous layer was separated and extracted with Et2O (2 x 50 mL) 
and the combined organic layers were washed with saturated aqueous NH4Cl solution (80 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) gave the 
alkenylarene 82e (1.60 g, 93%) as a colourless oil. IR (film) 3030, 2929, 1604 (C=C), 




H NMR (500 MHz, CDCl3) δ 7.81 (2H, s, 
ArH), 7.79 (1H, s, ArH), 7.45-7.38 (2H, m, ArH), 7.35-7.28 (3H, m, ArH), 6.54-6.49 
(2H, m, CH=CH), 2.96-2.88 (2H, m, =CHCH2), 2.72-2.63 (2H, m, CH2Ph); 
13
C NMR 
(125.8 MHz, CDCl3)  141.2 (C), 139.7 (C), 134.3 (CH), 131.8 (2 x C, q, J = 33.1 Hz, 
CCF3), 128.5 (2 x CH), 128.4 (2 x CH), 128.1 (CH), 126.1 (CH), 125.8 (2 x CH, d, J = 
2.7 Hz, ArC), 123.4 (2 x C, q, J = 272.6 Hz, CF3), 120.3 (CH, td, J = 7.7, 3.8 Hz, ArC), 








A solution of 1-iodo-3-nitrobenzene (996 mg, 4.00 mmol), alkenylboronic ester 85a
195
 
(1.14 g, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 (210 mg, 0.80 mmol), and 
NaOH (480 mg, 12.0 mmol) in dry THF (40 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (50 mL) and H2O 
(30 mL). The aqueous layer was separated and extracted with Et2O (2 x 40 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (50 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82f 
(957 mg, 95%) as a dark yellow oil. IR (film) 3028, 2925, 2856, 1529 (N-O), 1350 (N-




H NMR (500 MHz, CDCl3) δ 8.19 (1H, s, ArH), 
8.10-8.02 (1H, m, ArH), 7.62 (1H, d, J = 7.7 Hz, ArH), 7.46 (1H, t, J = 7.9 Hz, ArH), 
7.33 (2H, t, J = 7.6 Hz, ArH), 7.29-7.20 (3H, m, ArH), 6.51-6.38 (2H, m, ArCH=CH), 
2.89-2.80 (2H, m, CH2CH2Ph), 2.65-2.55 (2H, m, CH2CH2Ph); 
13
C NMR (125.8 MHz, 
CDCl3)  148.6 (C), 141.2 (C), 139.4 (C), 133.4 (CH), 131.8 (CH), 129.3 (CH), 128.4 (2 
x CH), 128.4 (2 x CH), 128.3 (CH), 126.0 (CH), 121.5 (CH), 120.5 (CH), 35.5 (CH), 
34.7 (CH2); HRMS (EI) Exact mass calcd for C16H15N1O2 [M]
+





A solution of 1-iodo-2-nitrobenzene (747 mg, 3.00 mmol), alkenylboronic ester 85b
75
 
(693 mg, 3.30 mmol), Pd(OAc)2 (34 mg, 0.15 mmol), PPh3 (157 mg, 0.60 mmol), and 
NaOH (360 mg, 9.0 mmol) in dry THF (30 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (50 mL) and H2O 
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(30 mL). The aqueous layer was separated and extracted with Et2O (2 x 25 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (40 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82g 
(575 mg, 93%) as a yellow oil. IR (film) 2929, 2858, 1606, 1522 (N-O), 1466, 1346 (N-




H NMR (500 MHz, CDCl3) δ 7.84 (1H, dd, J = 8.2, 1.1 Hz, 
ArH), 7.57 (1H, dd, J = 7.9, 1.1 Hz, ArH), 7.50 (1H, t, J = 7.6 Hz, ArH), 7.35-7.28 (1H, 
m, ArH), 6.82 (1H, d, J = 15.7 Hz, ArCH=), 6.23 (1H, td, J = 15.6, 6.9 Hz, ArCH=CH), 
2.56 (2H, ddd, J = 8.3, 7.3, 1.4 Hz, =CHCH2), 1.59-1.32 (4H, m, CH2CH2CH3), 0.93 
(3H, t, J = 7.3 Hz, CH3); 
13
C NMR (125.8 MHz, CDCl3)  147.5 (C), 136.8 (CH), 133.2 
(C), 128.2 (CH), 127.2 (CH), 124.7 (CH), 124.2 (CH), 32.8 (CH2), 31.0 (CH2), 22.1 
(CH2), 13.8 (CH3); HRMS (EI) Exact mass calcd for C12H15N1O2 [M]
+





A solution of 2-iodobenzonitrile (687 mg, 3.00 mmol), alkenylboronic ester 85b
75
 (693 
mg, 3.30 mmol), Pd(OAc)2 (34 mg, 0.15 mmol), PPh3 (157 mg, 0.60 mmol), and NaOH 
(360 mg, 9.0 mmol) in dry THF (30 mL) was heated to reflux for 16 h. The mixture was 
cooled to room temperature, and partitioned between Et2O (50 mL) and H2O (30 mL). 
The aqueous layer was separated and extracted with Et2O (2 x 25 mL) and the combined 
organic layers were washed with saturated aqueous NH4Cl solution (40 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82h 
(519 mg, 93%) as a yellow oil. IR (film) 2958, 2929, 2871, 2224 (C≡N), 1649, 1597, 




H NMR (500 MHz, CDCl3) δ 7.61 (2H, t, J = 8.5 Hz, ArH), 
7.51 (1H, t, J = 7.3 Hz, ArH), 7.30-7.24 (1H, m, ArH), 6.75 (1H, d, J = 15.7 Hz, 
ArCH=), 6.45 (1H, td, J = 15.6, 7.0 Hz, ArCH=CH), 2.30 (2H, dt, J = 8.3, 1.7 Hz, 




(125.8 MHz, CDCl3)  141.2 (C), 136.9 (CH), 132.9 (CH), 132.7 (CH), 126.9 (CH), 
125.8 (CH), 125.3 (CH), 118.2 (C), 110.4 (C), 33.0 (CH2), 31.2 (CH2), 22.3 (CH2), 14.0 
(CH3); HRMS (ES) Exact mass calcd for C13H19N2 [M+NH4]
+





A solution of 2-bromo-5-nitrothiophene (832 mg, 4.00 mmol), alkenylboronic ester 
85a
195
 (1.14 g, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 (210 mg, 0.80 mmol), 
and NaOH (480 mg, 12.0 mmol) in dry THF (40 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (50 mL) and H2O 
(30 mL). The aqueous layer was separated and extracted with Et2O (2 x 40 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (50 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the alkenylarene 82i (417 mg, 40%) as a red 
solid. m.p. 64-66 C; IR (film) 3026, 2933, 1525 (N-O), 1489, 1433, 1329 (N-O), 1032, 




H NMR (500 MHz, CDCl3) δ 7.79 (1H, d, J = 4.2 Hz, ArH), 7.36-
7.29 (2H, m, ArH), 7.27-7.18 (3H, m, ArH), 6.81 (1H, d, J = 4.2 Hz, ArH), 6.47 (1H, d, J 
= 15.8 Hz, ArCH=), 6.43-6.34 (1H, m, ArCH=CH), 2.82 (2H, t, J = 7.7 Hz, CH2CH2Ph), 
2.62-2.53 (2H, m, CH2CH2Ph); 
13
C NMR (125.8 MHz, CDCl3)  150.4 (C), 140.8 (C), 
136.2 (CH), 129.4 (CH), 128.5 (2 x CH), 128.4 (2 x CH), 126.2 (CH), 123.5 (CH), 122.8 
(CH), 35.0 (CH2), 34.7 (CH2) (1 C next to sulfur was not observed); HRMS (EI) Exact 
mass calcd for C14H13N1O2S1 [M]
+





A solution of 1-iodo-4-nitrobenzene (1.25 g, 5.00 mmol), alkenylboronic ester 85b
75
 
(1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), and 
NaOH (600 mg, 15.0 mmol) in dry THF (50 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (100 mL) and 
H2O (50 mL). The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and 
the combined organic layers were washed with saturated aqueous NH4Cl solution (80 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the 
alkenylarene 82j (906 mg, 88%) as a yellow oil. IR (film) 2929, 2858, 1649, 1597, 1518 




H NMR (500 MHz, CDCl3) δ 8.08 (2H, d, 
J = 8.9 Hz, ArH), 7.38 (2H, d, J = 8.9 Hz, ArH), 6.41-6.34 (2H, m, CH=CH), 2.26-2.15 
(2H, m, =CHCH2), 1.50-1.29 (4H, m, CH2CH2CH3), 0.91 (3H, t, J = 7.3 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  146.1 (C), 144.2 (C), 136.4 (CH), 127.8 (CH), 126.0 (2 
x CH), 123.6 (2 x CH), 32.7 (CH2), 30.9 (CH2), 22.1 (CH2), 13.7 (CH3); HRMS (EI) 
Exact mass calcd for C12H15N1O2 [M]
+




A solution of 1-iodo-4-nitrobenzene (996 mg, 4.00 mmol), alkenylboronic ester 85f (854 
mg, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 (210 mg, 0.80 mmol), and NaOH 
(480 mg, 12.0 mmol) in  THF (40 mL) was heated to reflux for 16 h. The mixture was 
cooled to room temperature, and partitioned between Et2O (50 mL) and H2O (30 mL). 
The aqueous layer was separated and extracted with Et2O (2 x 40 mL) and the combined 
organic layers were washed with saturated aqueous NH4Cl solution (50 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82k 
(717 mg, 95%) as a yellow solid. m.p. 64-66 C; IR (film) 3014, 1649, 1593, 1508 (N-O), 




H NMR (400 MHz, CDCl3) δ 8.15-8.07 
(2H, m, ArH), 7.41-7.34 (2H, m, ArH), 6.50 (1H, d, J = 15.7 Hz, ArCH=), 5.90 (1H, dd, 
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J = 15.7, 9.3 Hz, ArCH=CH), 1.69-1.54 (1H, m, =CHCH), 0.98-0.83 (2H, m, CH2CH2), 
0.65-0.52 (2H, m, CH2CH2); 
13
C NMR (100.6 MHz, CDCl3)  146.0 (C), 144.2 (C), 
140.7 (CH), 125.7 (2 x CH), 125.4 (CH), 123.9 (2 x CH), 15.0 (CH), 7.9 (2 x CH2); 
HRMS (EI) Exact mass calcd for C11H11N1O2 [M]
+




A solution of 1-iodo-4-nitrobenzene (1.01 g, 5.00 mmol), alkenylboronic ester 85e (1.09 
g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), and NaOH 
(600 mg, 15.0 mmol) in  THF (50 mL) was heated to reflux for 5 h. The mixture was 
cooled to room temperature, and partitioned between Et2O (50 mL) and H2O (30 mL). 
The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and the combined 
organic layers were washed with saturated aqueous NH4Cl solution (50 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (10% EtOAc/hexane) gave the alkenylarene 82l (857 mg, 89%) as a 
cream solid. m.p. 34-36 C; IR (film) 2930, 1594, 1515, (N-O), 1341 (N-O), 1188, 1120, 




H NMR (400 MHz, CDCl3) δ 8.11-8.04 (2H, m, ArH), 7.48-
7.38 (2H, m, ArH), 6.61 (1H, d, J = 16.0 Hz, ArCH=), 6.39 (1H, dt, J = 16.0, 5.3 Hz, 
ArCH=CH), 4.07 (2H, dd, J = 5.4, 1.7 Hz, CH2OCH3), 3.36 (3H, s, OCH3); 
13
C NMR 
(100.6 MHz, CDCl3)  146.6 (C), 143.0 (C), 131.1 (CH), 129.0 (CH), 126.6 (2 x CH), 
123.6 (2 x CH), 72.1 (CH2), 58.1 (CH3); m/z (EI) 193 ([M]
+




A solution of 1-iodo-4-nitrobenzene (4.98 g, 20.0 mmol), alkenylboronic ester 85c
75
 
(7.18 g, 22.0 mmol), Pd(OAc)2 (225 mg, 1.00 mmol), PPh3 (1.05 g, 4.00 mmol), and 
NaOH (2.40 g, 60.0 mmol) in  THF (200 mL) was heated to reflux for 16 h. The mixture 
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was cooled to room temperature, and partitioned between Et2O (150 mL) and H2O (100 
mL). The aqueous layer was separated and extracted with Et2O (2 x 150 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (200 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the alkenylarene 82m (4.91 g, 76%) as a 





H NMR (500 MHz, CDCl3) δ 8.08-8.02 (2H, m, ArH), 7.39-7.33 (2H, m, 
ArH), 6.45-6.34 (2H, m, CH=CH), 3.63 (2H, t, J = 6.2 Hz, CH2O), 2.34-2.24 (2H, m, 
=CHCH2), 1.72-1.62 (2H, m, =CHCH2CH2), 0.87 (9H, s, C(CH3)3), 0.02 (6H, s, 
Si(CH3)2); 
13
C NMR (125.8 MHz, CDCl3)  146.1 (C), 144.1 (C), 135.8 (CH), 128.1 
(CH), 126.0 (2 x CH), 123.6 (2 x CH), 62.0 (CH2), 31.8 (CH2), 29.4 (CH2), 25.7 (3 x 
CH3), 18.0 (C), –5.6 (2 x CH3); HRMS (ES) Exact mass calcd for C17H28N1O3Si1 
[M+H]
+




A solution of 1-iodo-4-nitrobenzene (747 mg, 3.00 mmol), alkenylboronic ester 85d
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(679 mg, 3.00 mmol), Pd(OAc)2 (34 mg, 0.15 mmol), PPh3 (157 mg, 0.60 mmol), and 
NaOH (360 mg, 9.00 mmol) in  THF (30 mL) was heated to reflux for 16 h. The mixture 
was cooled to room temperature, and partitioned between Et2O (40 mL) and H2O (25 
mL). The aqueous layer was separated and extracted with Et2O (2 x 40 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (40 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (10% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82o 
(523 mg, 79%) as a yellow solid. m.p. 37-39 C; IR (film) 2956, 1591, 1521 (N-O), 1341 




H NMR (400 MHz, CDCl3) δ 8.24-8.18 
(2H, m, ArH), 7.61-7.53 (2H, m, ArH), 6.95 (1H, d, J = 19.1 Hz, ArCH=), 6.74 (1H, d, J 
= 19.1 Hz, ArCH=CH), 0.21 (9H, s, Si(CH3)3); 
13
C NMR (100.6 MHz, CDCl3)  147.1 
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(C), 144.4 (C), 141.2 (CH), 136.1 (CH), 126.8 (2 x CH), 123.9 (2 x CH), –1.5 (3 x CH3); 
m/z (EI) 221 ([M]
+
, 10), 206 (100), 147 (91). 
 
5-[(E)-Hex-1-enyl]-2-nitrobenzoic acid methyl ester (82p) 
 
A solution of methyl 5-chloro-2-nitrobenzoate (1.08 g, 5.00 mmol), alkenylboronic ester 
85b
75
 (1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), 
and CsF (2.28 g, 15.0 mmol) in  THF (50 mL) was heated to reflux for 16 h. The mixture 
was cooled to room temperature, and partitioned between Et2O (100 mL) and H2O (50 
mL). The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (80 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the alkenylarene 82p 
(407 mg, 31%) as a yellow oil. IR (film) 2956, 1739 (C=O), 1585, 1525 (N-O), 1437, 




H NMR (500 MHz, CDCl3) δ 7.86 (1H, d, J = 
8.5 Hz, ArH), 7.56 (1H, d, J = 1.9 Hz, ArH), 7.46 (1H, dd, J = 8.5, 1.9 Hz, ArH), 6.48-
6.33 (2H, m, CH=CH), 3.89 (3H, s, OCH3), 2.25-2.21 (2H, m, =CHCH2), 1.50-1.40 (2H, 
m, CH2CH2CH3), 1.39-1.29 (2H, m, CH2CH3), 0.90 (3H, t, J = 7.3 Hz, CH2CH3); 
13
C 
NMR (125.8 MHz, CDCl3)  166.3 (C), 145.3 (C), 143.3 (C), 137.4 (CH), 128.6 (C), 
128.0 (CH), 127.0 (CH), 126.3 (CH), 124.4 (CH), 53.0 (CH3), 32.7 (CH2), 30.8 (CH2), 
22.1 (CH2), 13.7 (CH3); HRMS (ASAP) Exact mass calcd for C14H17N1O4 [M]
–
: 




A solution of 4-bromo-1-nitro-2-(trifluoromethyl)benzene (1.08 g, 4.00 mmol), 
alkenylboronic ester 85b
75
 (925 mg, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 
 121 
(210 mg, 0.80 mmol), and NaOH (480 mg, 12.0 mmol) in THF (40 mL) was heated to 
reflux for 16 h. The mixture was cooled to room temperature, and partitioned between 
Et2O (50 mL) and H2O (30 mL). The aqueous layer was separated and extracted with 
Et2O (2 x 40 mL) and the combined organic layers were washed with saturated aqueous 
NH4Cl solution (50 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification 
of the residue by column chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) 
gave the alkenylarene 82q (640 mg, 59%) as a yellow oil. IR (film) 2931, 1651, 1591, 




H NMR (500 MHz, CDCl3) 
δ 7.87 (1H, d, J = 8.4 Hz, ArH), 7.74 (1H, d, J = 1.8 Hz, ArH), 7.61 (1H, dd, J = 8.4, 1.8 
Hz, ArH), 6.54-6.41 (2H, m, CH=CH), 2.33-2.25 (2H, m, =CHCH2), 1.55-1.46 (2H, m, 
CH2CH2CH3), 1.43-1.36 (2H, m, CH2CH3), 0.95 (3H, t, J = 7.3 Hz, CH3); 
13
C NMR 
(125.8 MHz, CDCl3)  145.9 (C), 143.0 (C), 138.0 (CH), 129.3 (CH), 126.9 (CH), 125.8 
(CH), 125.0 (CH, q, J = 5.5 Hz), 124.2 (C, q J = 33.8 Hz), 122.0 (C, q, J = 273.4 Hz), 
32.8 (CH2), 30.9 (CH2), 22.2 (CH2), 13.8 (CH3); 
19
F NMR (376 MHz, CDCl3) δ –60.5 
(3F, s); HRMS (ASAP) Exact mass calcd for C13H14F3N1O2 [M]
–





A solution of 5-chloro-2-nitrotoluene (858 mg, 5.00 mmol), alkenylboronic ester 85b
75
 
(1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), and CsF 
(2.28 g, 15.0 mmol) in THF (50 mL) was heated to reflux for 16 h. The mixture was 
cooled to room temperature, and partitioned between Et2O (100 mL) and H2O (50 mL). 
The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and the combined 
organic layers were washed with saturated aqueous NH4Cl solution (80 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane) gave the alkenylarene 82r (407 mg, 31%) as a 





H NMR (500 MHz, CDCl3) δ 7.97 (1H, d, J = 8.5 Hz, ArH), 7.31-7.26 (1H, 
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m, ArH), 7.25 (1H, br s, ArH), 6.45-6.34 (2H, m, CH=CH), 2.62 (3H, s, ArCH3), 2.30-
2.22 (2H, m, CH2CH2CH2CH3), 1.53-1.44 (2H, m, CH2CH2CH3), 1.43-1.34 (2H, m, 
CH2CH3), 0.94 (3H, t, J = 7.3 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  147.2 (C), 
142.9 (C), 136.0 (CH), 134.3 (C), 130.1 (CH), 128.0 (CH), 125.4 (CH), 123.9 (CH), 32.8 
(CH2), 31.1 (CH2), 22.2 (CH2), 21.0 (CH3), 13.9 (CH3); HRMS (ASAP) Exact mass calcd 
for C13H18N1O2 [M+H]
+




A solution of 5-chloro-2-nitrobenzonitrile (913 mg, 5.00 mmol), alkenylboronic ester 
85b
75
 (1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), 
and CsF (2.28 g, 15.0 mmol) in dry THF (50 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (100 mL) and 
H2O (50 mL). The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and 
the combined organic layers were washed with saturated aqueous NH4Cl solution (80 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the 
alkenylarene 82s (727 mg, 63%) as a yellow oil. IR (film) 2929, 2860, 2235 (C≡N), 




H NMR (500 MHz, CDCl3) δ 8.23 (1H, d, 
J = 8.7 Hz, ArH), 7.79 (1H, d, J = 2.0 Hz, ArH), 7.69 (1H, dd, J = 8.7, 2.0 Hz, ArH), 
6.60-6.51 (1H, m, ArCH=CH), 6.43 (2H, d, J = 15.9 Hz, ArCH=CH), 2.33-2.23 (2H, m, 
CH2CH2CH2CH3), 1.53-1.43 (2H, m, CH2CH2CH3), 1.41-1.31 (2H, m, CH2CH2CH3), 
0.91 (3H, t, J = 7.3 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  145.8 (C), 144.5 (C), 
139.6 (CH), 132.3 (CH), 130.0 (CH), 126.0 (CH), 125.8 (CH), 115.1 (C), 108.2 (C), 32.7 
(CH2), 30.6 (CH2), 22.1 (CH2), 13.7 (CH3); HRMS (EI) Exact mass calcd for C13H14O2N2 
[M]
–





A solution of 2-trifluoromethyl-4-iodobenzonitrile (1.19 g, 4.00 mmol), alkenylboronic 
ester 85b
75
 (925 mg, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 (210 mg, 0.80 
mmol), and NaOH (480 mg, 12.0 mmol) in THF (40 mL) was heated to reflux for 16 h. 
The mixture was cooled to room temperature, and partitioned between Et2O (50 mL) and 
H2O (30 mL). The aqueous layer was separated and extracted with Et2O (2 x 40 mL) and 
the combined organic layers were washed with saturated aqueous NH4Cl solution (50 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the 
alkenylarene 82t (917 mg, 91%) as a colorless oil. IR (film) 2960, 2931, 2229 (C≡N), 




H NMR (500 MHz, CDCl3) δ 
7.74 (1H, d, J = 8.0 Hz, ArH), 7.71 (1H, br s, ArH), 7.58 (1H, dd, J = 8.0, 1.2 Hz, ArH), 
6.53-6.41 (2H, m, CH=CH), 2.31-2.27 (2H, m, =CHCH2), 1.53-1.47 (2H, m, 
CH2CH2CH3), 1.42-1.35 (2H, CH2CH3), 0.94 (3H, t, J = 7.3 Hz, CH3); 
13
C NMR 
(125.8 MHz, CDCl3)  142.8 (C), 137.8 (CH), 134.7 (CH), 132.7 (C, q, J = 32.3 Hz), 
128.8 (CH), 127.1 (CH), 123.6 (CH, q, J = 4.7 Hz), 122.4 (C, q, J = 273.8 Hz), 115.6 (C), 
106.9 (C, q, J = 2.0 Hz), 32.6 (CH2), 30.8 (CH2), 22.1 (CH2), 13.6 (CH3); 
19
F NMR (376 
MHz, CDCl3) δ –62.5 (3F, s); HRMS (ES) Exact mass calcd for C14H18N2F3 [M+NH4]
+
: 
271.1417, found: 271.1415. 
 
Methyl 4-[(E)-hex-1-enyl]-2-nitrobenzoate (82u) 
 
A solution of methyl 4-chloro-2-nitrobenzoate (1.08 g, 5.00 mmol), alkenylboronic ester 
85a
195
 (1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), 
and CsF (2.28 g, 15.0 mmol) in dry THF (50 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature, and partitioned between Et2O (100 mL) and 
H2O (50 mL). The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and 
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the combined organic layers were washed with saturated aqueous NH4Cl solution (80 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
column chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) gave the 
alkenylarene 82u (824 mg, 53%) as a colourless oil. IR (film) 3028, 2952, 1732, 1539 




H NMR (500 MHz, CDCl3) δ 7.74 
(1H, d, J = 1.6 Hz, ArH), 7.70 (1H, d, J = 8.0 Hz, ArH), 7.53 (1H, dd, J = 8.0, 1.7 Hz, 
ArH), 7.37-7.30 (2H, m, ArH), 7.27-7.21 (3H, m, ArH), 6.51-6.39 (2H, m, ArCH=CH), 
3.91 (3H, s, OCH3), 2.87-2.81 (2H, m, CH2CH2Ph), 2.65-2.57 (2H, m, CH2CH2Ph); 
13
C 
NMR (125.8 MHz, CDCl3)  165.2 (C), 149.1 (C), 142.0 (C), 140.9 (C), 135.4 (CH), 
130.2 (CH), 129.3 (CH), 128.3 (2 x CH), 128.2 (2 x CH), 127.5 (CH), 126.0 (CH), 124.2 
(C), 120.5 (CH), 52.9 (CH3) , 35.1 (CH2) , 34.6 (CH2); HRMS (ES) Exact mass calcd for 
C18H21O4N2 [M+NH4]
+




A solution of 2-bromo-5-nitropyridine (1.02 g, 5.00 mmol), alkenylboronic ester 85b
75
 
(1.16 g, 5.50 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), PPh3 (262 mg, 1.00 mmol), and CsF 
(2.28 g, 15.0 mmol) in  THF (50 mL) was heated to reflux for 16 h. The mixture was 
cooled to room temperature, and partitioned between Et2O (100 mL) and H2O (50 mL). 
The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and the combined 
organic layers were washed with saturated aqueous NH4Cl solution (80 mL), dried 
(MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (40% CH2Cl2/hexane→60% CH2Cl2/hexane) gave the 2-alkenylpyridine 
82v (581 mg, 56%) as a red oil. IR (film) 2958, 2929, 1649, 1593, 1576, 1518 (N-O), 




H NMR (500 MHz, CDCl3) δ 9.30 (1H, s, ArH), 8.35 
(1H, dd, J = 8.7, 2.7 Hz, ArH), 7.34 (1H, d, J = 8.7 Hz, ArH), 7.02 (1H, td, J = 15.5, 7.1 
Hz, ArCH=CH), 6.55 (1H, d, J = 15.6 Hz, ArCH=), 2.30 (2H, app qd, J = 7.5, 1.4 Hz, 
=CHCH2), 1.55-1.45 (2H, m, CH2CH2CH3), 1.41-1.34 (2H, m,  CH2CH3), 0.91 (3H, t, J 
= 7.3 Hz, CH3); 
13
C NMR (125.8 MHz, CDCl3)  161.3 (C), 145.1 (CH), 142.3 (CH), 
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142.1 (C), 131.5 (CH), 128.3 (CH), 120.5 (CH), 32.7 (CH2), 30.6 (CH2), 22.2 (CH2), 13.8 
(CH3); HRMS (ASAP) Exact mass calcd for C11H14N2O2 [M]
–





A solution of 4-bromo-3-fluoronitrobenzene (1.32 g, 6.00 mmol), alkenylboronic ester 
85a
195
 (1.70 g, 6.60 mmol), Pd(OAc)2 (67 mg, 0.30 mmol), PPh3 (315 mg, 1.20 mmol), 
and CsF (2.73 g, 18.0 mmol) in  THF (60 mL) was heated to reflux for 16 h. The mixture 
was cooled to room temperature, and partitioned between Et2O (100 mL) and H2O (50 
mL). The aqueous layer was separated and extracted with Et2O (2 x 50 mL) and the 
combined organic layers were washed with saturated aqueous NH4Cl solution (80 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) gave the alkenylarene 82w 
(517 mg, 48%) as a green solid. m.p. 36-38 C; IR (film) 3028, 2927, 1603, 1523 (N-O), 




H NMR (500 MHz, CDCl3) δ 7.99 (1H, dd, 
J = 8.6, 2.2 Hz, ArH), 7.92 (1H, dd, J = 10.2, 2.3 Hz, ArH), 7.60-7.54 (1H, m, ArH), 
7.38-7.32 (2H, m, ArH), 7.29-7.23 (3H, m, ArH), 6.67-6.54 (2H, m, CH=CH), 2.91-2.85 
(2H, m, CH2Ph), 2.71-2.62 (2H, m, =CHCH2); 
13
C NMR (125.8 MHz, CDCl3)  158.8 
(C, d, J = 252.8 Hz), 146.7 (C, d, J = 8.9 Hz), 141.0 (C), 137.8 (CH, d, J = 4.6 Hz), 132.2 
(C, d, J = 12.6 Hz), 128.4 (2 x CH), 128.3 (2 x CH), 127.2 (CH, d, J = 4.4 Hz), 126.1 
(CH), 121.4 (CH, d, J = 3.3 Hz), 119.3 (CH, d, J = 3.5 Hz), 111.6 (CH, d, J = 27.6 Hz), 
35.3 (CH2), 35.2 (CH2); 
19
F NMR (376 MHz, CDCl3) δ –115.3 (1F, dd, J = 10.2, 7.5 Hz); 
HRMS (EI) Exact mass calcd for C16H14F1N1O2 [M]
+





A solution of 4-nitronaphthalen-1-yl trifluoromethanesulfonate
197
 (1.93 g, 6.00 mmol), 
alkenylboronic ester 85a
195
 (1.70 g, 6.60 mmol), Pd(OAc)2 (67 mg, 0.30 mmol), PPh3 
(315 mg, 1.20 mmol), and NaOH (720 mg, 18.0 mmol) in THF (60 mL) was heated to 
reflux for 16 h. The mixture was cooled to room temperature, and partitioned between 
Et2O (100 mL) and H2O (50 mL). The aqueous layer was separated and extracted with 
Et2O (2 x 50 mL) and the combined organic layers were washed with saturated aqueous 
NH4Cl solution (80 mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification 
of the residue by column chromatography (5% CH2Cl2/hexane) gave the alkenylarene 
82x (980 mg, 54%) as a red solid. m.p. 52-54 C; IR (film) 3026, 2925, 1572, 1512 (N-




H NMR (500 MHz, CDCl3) δ 8.61 
(1H, d, J = 8.7 Hz, ArH), 8.19 (1H, d, J = 8.0 Hz, ArH), 8.06 (1H, d, J = 8.5 Hz, ArH), 
7.75-7.68 (1H, m, ArH), 7.64-7.58 (1H, m, ArH), 7.55 (1H, d, J = 8.0 Hz, ArH), 7.37-
7.31 (2H, m, ArH), 7.29-7.22 (3H, m, ArH), 7.08 (1H, d, J = 15.6 Hz, ArCH=), 6.37 
(1H, dt, J = 15.6, 6.9 Hz, ArCH=CH), 2.92 (2H, t, J = 7.5 Hz, CH2Ph), 2.76-2.68 (2H, m, 
CH2CH2Ph); 
13
C NMR (125.8 MHz, CDCl3)  145.4 (C), 142.6 (C), 141.2 (C), 137.1 
(CH), 131.7 (C), 129.1 (CH), 128.6 (2 x CH), 128.5 (2 x CH), 127.1 (CH), 127.0 (CH), 
126.1 (CH), 125.4 (C), 124.7 (CH), 124.0 (CH), 123.5 (CH), 122.0 (CH), 35.4 (CH2), 
35.2 (CH2); HRMS (ES) Exact mass calcd for C20H18N1O2 [M+H]
+





A solution of 4-nitrophenylboronic acid pinacol ester (996 mg, 4.00 mmol), (E)-2-bromo-
2-butene (446 µL, 4.40 mmol), Pd(OAc)2 (45 mg, 0.20 mmol), PPh3 (210 mg, 0.80 
mmol), and NaOH (480 mg, 12.0 mmol) in dry THF (40 mL) was heated to reflux for 16 
h. The mixture was cooled to room temperature, and partitioned between Et2O (50 mL) 
and H2O (30 mL). The aqueous layer was separated and extracted with Et2O (2 x 40 mL) 
and the combined organic layers were washed with saturated aqueous NH4Cl solution (50 
mL), dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by 
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column chromatography (10% CH2Cl2/hexane→30% CH2Cl2/hexane) gave the 
alkenylarene 82y (577 mg, 81%) as a yellow liquid. IR (film) 2920, 1595, 1514 (N-O), 




H NMR (400 MHz, CDCl3) δ 8.17-8.11 (2H, 
m, ArH), 7.51-7.45 (2H, m, ArH), 6.10-6.01 (1H, m, =CH), 2.08-2.03 (3H, m, ArCCH3), 
1.85 (3H, dd, J = 6.9, 1.1 Hz, =CHCH3); 
13
C NMR (100.6 MHz, CDCl3)  150.3 (C), 
146.2 (C), 134.0 (C), 126.8 (CH), 125.9 (2 x CH), 123.5 (2 x CH), 15.1 (CH3), 14.5 
(CH3); HRMS (APCI) Exact mass calcd for C10H11N1O2 [M+H]
+





A solution of trans-4-nitrocinnamaldehyde (532 mg, 3.00 mmol) and 4-chloro-N-
methylaniline (363 µL, 3.00 mmol) in CH2Cl2 (20 mL) was stirred at room temperature 
for 2 h. NaBH(OAc)3 (1.91 g, 9.00 mmol) was added in one portion and the reaction was 
stirred for a further 3 h. The mixture was partitioned between CH2Cl2 (20 mL) and H2O 
(10 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 20 mL) and 
the combined organic layers were washed with saturated aqueous NaHCO3 solution (20 
mL), brine (20 mL), dried (Na2SO4), filtered, and concentrated in vacuo. Purification of 
the residue by column chromatography (20% CH2Cl2/hexane→50% CH2Cl2/hexane) 
gave the alkenylarene 82z (800 mg, 88%) as a yellow solid. m.p. 88-90 °C; IR (film) 





(400 MHz, CDCl3) δ 8.20-8.13 (2H, m, ArH), 7.50-7.44 (2H, m, ArH), 7.22-7.16 (2H, m, 
ArH), 6.71-6.64 (2H, m, ArH), 6.55 (1H, d, J = 16.0 Hz, ArCH=), 6.42 (1H, dt, J = 16.0, 
4.9 Hz, ArCH=CH), 4.12 (2H, dd, J = 4.9, 1.5 Hz, CH2N), 3.01 (3H, s, NCH3); 
13
C NMR 
(100.6 MHz, CDCl3)  147.7 (C), 146.8 (C), 143.1 (C), 130.6 (CH), 129.2 (CH), 129.0 (2 
x CH), 126.8 (2 x CH), 124.0 (2 x CH), 121.7 (C), 113.6 (2 x CH), 54.9 (CH2), 38.5 
(CH3); m/z (EI) 302 ([M]
+
, 41), 207 (47), 116 (100). 
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Enantioselective Rhodium-Catalyzed Addition of Arylboronic Acids to 
Alkenylarenes: General Procedure A 
 
A solution of [Rh(C2H4)2Cl]2 (1.9 mg, 0.005 mmol) and ligand L5 (4.6 mg, 0.012 mmol) 
in dioxane (0.3 mL) was stirred under nitrogen at room temperature for 15 min. This 
solution was then added via cannula to a sealed nitrogen-flushed microwave vial 
containing the appropriate alkenylarene (0.20 mmol), the appropriate arylboronic acid 
(0.48 mmol), KOH (28 mg, 0.50 mmol), and H2O (0.1 mL), using further dioxane (0.2 
mL) as a rinse. The resulting mixture was irradiated in a microwave reactor at 80 °C for 
30 min. After cooling to room temperature, the mixture was filtered through a short plug 
of SiO2 using CH2Cl2 as eluent and concentrated in vacuo. Purification of the residue by 
column chromatography gave the arylated product. 
  
1-[(S)-2,4-Diphenylbutyl)]-4-nitrobenzene (83a). Using 
microwave irradiation: The title compound was prepared according 
to the General Procedure A from alkenylarene 82a (51 mg, 0.20 mmol) and 
phenylboronic acid (59 mg, 0.48 mmol) and purified by column chromatography (5% 
CH2Cl2/hexane→20% CH2Cl2/hexane) to give a yellow oil (61 mg, 92%). []
24
D  +72.9 (c 





H NMR (400 MHz, CDCl3) δ 8.06-7.99 (2H, m, ArH), 7.34-7.15 (6H, m, 
ArH), 7.13-7.05 (6H, m, ArH), 3.06 (1H, dd, J = 13.2, 6.3 Hz, ArCH2CH), 2.96 (1H, dd, 
J = 13.2, 8.5 Hz, ArCH2CH), 2.92-2.81 (1H, m, ArCH2CH), 2.60-2.40 (2H, m, 
CH2CH2Ph), 2.10-1.99 (2H, m, CH2CH2Ph); 
13
C NMR (100.6 MHz, CDCl3)  148.3 (C), 
146.3 (C), 143.2 (C), 141.9 (C), 129.8 (2 x CH), 128.5 (2 x CH), 128.3 (2 x CH), 128.3 (2 
x CH), 127.7 (2 x CH), 126.6 (CH), 125.8 (CH), 123.3 (2 x CH), 47.2 (CH), 43.7 (CH2), 




349.1911, found: 349.1911. Enantiomeric excess was determined by HPLC with a 
Chiralpak AS-H column (99:1 hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr 
(major) = 18.1 min, tr (minor) = 19.9 min; 95% ee. 
Using thermal heating: A repeat of the above reaction using thermal heating (oil bath 
temperature 80 °C) under otherwise identical conditions gave the alkenylarene 83a (60 




A solution of [Rh(C2H4)2Cl]2 (4.9 mg, 0.0125 mmol) and ligand L5 (11.6 mg, 0.030 
mmol) in dioxane (1.5 mL) was stirred under nitrogen at room temperature for 15 min. 
This solution was then added via cannula to a sealed nitrogen-flushed microwave vial 
containing alkenylarene 82j (205 mg, 1.00 mmol), phenylboronic acid (293 mg, 2.40 
mmol), KOH (140 mg, 2.50 mmol), and H2O (0.5 mL), using further dioxane (1.0 mL) as 
a rinse. The resulting mixture was heated to 80 ˚C in an oil bath for 1 h. After cooling to 
room temperature, the mixture was filtered through a short plug of SiO2 using CH2Cl2 as 
eluent and concentrated in vacuo. Purification of the residue by column chromatography 
(5% CH2Cl2/hexane→20% CH2Cl2/hexane) gave the arylation product 83b (236 mg, 
83%) as a yellow oil. [] 24D  +137.0 (c 1.07, CHCl3); IR (film) 2956, 2929, 2858, 1603, 




H NMR (500 MHz, CDCl3) δ 8.07-
8.01 (2H, m, ArH), 7.30-7.23 (2H, m, ArH), 7.22-7.16 (1H, m, ArH), 7.15-7.10 (2H, m, 
ArH), 7.09-7.04 (2H, m, ArH), 3.06 (1H, dd, J = 13.3, 6.1 Hz, ArCH2), 2.94 (1H, dd, J = 
13.3, 8.8 Hz, ArCH2), 2.88-2.78 (1H, m, ArCH2CH), 1.71 (2H, app q, J = 7.6 Hz, 
CH2CH2CH2CH3), 1.37-1.10 (4H, m, CH2CH2CH3), 0.84 (3H, t, J = 7.2 Hz, CH3); 
13
C 
NMR (125.8 MHz, CDCl3)  148.7 (C), 146.2 (C), 143.8 (C), 129.8 (2 x CH), 128.3 (2 x 
CH), 127.6 (2 x CH), 126.3 (CH), 123.2 (2 x CH), 47.9 (CH), 43.6 (CH2), 35.6 (CH2), 
 130 
29.6 (CH2), 22.6 (CH2), 13.9 (CH3); HRMS (ASAP) Exact mass calcd for C18H22N1O2 
[M+H]
+
: 284.1645, found: 284.1646. Enantiomeric excess was determined by HPLC with 
a Chiralcel OD-H column (98:1 hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr 
(major) = 8.2 min, tr (minor) = 9.2 min; 95% ee.  
 
1-[(R)-2-Cyclopropyl-2-phenylethyl]-4-nitrobenzene (83c). The 
title compound was prepared according to the General Procedure A 
from alkenylarene 82k (38 mg, 0.20 mmol) and phenylboronic acid 
(59 mg, 0.48 mmol) and purified by column chromatography (5% CH2Cl2/hexane→20% 
CH2Cl2/hexane) to give a yellow oil (40 mg, 74%). []
24
D  +49.4 (c 0.89, CHCl3); IR 





NMR (500 MHz, CDCl3) δ 8.08-8.03 (2H, m, ArH), 7.32-7.26 (2H, m, ArH), 7.25-7.20 
(1H, m, ArH), 7.18-7.09 (4H, m, ArH), 3.23 (1H, dd, J = 13.3, 6.2 Hz, ArCH2), 3.13 
(1H, dd, J = 13.3, 8.4 Hz, ArCH2), 2.15-2.07 (1H, m, ArCH2CH), 1.18-1.06 (1H, m, 
CHCH2CH2), 0.65-0.57 (1H, m, CH2CH2), 0.50-0.42 (1H, m, CH2CH2), 0.17-0.11 (2H, 
m, CH2CH2); 
13
C NMR (125.8 MHz, CDCl3)  148.4 (C), 146.3 (C), 143.8 (C), 130.0 (2 
x CH), 128.3 (2 x CH), 127.6 (2 x CH), 126.5 (CH), 123.2 (2 x CH), 52.9 (CH), 43.4 
(CH2), 16.8 (CH), 5.9 (CH2), 4.0 (CH2); HRMS (EI) Exact mass calcd for C17H17N1O2 
[M]
+
: 267.1254, found: 267.1252. Enantiomeric excess was determined by HPLC with a 
Chiralpak AD-H column (99:1 hexane:isopropanol, 0.8 mL/min, 280 nm, 25 °C); tr 
(minor) = 9.3 min, tr (major) = 10.2 min; 92% ee. 
 
(4-Chlorophenyl)methyl-[(S)-3-(4-nitrophenyl)-2-
phenylpropyl]amin (83d). The title compound was prepared 
according to the General Procedure A from alkenylarene 82z (61 
mg, 0.20 mmol) and phenylboronic acid (59 mg, 0.48 mmol) and 
purified by column chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) to give 
a yellow gum (65 mg, 85%). [] 24D  –28.7 (c 1.05, CHCl3); IR (film) 1597, 1510, 1500 (N-




H NMR (500 MHz, CDCl3) δ 
8.06-8.00 (2H, m, ArH), 7.30-7.24 (2H, m, ArH), 7.24-7.19 (1H, m, ArH), 7.18-7.12 
(4H, m, ArH), 7.11-7.06 (2H, m, ArH), 6.53-6.47 (2H, m, ArH), 3.70 (1H, dd, J = 14.8, 
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7.0 Hz, CH2N), 3.46 (1H, dd, J = 14.8, 7.6 Hz, CH2N), 3.34-3.24 (1H, m, ArCH2CH), 
3.16 (1H, dd, J = 13.6, 5.5 Hz, ArCH2), 3.02 (1H, dd, J = 13.6, 9.8 Hz, ArCH2), 2.72 
(3H, s, CH3); 
13
C NMR (125.8 MHz, CDCl3)  147.8 (C), 147.3 (C), 146.4 (C), 141.4 
(C), 129.7 (2 x CH), 129.0 (2 x CH), 128.7 (2 x CH), 127.8 (2 x CH), 127.1 (CH), 123.4 
(2 x CH), 121.2 (C), 113.1 (2 x CH), 59.3 (CH2), 46.0 (CH), 39.8 (CH2), 39.7 (CH3); m/z 
(ES) 381 ([M+H]
+
, 100). Enantiomeric excess was determined by HPLC with a Chiralcel 
AD-H column (98:2 hexane:isopropanol, 0.8 mL/min, 280 nm, 25 °C); tr (minor) = 18.0 
min, tr (major) = 19.8 min; 91% ee. 
 
1-[(S)-3-Methoxy-2-phenylpropyl]-4-nitrobenzene (83e). The 
title compound was prepared according to the General Procedure 
A from alkenylarene 82l (39 mg, 0.20 mmol) and phenylboronic acid (59 mg, 0.48 mmol) 
and purified by column chromatography (40% CH2Cl2/hexane) to give a colorless oil (45 
mg, 82%). [] 24D  +106.0 (c 1.00, CHCl3); IR (film) 2921, 1644, 1604, 1516 (N-O), 1494, 




H NMR (400 MHz, CDCl3) δ 8.07-8.01 (2H, m, 
ArH), 7.31-7.24 (2H, m, ArH), 7.24-7.18 (1H, m, ArH), 7.18-7.13 (2H, m, ArH), 7.13-
7.07 (2H, m, ArH), 3.58-3.56 (2H, m, CH2O), 3.37 (3H, s, OCH3), 3.29 (1H, dd, J = 
13.3, 5.5 Hz, ArCH2), 3.21-3.10 (1H, m, ArCH2CH), 2.96 (1H, dd, J = 13.3, 9.1 Hz, 
ArCH2); 
13
C NMR (100.6 MHz, CDCl3)  148.2 (C), 146.3 (C), 141.1 (C), 129.9 (2 x 
CH), 128.5 (2 x CH), 127.8 (2 x CH), 126.9 (CH), 123.3 (2 x CH), 76.0 (CH2), 58.9 
(CH3), 47.7 (CH), 39.1 (CH2); m/z (ES) 294 ([M+Na]
+
, 100). Enantiomeric excess was 
determined by HPLC with a Chiralcel AS-H column (99:1 hexane:isopropanol, 0.8 
mL/min, 280 nm, 25 °C); tr (minor) = 19.8 min, tr (major) = 21.0 min; 91% ee.  
 






A solution of [Rh(C2H4)2Cl]2 (3.8 mg, 0.010 mmol) and ligand L5 (9.2 mg, 0.024 mmol) 
in dioxane (0.6 mL) was stirred under nitrogen at room temperature for 15 min. This 
solution was then added via cannula to a sealed nitrogen-flushed microwave vial 
containing alkenylarene 82o (89 mg, 0.40 mmol), 4-methoxyphenylboronic acid (146 mg, 
0.96 mmol), KOH (56 mg, 1.00 mmol), and H2O (0.2 mL), using further dioxane (0.4 
mL) as a rinse. The resulting mixture was irradiated in a microwave reactor at 80 °C for 
30 min. After cooling to room temperature, the mixture was filtered through a short plug 
of SiO2 using CH2Cl2 as eluent and concentrated in vacuo. Purification of the residue by 
column chromatography (20% CH2Cl2/hexane→40% CH2Cl2/hexane) gave the arylation 
product 83f (75 mg, 57%) as a yellow oil. [] 24D  +142.2 (c 0.97, CHCl3); IR (film) 2953, 




H NMR (500 
MHz, CDCl3) δ 8.03-7.97 (2H, m, ArH), 7.20-7.14 (2H, m, ArH), 6.91-6.84 (2H, m, 
ArH), 6.78-6.71 (2H, m, ArH), 3.75 (3H, s, OCH3), 3.15 (1H, dd, J = 14.5, 4.2 Hz, 
ArCH2), 3.09 (1H, dd, J = 14.5, 11.8 Hz, ArCH2), 2.30 (1H, dd, J = 11.8, 4.2 Hz, 
ArCH2CH), 0.02 (9H, s, Si(CH3)3); 
13
C NMR (125.8 MHz, CDCl3)  157.0 (C), 150.0 
(C), 146.1 (C), 133.6 (C), 129.2 (2 x CH), 128.6 (2 x CH), 123.3 (2 x CH), 113.7 (2 x 
CH), 55.1 (CH3), 37.6 (CH), 36.0 (CH2), –2.9 (3 x CH3); m/z (ES) 352 ([M+Na]
+
, 100). 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column (99:1 
hexane:isopropanol, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 8.4 min, tr (minor) = 9.1 




A solution of [Rh(C2H4)2Cl]2 (24 mg, 0.0625 mmol) and ligand L5 (58 mg, 0.15 mmol) 
in dioxane (7.5 mL) was stirred under nitrogen at room temperature for 15 min. This 
solution was then added via cannula to a sealed nitrogen-flushed microwave vial 
containing alkenylarene 82m (1.61 g, 5.00 mmol), phenylboronic acid (1.46 g, 12.0 
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mmol), KOH (701 mg, 2.50 mmol), and H2O (2.5 mL), using further dioxane (5.0 mL) as 
a rinse. The resulting mixture was heated to 80 ˚C in an oil bath for 1.5 h. After cooling 
to room temperature, the mixture was filtered through a short plug of SiO2 using CH2Cl2 
as eluent and concentrated in vacuo. Purification of the residue by column 
chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) gave the arylation product 
83g (1.75 g, 88%) as a yellow oil. [] 24
D
 +79.3 (c 1.12, CHCl3); IR (film) 2929, 2856, 




H NMR (500 MHz, 
CDCl3) δ 8.09-8.02 (2H, m, ArH), 7.31-7.24 (2H, m, ArH), 7.23-7.17 (1H, m, ArH), 
7.17-7.12 (2H, m, ArH), 7.11-7.05 (2H, m, ArH), 3.61-3.51 (2H, m, CH2O), 3.06 (1H, 
dd, J = 13.3, 6.4 Hz, ArCH2), 2.97 (1H, dd, J = 13.3, 8.4 Hz, ArCH2), 2.91-2.81 (1H, m, 
ArCH2CH), 1.85-1.78 (1H, m, CH2CH2CH2O), 1.75-1.68 (1H, m, CH2CH2CH2O), 1.48-
1.36 (2H, m, CH2CH2O), 0.89 (9H, s, C(CH3)3), 0.02 (3H, s, SiCH3), 0.01 (3H, s, 
SiCH3); 
13
C NMR (125.8 MHz, CDCl3)  148.6 (C), 146.3 (C), 143.6 (C), 129.8 (2 x 
CH), 128.4 (2 x CH), 127.6 (2 x CH), 126.4 (CH), 123.2 (2 x CH), 62.8 (CH2), 47.6 
(CH), 43.7 (CH2), 31.9 (CH2), 30.6 (CH2), 25.9 (3 x CH3), 18.3 (C), –5.4 (2 x CH3); 
HRMS (ES) Exact mass calcd for C23H34N1O3Si1 [M+H]
+
: 400.2302, found: 400.2306. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column (99:1 
hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr (major) = 7.1 min, tr (minor) = 7.8 
min; 93% ee. 
 
4-[(S)-2-(4-Methylphenyl)hexyl]-1-nitrobenzene (83h). The title 
compound was prepared according to the General Procedure A from 
alkenylarene 82j (41 mg, 0.20 mmol) and 4-methylphenylboronic 
acid (65 mg, 0.48 mmol) and purified by column chromatography 
(5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a yellow oil (52 mg, 87%). []
24
D  
+154.6 (c 0.97, CHCl3); IR (film) 2956, 2927, 2858, 1603, 1518 (N-O), 1344 (N-O), 




H NMR (500 MHz, CDCl3) δ 8.06-8.01 (2H, m, ArH), 7.15-
7.09 (2H, m, ArH), 7.06 (2H, d, J = 7.8 Hz, ArH), 6.97-6.92 (2H, m, ArH), 3.02 (1H, dd, 
J = 13.3, 6.2 Hz, ArCH2), 2.91 (1H, dd, J = 13.3, 8.7 Hz, ArCH2), 2.83-2.73 (1H, m, 
ArCH2CH), 2.31 (3H, s, ArCH3), 1.70-1.63 (2H, m, CH2CH2CH2CH3), 1.35-1.09 (4H, 
m, CH2CH2CH3), 0.83 (3H, t, J = 7.2 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  
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148.9 (C), 146.2 (C), 140.8 (C), 135.8 (C), 129.8 (2 x CH), 129.0 (2 x CH), 127.5 (2 x 
CH), 123.2 (2 x CH), 47.4 (CH), 43.7 (CH2), 35.7 (CH2), 29.7 (CH2), 22.6 (CH2), 21.0 
(CH3), 13.9 (CH3); HRMS (ES) Exact mass calcd for C19H27N2O2 [M+NH4]
+
: 315.2067, 
found: 315.2068. Enantiomeric excess was determined by HPLC with a Chiralpak AS-H 
column (99.3:0.7 hexane:isopropanol, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 8.2 min, 
tr (minor) = 9.0 min; 94% ee. 
 
4-[(S)-2-(3-Methylphenyl)hexyl]-1-nitrobenzene (83i). The title 
compound was prepared according to the General Procedure A from 
alkenylarene 82j (41 mg, 0.20 mmol) and 3-methylphenylboronic 
acid (65 mg, 0.48 mmol) and purified by column chromatography (5% 
CH2Cl2/hexane→20% CH2Cl2/hexane) to give a yellow oil (53 mg, 90%). []
24
D  +130.9 





H NMR (500 MHz, CDCl3) δ 8.07-8.02 (2H, m, ArH), 7.17-7.10 (3H, m, 
ArH), 7.00 (1H, d, J = 7.5 Hz, ArH), 6.89-6.82 (2H, m, ArH), 3.01 (1H, dd, J = 13.4, 6.4 
Hz, ArCH2), 2.93 (1H, dd, J = 13.4, 8.4 Hz, ArCH2), 2.82-2.72 (1H, m, ArCH2CH), 2.31 
(3H, s, ArCH3), 1.70-1.62 (2H, m, CH2CH2CH2CH3), 1.35-1.08 (4H, m, CH2CH2CH3), 
0.83 (3H, t, J = 7.2 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  148.9 (C), 146.2 (C), 
143.9 (C), 137.9 (C), 129.8 (2 x CH), 128.4 (CH), 128.2 (CH), 127.1 (CH), 124.6 (CH), 
123.2 (2 x CH), 47.8 (CH), 43.6 (CH2), 35.6 (CH2), 29.7 (CH2), 22.6 (CH2), 21.5 (CH3), 
13.9 (CH3); HRMS (ASAP) Exact mass calcd for C19H24N1O2 [M+H]
+
: 298.1802, found: 
298.1804. Enantiomeric excess was determined by HPLC with a Chiralpak AS-H column 
(99.3:0.7 hexane:isopropanol, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 8.0 min, tr 
(minor) = 8.7 min; 92% ee. 
 
4-[(S)-2-(2-Methylphenyl)hexyl]-1-nitrobenzene (83j). The title 
compound was prepared according to the General Procedure A from 
alkenylarene 82j (41 mg, 0.20 mmol) and 2-methylphenylboronic 
acid (65 mg, 0.48 mmol) but for a reaction time of 1 h and purified by column 
chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a yellow oil (36 mg, 
61%). [] 24D  +107.9 (c 0.95, CHCl3); IR (film) 2929, 2858, 1603, 1518 (N-O), 1462, 
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H NMR (500 MHz, CDCl3) δ 8.06-8.00 (2H, m, 
ArH), 7.26-7.18 (2H, m, ArH), 7.13-7.01 (4H, m, ArH), 3.22-3.11 (1H, m, ArCH2CH), 
3.02 (1H, dd, J = 13.2, 6.0 Hz, ArCH2), 2.90 (1H, dd, J = 13.2, 8.8 Hz, ArCH2), 2.04 
(3H, s, ArCH3), 1.69-1.64 (2H, m, CH2CH2CH2CH3), 1.35-1.09 (4H, m, CH2CH2CH3), 
0.84 (3H, t, J = 7.2 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  148.8 (C), 146.2 (C), 
142.2 (C), 136.1 (C), 130.2 (CH), 129.8 (2 x CH), 126.2 (CH), 125.9 (CH), 125.7 (CH), 
123.2 (2 x CH), 43.5 (CH2), 42.0 (CH), 35.7 (CH2), 29.6 (CH2), 22.8 (CH2), 19.7 (CH3), 
13.9 (CH3); HRMS (ASAP) Exact mass calcd for C19H24N1O2 [M+H]
+
: 298.1802, found: 
298.1804. Enantiomeric excess was determined by HPLC with a Chiralpak AS-H column 
(99:1 hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr (major) = 7.3 min, tr (minor) = 
8.3 min; 97% ee. 
 
2-[(S)-1-(4-Nitrobenzyl)-3-phenylpropyl]naphthalene (83k). The 
title compound was prepared according to the General Procedure A 
from alkenylarene 82a (51 mg, 0.20 mmol) and 2-naphthylboronic 
acid (83 mg, 0.48 mmol) and purified by column chromatography 
(5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a dark brown viscous oil (60 mg, 
79%). [] 24D  +108.0 (c 0.69, CHCl3); IR (film) 3057, 2933, 1601, 1518 (N-O), 1454, 




H NMR (500 MHz, CDCl3) δ 8.03-7.97 (2H, m, 
ArH), 7.87-7.80 (2H, m, ArH), 7.79-7.47 (1H, m, ArH), 7.52-7.43 (3H, m, ArH), 7.33-
7.24 (3H, m, ArH), 7.22-7.16 (1H, m, ArH), 7.13-7.04 (4H, m, ArH), 3.19-3.00 (3H, m, 
ArCH2CH), 2.60-2.43 (2H, m, CH2CH2Ph), 2.21-2.06 (2H, m, CH2CH2Ph); 
13
C NMR 
(125.8 MHz, CDCl3)  148.2 (C), 146.3 (C), 141.8 (C), 140.6 (C), 133.4 (C), 132.4 (C), 
129.8 (2 x CH), 128.34 (2 x CH), 128.31 (2 x CH), 127.6 (CH), 127.5 (CH), 126.7 (CH), 
126.1 (CH), 125.9 (CH), 125.5 (2 x CH), 123.3 (2 x CH), 47.3 (CH), 43.5 (CH2), 37.4 
(CH2), 33.6 (CH2); m/z (ES) 404 ([M+Na]
+
, 100). Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (99:1 hexane:isopropanol, 0.8 mL/min, 225 
nm, 25 °C); tr (minor) = 45.2 min, tr (major) = 48.3 min; 89% ee. 
 
 136 
4-[(S)-2-(4-Chlorophenyl)hexyl]-1-nitrobenzene (83l). The title 
compound was prepared according to the General Procedure A from 
alkenylarene 82j (41 mg, 0.20 mmol) and 4-chlorophenylboronic 
acid (75 mg, 0.48 mmol) and purified by column chromatography 




+158.6 (c 0.90, CHCl3); IR (film) 2927, 2858, 1601, 1518 (N-O), 1491, 1454, 1344 (N-




H NMR (500 MHz, CDCl3) δ 8.07-8.02 (2H, m, ArH), 7.25-
7.19 (2H, m, ArH), 7.13-7.08 (2H, m, ArH), 7.01-6.95 (2H, m, ArH), 3.04 (1H, dd, J = 
13.2, 5.8 Hz, ArCH2), 2.88 (1H, dd, J = 13.2, 9.0 Hz, ArCH2), 2.84-2.75 (1H, m, 
ArCH2CH), 1.75-1.59 (2H, m, CH2CH2CH2CH3), 1.35-1.06 (4H, m, CH2CH2CH3), 0.83 
(3H, t, J = 7.3 Hz, CH3); 
13
C NMR (125.8 MHz, CDCl3)  148.2 (C), 146.3 (C), 142.3 
(C), 132.0 (C), 129.8 (2 x CH), 128.9 (2 x CH), 128.5 (2 x CH), 123.3 (2 x CH), 47.4 
(CH), 43.5 (CH2), 35.6 (CH2), 29.6 (CH2), 22.6 (CH2), 13.9 (CH3); HRMS (ASAP) Exact 
mass calcd for C18H20Cl1N1O2 [M]
–
: 317.1188, found: 317.1186. Enantiomeric excess 
was determined by HPLC with a Chiralpak AS-H column (99:1 hexane:isopropanol, 0.8 
mL/min, 254 nm, 25 °C); tr (major) = 12.3 min, tr (minor) = 13.3 min; 94% ee.  
 
4-[(S)-2-(4-Fluorophenyl)hexyl]-1-nitrobenzene (83m). The title 
compound was prepared according to the General Procedure A from 
alkenylarene 82j (41 mg, 0.20 mmol) and 4-fluorophenylboronic 
acid (67 mg, 0.48 mmol) and purified by column chromatography 
(5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a yellow oil (49 mg, 81%). []
24
D  
+119.1 (c 0.94, CHCl3); IR (film) 2929, 2858, 1603, 1510 (N-O), 1346 (N-O), 1223, 




H NMR (500 MHz, CDCl3) δ 8.07-8.01 (2H, m, ArH), 7.13-
7.06 (2H, m, ArH), 7.03-6.89 (4H, m, ArH), 3.04 (1H, dd, J = 12.8, 5.5 Hz, ArCH2), 
2.92-2.75 (2H, m, ArCH2CH), 1.77-1.58 (2H, m, CH2CH2CH2CH3), 1.37-1.05 (4H, m, 
CH2CH2CH3), 0.83 (3H, t, J = 7.2 Hz, CH3); 
13
C NMR (125.8 MHz, CDCl3)  161.4 (C, 
d, J = 244.3 Hz), 148.4 (C), 146.3 (C), 139.4 (C, d, J = 3.2 Hz), 129.8 (2 x CH), 128.9 (2 
x CH, d, J = 7.7 Hz), 123.3 (2 x CH), 115.2 (2 x CH, d, J = 21.1 Hz), 47.2 (CH), 43.7 
(CH2), 35.8 (CH2), 29.6 (CH2), 22.6 (CH2), 13.9 (CH3); 
19
F NMR (376 MHz, CDCl3) δ –




301.1484, found: 301.1483. Enantiomeric excess was determined by HPLC with a 
Chiralpak AS-H column (99:1 hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr 
(major) = 11.5 min, tr (minor) = 12.5 min; 94% ee.  
 
4-[(S)-2-(4-Methoxyphenyl)hexyl]-1-nitrobenzene (83n). The title 
compound was prepared according to the General Procedure A from 
alkenylarene 82j (41 mg, 0.20 mmol) and 4-methoxyphenylboronic 
acid (73 mg, 0.48 mmol) and purified by column chromatography 
(5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a yellow amorphous solid (52 mg, 
83%). [] 24D  +147.6 (c 0.75, CHCl3); IR (film) 2929, 2856, 1606, 1514 (N-O), 1344 (N-




H NMR (500 MHz, CDCl3) δ 8.06-8.01 (2H, m, 
ArH), 7.13-7.07 (2H, m, ArH), 6.98-6.92 (2H, m, ArH), 6.81-6.76 (2H, m, ArH), 3.78 
(3H, s, OCH3), 3.01 (1H, dd, J = 13.3, 5.9 Hz, ArCH2), 2.88 (1H, dd, J = 13.3, 8.9 Hz, 
ArCH2), 2.81-2.71 (1H, m, ArCH2CH), 1.73-1.59 (2H, m, CH2CH2CH2CH3), 1.35-1.09 
(4H, m, CH2CH2CH3), 0.83 (3H, t, J = 7.2 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3) 
 158.0 (C), 148.9 (C), 146.2 (C), 135.8 (C), 129.8 (2 x CH), 128.5 (2 x CH), 123.2 (2 x 
CH), 113.7 (2 x CH), 55.2 (CH3), 47.1 (CH), 43.8 (CH2), 35.9 (CH2), 29.7 (CH2), 22.6 
(CH2), 14.0 (CH3); HRMS (ASAP) Exact mass calcd for C19H23N1O3 [M]
–
: 313.1683, 
found: 313.1688.  Enantiomeric excess was determined by HPLC with a Chiralpak AS-H 
column (98:2 hexane:isopropanol, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 10.8 min, tr 
(minor) = 12.2 min; 93% ee. 
 
2-Nitro-5-[(S)-2-phenylhexyl]benzoic acid methyl ester (83o). 
The title compound was prepared according to the General 
Procedure A from alkenylarene 82p (53 mg, 0.20 mmol) and phenylboronic acid (59 mg, 
0.48 mmol) and purified by column chromatography (5% CH2Cl2/hexane→20% 
CH2Cl2/hexane) to give a colorless oil (54 mg, 80%). []
24
D  +90.0 (c 0.76, CHCl3); IR 





H NMR (500 MHz, CDCl3) δ 7.74 (1H, d, J = 8.3 Hz, ArH), 7.32 (1H, d, J = 1.8 
Hz, ArH), 7.29-7.23 (2H, m, ArH), 7.22-7.16 (1H, m, ArH), 7.10 (1H, dd, J = 8.3, 1.9 






ArCH2), 2.92 (1H, dd, J = 13.4, 8.7 Hz, ArCH2), 2.85-2.75 (1H, m, ArCH2CH), 1.69 
(2H, app q, J = 7.6 Hz, CH2CH2CH2CH3), 1.35-1.05 (4H, m, CH2CH2CH3), 0.83 (3H, t, 
J = 7.2 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  166.3 (C), 147.3 (C), 145.8 (C), 
143.5 (C), 131.9 (CH), 130.1 (CH), 128.5 (2 x CH), 127.7 (C), 127.6 (2 x CH), 126.5 
(CH), 123.7 (CH), 53.2 (CH3), 47.8 (CH), 43.4 (CH2), 35.6 (CH2), 29.7 (CH2), 22.6 
(CH2), 13.9 (CH3); HRMS (ES) Exact mass calcd for C20H27N2O4 [M+NH4]
+
: 359.1965, 
found: 359.1965. Enantiomeric excess was determined by HPLC with a Chiralpak AS-H 
column (99:1 hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr (major) = 19.7 min, tr 
(minor) = 23.2 min; 91% ee. 
 
1-Nitro-4-[(S)-2-phenylhexyl]-2-trifluoromethylbenzene (83p). 
The title compound was prepared according to the General Procedure 
A from alkenylarene 82q (55 mg, 0.20 mmol) and phenylboronic acid (59 mg, 0.48 
mmol) and purified by column chromatography (5% CH2Cl2/hexane→20% 
CH2Cl2/hexane) to give a colorless oil (60 mg, 85%). []
24
D  +89.7 (c 0.98, CHCl3); IR 





NMR (500 MHz, CDCl3) δ 7.71 (1H, d, J = 8.3 Hz, ArH), 7.34 (1H, d, J = 1.4 Hz, ArH), 
7.30-7.17 (4H, m, ArH), 7.07-7.00 (2H, m, ArH), 3.09 (1H, dd, J = 13.4, 5.7 Hz, 
ArCH2), 2.95 (1H, dd, J = 13.4, 9.2 Hz, ArCH2), 2.85-2.75 (1H, m, ArCH2CH), 1.79-
1.66 (2H, m, CH2CH2CH2CH3), 1.38-1.11 (4H, m, CH2CH2CH3), 0.85 (3H, t, J = 7.2 Hz, 
CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  146.9 (C), 146.0 (C), 143.1 (C), 133.2 (CH), 
128.5 (CH), 128.4 (CH, q, J = 5.4 Hz), 127.6 (CH), 126.7 (CH), 124.9 (CH), 123.3 (C, q, 
J = 33.7 Hz), 121.9 (C, q, J = 273.4 Hz), 47.8 (CH), 43.4 (CH2), 35.6 (CH2), 29.6 (CH2), 
22.6 (CH2), 13.9 (CH3); 
19
F NMR (376 MHz, CDCl3) δ –60.4 (3F, s); HRMS (ASAP) 
Exact mass calcd for C19H21F3N1O2 [M+H]
+
: 352.1519, found: 352.1521. Enantiomeric 
excess was determined by HPLC with a Chiralcel OD-H column (99:1 
hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr (major) = 8.9 min, tr (minor) = 10.0 









A solution of [Rh(C2H4)2Cl]2 (9.8 mg, 0.025 mmol) and ligand L5 (23 mg, 0.060 mmol) 
in dioxane (2.0 mL) was stirred under nitrogen at room temperature for 15 min. This 
solution was then added via cannula to a sealed nitrogen-flushed microwave vial 
containing alkenylarene 82r (219 mg, 1.00 mmol), phenylboronic acid (293 mg, 2.40 
mmol), KOH (140 mg, 2.50 mmol), and H2O (0.5 mL), using further dioxane (0.5 mL) as 
a rinse. The resulting mixture was irradiated in a microwave reactor at 80 °C for 30 min. 
After cooling to room temperature, the mixture was filtered through a short plug of SiO2 
using CH2Cl2 as eluent and concentrated in vacuo. Purification of the residue by column 
chromatography (20% CH2Cl2/hexane) gave the arylation product 83q (235 mg, 79%) as 
a yellow oil. [] 24D  +104.7 (c 1.05, CHCl3); IR (film) 2956, 2929, 2858, 1610, 1587, 1516 




H NMR (500 MHz, CDCl3) δ 7.87-7.81 (1H, 
m, ArH), 7.31-7.24 (2H, m, ArH), 7.22-7.16 (1H, m, ArH), 7.11-7.05 (2H, m, ArH), 
6.96-6.90 (2H, m, ArH), 2.97 (1H, dd, J = 13.2, 6.3 Hz, ArCH2), 2.88 (1H, dd, J = 13.2, 
8.3 Hz, ArCH2), 2.85-2.76 (1H, m, ArCH2CH), 2.53 (3H, s, ArCH3), 1.73-1.64 (2H, m, 
CH2CH2CH2CH3), 1.37-1.09 (4H, m, CH2CH2CH3), 0.84 (3H, t, J = 7.2 Hz, CH2CH3); 
13
C NMR (125.8 MHz, CDCl3)  147.0 (C), 146.9 (C), 144.1 (C), 133.5 (C), 133.4 (CH), 
128.3 (2 x CH), 127.6 (2 x CH), 127.4 (CH), 126.3 (CH), 124.6 (CH), 47.7 (CH), 43.4 
(CH2), 35.5 (CH2), 29.7 (CH2), 22.6 (CH2), 20.7 (CH3), 13.9 (CH3); HRMS (ASAP) 
Exact mass calcd for C19H24N1O2 [M+H]
+
: 298.1802, found: 298.1800. Enantiomeric 
excess was determined by HPLC with a Chiralcel OD-H column (98:2 
hexane:isopropanol, 0.8 mL/min, 254 nm, 25 °C); tr (major) = 7.2 min, tr (minor) = 8.1 
min; 87% ee. 
 
1-[(S)-2,4-diphenylbutyl]-4-nitronaphthalene (83r). The title 
compound was prepared according to the General Procedure A from 
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alkenylarene 82x  (61 mg, 0.20 mmol) and phenylboronic acid (59 mg, 0.48 mmol) and 
purified by column chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a 
yellow oil (41 mg, 54%). [] 24
D
 +55.9 (c 1.36, CHCl3); IR (film) 3026, 2927, 2856, 1736, 




H NMR (500 MHz, CDCl3) δ 8.59 
(1H, d, J = 8.6 Hz, ArH), 8.06 (1H, d, J = 8.5 Hz, ArH), 7.98 (1H, d, J = 7.8 Hz, ArH), 
7.74-7.67 (1H, m, ArH), 7.64-7.58 (1H, m, ArH), 7.32-7.22 (5H, m, ArH), 7.20-7.17 
(1H, m, ArH), 7.13-7.05 (5H, m, ArH), 3.50 (1H, dd, J = 13.8, 6.7 Hz, ArCH2CH), 3.34 
(1H, dd, J = 13.8, 7.9 Hz, ArCH2CH), 3.10-2.99 (1H, m, ArCH2CH), 2.58-2.39 (2H, m, 
CH2Ph), 2.17-2.08 (2H, m, CH2CH2Ph); 
13
C NMR (125.8 MHz, CDCl3)  145.5 (C), 
144.3 (C), 143.8 (C), 141.8 (C), 132.6 (C), 128.7 (CH), 128.6 (2 x CH), 128.33 (2 x CH), 
128.27 (2 x CH), 127.6 (2 x CH), 127.1 (CH), 126.7 (CH), 125.8 (CH), 125.7 (CH), 
125.5 (C), 124.4 (CH), 123.8 (CH), 123.3 (CH), 46.5 (CH), 41.7 (CH2), 37.7 (CH2), 33.7 
(CH2); HRMS (ASAP) Exact mass calcd for C26H24N1O2 [M+H]
+
: 382.1802, found: 
382.1802. Enantiomeric excess was determined by HPLC with a Chiralcel IB-3 column 
(99:1 hexane:isopropanol, 0.8 mL/min, 210 nm, –2.5 °C); tr (minor) = 15.1 min, tr (major) 
= 15.6 min; 84% ee. 
 
1-[(S)-2,4-Diphenylbutyl]-2-fluoro-4-nitrobenzene (83s). The title 
compound was prepared according to the General Procedure A from 
alkenylarene 82w (54 mg, 0.20 mmol) and phenylboronic acid (59 mg, 0.48 mmol) and 
purified by column chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a 
yellow oil (63 mg, 90%). [] 24D  +75.9 (c 0.90, CHCl3); IR (film) 3028, 2927, 1639, 1525 




H NMR (500 MHz, CDCl3) δ 
7.86-7.80 (2H, m, ArH), 7.34-7.17 (6H, m, ArH), 7.16-7.08 (4H, m, ArH), 7.04-6.98 
(1H, m, ArH), 3.22-3.11 (1H, m, ArCH2), 3.00-2.90 (2H, m, ArCH2CH), 2.60-2.45 (2H, 
m, CH2CH2Ph), 2.15-2.02 (2H, m, CH2CH2Ph); 
13
C NMR (125.8 MHz, CDCl3)  160.3 
(C, d, J = 249.6 Hz), 147.0 (C, d, J = 8.9 Hz), 143.0 (C), 141.8 (C), 135.5 (C, d, J = 16.2 
Hz), 131.8 (CH, d, J = 5.4 Hz), 128.5 (2 x CH), 128.3 (2 x CH), 128.3 (2 x CH), 127.6 (2 
x CH), 126.7 (CH), 125.8 (CH), 118.7 (CH, d, J = 3.5 Hz), 110.9 (CH, d, J = 27.9 Hz), 
45.9 (CH), 37.5 (CH2), 36.8 (CH2), 33.6 (CH2); 
19
F NMR (376 MHz, CDCl3) δ –114.1 




350.1551, found: 350.1549. Enantiomeric excess was determined by HPLC with a 
Chiralcel OD-H column (99:1 hexane:isopropanol, 0.8 mL/min, 280 nm, 25 °C); tr 
(minor) = 27.1 min, tr (major) = 32.9 min; 88% ee. 
 
5-Nitro-2-[(S)-2-phenylhexyl]pyridine (83t). The title compound 
was prepared according to the General Procedure A from 
alkenylpyridine 82v (41 mg, 0.20 mmol) and phenylboronic acid (59 mg, 0.48 mmol) and 
purified by column chromatography (5% CH2Cl2/hexane→20% CH2Cl2/hexane) to give a 
yellow oil (52 mg, 91%). [] 24D  +125.1 (c 0.90, CHCl3); IR (film) 2956, 2927, 2858, 




H NMR (500 MHz, CDCl3) 
δ 9.33 (1H, d, J = 2.6 Hz, ArH), 8.19 (1H, dd, J = 8.5 Hz, 2.7 Hz, ArH), 7.26-7.20 (2H, 
m, ArH), 7.19-7.12 (1H, m, ArH), 7.10-7.05 (2H, m, ArH), 6.96 (1H, d, J = 8.5 Hz, 
ArH), 3.32-3.21 (1H, m, ArCH2), 3.18-3.05 (2H, m, ArCH2CH), 1.78-1.67 (2H, m, 
CH2CH2CH2CH3), 1.37-1.08 (4H, m, CH2CH2CH3), 0.83 (3H, t, J = 7.2 Hz, CH3); 
13
C 
NMR (125.8 MHz, CDCl3)  167.7 (C), 144.6 (CH), 143.8 (C), 142.4 (C), 130.7 (CH), 
128.4 (2 x CH), 127.5 (2 x CH), 126.4 (CH), 123.6 (CH), 46.4 (CH), 46.0 (CH2), 36.0 
(CH2), 29.6 (CH2), 22.6 (CH2), 13.9 (CH3); HRMS (ASAP) Exact mass calcd for 
C17H20N2O2 [M]
–
: 284.1530, found: 284.1522. Enantiomeric excess was determined by 
HPLC with a Chiralcel OD-H column (99:1 hexane:isopropanol, 0.8 mL/min, 280 nm, 25 




A solution of [Rh(C2H4)2Cl]2 (3.8 mg, 0.010 mmol) and ligand L5 (9.2 mg, 0.024 mmol) 
in dioxane (0.3 mL) was stirred under nitrogen at room temperature for 15 min. This 
solution was then added via cannula to a sealed nitrogen-flushed microwave vial 
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containing alkenylarene 82t (51 mg, 0.20 mmol), phenylboronic acid (59 mg, 0.48 
mmol), KOH (28 mg, 0.50 mmol), and H2O (0.1 mL), using further dioxane (0.2 mL) as 
a rinse. The resulting mixture was irradiated in a microwave reactor at 80 °C for 1.5 h. 
After cooling to room temperature, the mixture was filtered through a short plug of SiO2 
using CH2Cl2 as eluent and concentrated in vacuo. Purification of the residue twice by 
column chromatography (5% CH2Cl2/hexane) gave the arylation product 83u (39 mg, 
59%) as a colorless oil. [] 24
D
 +58.9 (c 1.39, CHCl3); IR (film) 2931, 2860, 2231 (C≡N), 




H NMR (500 MHz, CDCl3) δ 7.61 (1H, 
d, J = 7.9 Hz, ArH), 7.32 (1H, s, ArH), 7.27-7.23 (2H, m, ArH), 7.22-7.16 (2H, m, ArH), 
7.04-6.98 (2H, m, ArH), 3.07 (1H, dd, J = 13.4, 5.8 Hz, ArCH2), 2.93 (1H, dd, J = 13.4, 
9.2 Hz, ArCH2), 2.83-2.74 (1H, m, ArCH2CH), 1.77-1.66 (2H, m, CH2CH2CH2CH3), 
1.39-1.09 (4H, m, CH2CH2CH3), 0.84 (3H, t, J = 7.2 Hz, CH3); 
13
C NMR (125.8 MHz, 
CDCl3)  147.1 (C), 143.2 (C), 134.3 (CH), 132.7 (CH), 132.3 (C, d, J = 32.4 Hz), 128.5 
(2 x CH), 127.6 (2 x CH), 127.4 (CH, q, J = 4.6 Hz), 126.6 (CH), 122.4 (C, q, J = 273.8 
Hz), 115.7 (C), 107.3 (C, q, J = 2.2 Hz), 47.8 (CH), 43.8 (CH2), 35.6 (CH2), 29.6 (CH2), 
22.6 (CH2), 13.9 (CH3); 
19
F NMR (376 MHz, CDCl3) δ –62.4 (3F, s); HRMS (ASAP) 
Exact mass calcd for C20H21N1F3 [M+H]
+
: 332.1621, found: 332.1624. Enantiomeric 
excess was determined by HPLC with a Chiralcel OD-H column (99:1 
hexane:isopropanol, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 8.1 min, tr (minor) 9.2 
min; 84% ee. 
 




To a solution of nitroarene 83q (119 mg, 0.40 mmol) in THF (4 mL) at –40 ºC was added  
vinylmagnesium bromide (1 M in THF, 1.32 mL, 1.32 mmol) over 1 min and the 
resulting mixture was stirred at –40 ºC for 2 h. The reaction was warmed to room 
temperature and quenched carefully with saturated aqueous NH4Cl solution (20 mL). The 
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aqueous layer was extracted with Et2O (3 x 40 mL) and the combined organic layers were 
washed with H2O (20 mL), brine (20 mL), dried (MgSO4), filtered, and concentrated in 
vacuo. Purification of the residue by column chromatography (10% CH2Cl2/hexane) gave 
the indole 91 (78 mg, 67%) as a pale yellow gum. [] 24
D
 +57.6 (c 1.25, CHCl3);  IR (film) 




H NMR (400 
MHz, CDCl3) δ 7.97 (1H, br s, NH), 7.33-7.24 (2H, m, ArH), 7.23-7.14 (5H, m, ArH), 
6.74 (1H, br s, NCH=CH), 6.48 (1H, dd, J = 3.2, 2.0 Hz, NCH=CH), 3.04-2.79 (3H, m, 
ArCH2CH), 2.45 (3H, s, ArCH3), 1.79-1.52 (2H, m, CH2CH2CH2CH3), 1.32-1.05 (4H, 
m, CH2CH2CH3), 0.79 (3H, t, J = 7.2 Hz, CH2CH3); 
13
C NMR (100.6 MHz, CDCl3)  
146.2 (C), 134.0 (C), 132.5 (C), 128.1 (2 x CH), 127.8 (2 x CH), 127.3 (C), 125.7 (CH), 
124.4 (CH), 123.7 (CH), 119.5 (C), 118.4 (CH), 102.8 (CH), 48.4 (CH), 44.0 (CH2), 35.0 
(CH2), 29.8 (CH2), 22.8 (CH2), 16.7 (CH3), 14.0 (CH3); HRMS (ES) Exact mass calcd for 
C21H26N1 [M+H]: 292.2060 found: 292.2061. 
 












A solution of nitroarene 83g (400 mg, 1.00 mmol) and 10% Pd/C (100 mg) in EtOH (20 
mL) at room temperature was stirred under an atmosphere of hydrogen (balloon) for 3 h. 
The solution was filtered through a short plug of celite using CH2Cl2 as eluent (50 mL) 
and concentrated in vacuo to leave the amine 207, which was used immediately without 
further purification. To the amine 207 was added a solution of TsCl (210 mg, 1.10 
mmol), Et3N (153 µL, 1.10 mmol), and DMAP (147 mg, 1.20 mmol) in CH2Cl2 (7.5 mL) 
via cannula and the resulting solution was stirred at room temperature for 16 h. The 
reaction was concentrated in vacuo and the residue was purified by column 
chromatography (20% CH2Cl2/hexane→40 % CH2Cl2/hexane) to give the sulfonamide 92 
(477 mg, 91%) as an off-white solid. Slow diffusion of hexane into a solution of 92 in 
EtOAc provided crystals that were suitable for X-ray crystallography. m.p. 84-86 C; 
[] 24D  +45.2 (c 1.06, CHCl3); IR (film) 3255 (NH), 2927, 1512, 1462, 1394, 1336, 1161, 




H NMR (500 MHz, CDCl3) δ 7.65 (2H, d, J = 8.3 Hz, ArH), 7.26-
7.13 (5H, m, ArH), 7.07-7.01 (2H, m, ArH), 6.93 (2H, d, J = 8.5 Hz, ArH), 6.86 (2H, d, J 
= 8.5 Hz, ArH), 3.53 (2H, t, J = 6.5 Hz, CH2O), 2.90-2.69 (3H, m, ArCH2CH), 2.39 (3H, 
s, ArCH3), 1.78-1.71 (1H, m, CH2CH2O), 1.66-1.60 (1H, m, CH2CH2O), 1.42-1.34 (2H, 
m, CH2CH2CH2O), 0.88 (9H, s, C(CH3)3), 0.02 (3H, s, SiCH3), 0.01 (3H, s, SiCH3); 
13
C 
NMR (125.8 MHz, CDCl3)  144.5 (C), 143.5 (C), 137.9 (C), 136.0 (C), 134.1 (C), 129.8 
(2 x CH), 129.4 (2 x CH), 128.1 (2 x CH), 127.7 (2 x CH), 127.2 (2 x CH), 126.0 (CH), 
121.7 (2 x CH), 63.0 (CH2), 47.7 (CH), 43.2 (CH2), 31.6 (CH2), 30.7 (CH2), 25.9 (3 x 
CH3), 21.5 (CH3), 18.2 (C), 5.4 (2 x CH3); HRMS (ES) Exact mass calcd for 
C30H42N1O3S1Si1 [M+H]: 524.2649 found: 524.2638. 
 
The sense of enantioinduction observed using ligand L5 is consistent with reported 
examples of arylation of acyclic electron-deficient alkenes using structurally similar 
chiral dienes,
43, 92
 and the absolute configurations of the remaining arylation products in 
this study were assigned by analogy with that of 83g. 
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THF and toluene were dried and purified by passage through activated alumina columns 
using a solvent purification system. All commercially available reagents were used as 
received. Thin layer chromatography (TLC) was performed on Merck DF-Alufoilien 
60F254 0.2 mm precoated plates. Product spots were visualized by UV light at 254 nm, 
and subsequently developed using vanillin, potassium permanganate, or ceric ammonium 
molybdate solution as appropriate. Flash column chromatography was carried out using 
silica gel (Fisher Scientific 60Å particle size 35-70 micron) employing the method of 
Still and co-workers.
194
 Melting points were recorded on a Gallenkamp melting point 
apparatus and are uncorrected. Infra-red spectra were recorded on a Jasco FT/IR-460 Plus 
instrument as a thin film on sodium chloride plates or as a dilute solution in CHCl3. 
1
H 
NMR spectra were recorded on a Bruker AV500 (500 MHz), a Bruker AVA400 (400 
MHz) spectrometer, or a Bruker OPEN400 (400 MHz) spectrometer. Chemical shifts () 
are quoted in parts per million (ppm) downfield of tetramethylsilane, using residual 
protonated solvent as internal standard (CDCl3 at 7.27 ppm). Abbreviations used in the 
description of resonances are: s (singlet), d (doublet), t (triplet), q, (quartet), app 





NMR spectra were recorded on a Bruker AV500 (125.8 MHz) 
spectrometer or a Bruker AVA400 (100.6 MHz) spectrometer. Chemical shifts () are 
quoted in parts per million (ppm) downfield of tetramethylsilane, using deuterated 
solvent as internal standard (CDCl3 at 77.0 ppm). Assignments were made using the 
DEPT sequence with secondary pulses at 90° and 135°. Proton-decoupled 
19
F NMR 
spectra were recorded on a Bruker AVA 400 MHz (376 MHz) spectrometer. Chemical 
shifts are reported in parts per million (ppm) downfield of CFCl3, using fluorobenzene as 
internal standard (C6H5F at –113.2 ppm). High resolution mass spectra were recorded on 
a Finnigan MAT 900 XLT spectrometer or a Finnigan MAT 95XP spectrometer at the 
EPSRC National Mass Spectrometry Service Centre, University of Wales, Swansea, or 
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on a Finnigan MAT 900 XLT spectrometer at the School of Chemistry, University of 
Edinburgh. Optical rotations were performed on an Optical Activity POLAAR 20 
polarimeter. Chiral HPLC analysis was performed on an Agilent 1100 instrument using 
4.6 x 250 mm columns. Authentic racemic samples of products for chiral HPLC assay 
determinations were obtained using rac-BINAP as the ligand. 
 




To a solution of trimethyl borate (6.9 mL, 62 mmol) in THF (45 mL) was added dropwise 
vinylmagnesium bromide 186 (1.0 M THF solution, 50 mL, 50 mmol) at –78 °C. The 
resulting suspension was stirred for 20 min at -78 °C and then allowed to warm to rt for 1 
h. The mixture was then cooled to 0 °C and KHF2 (19 g, 248 mmol) was added followed 
by the addition of water (35 mL) over 30 min. After stirring at rt for 20 min, the solution 
was concentrated and the crude material was dissolved in acetone, filtered and 
concentrated. The resulting white solid was purified by dissolving in hot acetone and 
precipitating with Et2O, to give 179 (3.5 g, 95%) as a white solid that displayed 





Preparation of Alkenylazaarenes 
 







A solution of 2-chloroquinoline (1.64 g, 10.0 mmol), potassium vinyltrifluoroborate (1.61 
g, 12.0 mmol), PdCl2(dppf)·CH2Cl2 (163 mg, 0.20 mmol), and Et3N (1.39 mL, 10.0 
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mmol) in i-PrOH (156 mL) was heated to reflux for 16 h. The mixture was cooled to 
room temperature and partitioned between CH2Cl2 (100 mL) and H2O (40 mL). The 
aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) and the combined 
organic layers were washed with brine (100 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification of the residue by column chromatography (5% 
EtOAc/hexane) gave 2-vinylquinoline (180a) (1.26 g, 81%) as a pale yellow oil that 








 A solution of 1-chloroisoquinoline (2.62 g, 16.0 mmol), potassium vinyltrifluoroborate 
(2.57 g, 19.2 mmol), PdCl2(dppf)·CH2Cl2 (261 mg, 0.32 mmol), and Et3N (2.23 mL, 16.0 
mmol) in i-PrOH (160 mL) was heated to reflux for 16 h. The mixture was cooled to 
room temperature and partitioned between CH2Cl2 (100 mL) and H2O (80 mL). The 
aqueous layer was separated and extracted with CH2Cl2 (2 x 100 mL) and the combined 
organic layers were washed with brine (100 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification of the residue by column chromatography (5% 
EtOAc/hexane→20% EtOAc/hexane) gave 1-vinylisoquinoline (180c) (1.41 g, 57%) as a 









A solution of 2-chloroquinoxaline (1.32 g, 8.00 mmol), potassium vinyltrifluoroborate 
(1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and Et3N (1.12 mL, 8.00 
mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The mixture was cooled to 
room temperature and partitioned between CH2Cl2 (100 mL) and H2O (40 mL). The 
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aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) and the combined 
organic layers were washed with brine (100 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification of the residue by column chromatography (5% 
EtOAc/hexane) gave the vinylquinoxaline 180d (944 mg, 76%) as an orange oil that 






A solution of 2-chloro-4,6-methoxypyrimidine (1.40 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and 
Et3N (1.12 mL, 8.00 mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (100 mL) and 
H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) 
and the combined organic layers were washed with brine (100 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the vinylpyrimidine 180e (1.00 g, 75%) as a 





H NMR (500 MHz, CDCl3)  6.70 (1H, dd, J = 17.3, 10.2 Hz, CH=CH2), 6.60 (1H, 
dd, J = 17.3, 2.2 Hz, CH=CH2), 5.92 (1H, s, ArH), 5.68 (1H, dd, J = 10.2, 2.2 Hz, 
CH=CH2), 3.97 (6H, s, 2 x OCH3); 
13
C NMR (125.8 MHz, CDCl3)  171.3 (2 x C), 163.3 
(C), 136.5 (CH), 123.6 (CH2), 88.0 (CH), 53.9 (2 x CH3); HRMS (ESI) Exact mass calcd 
for C8H11N2O2 [M+H]
+




 A solution of 6-chloro-2,4-methoxypyrimidine (1.40 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and 
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Et3N (1.12 mL, 8.00 mmol) in  i-PrOH (125 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (100 mL) and 
H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) 
and the combined organic layers were washed with brine (100 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the vinylpyrimidine 180f (1.07 g, 80%) as a 




H NMR (500 MHz, CDCl3)  6.60 (1H, dd, J =17.2, 10.4 Hz, CH=CH2), 6.46 (1H, dd, J 
= 17.2, 1.7 Hz, CH=CH2), 6.29 (1H, s, ArH), 5.58 (1H, dd, J = 10.4, 1.7 Hz, CH=CH2), 
4.02 (3H, s, OCH3), 3.98 (3H, s, OCH3); 
13
C NMR (125.8 MHz, CDCl3)  172.4 (C), 
165.3 (C), 164.1 (C), 134.7 (CH), 121.9 (CH2), 99.3 (CH), 54.6 (CH3), 53.9 (CH3); 
HRMS (ESI) Exact mass calcd for C8H11N2O2 [M+H]
+
: 167.0815, found:167.0814. 
 
2-Vinyl-4-phenyl-1,3-thiazole (180g)  
 
A solution of 2-bromo-4-phenylthiazole (1.92 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and 
Et3N (1.12 mL, 8.00 mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (100 mL) and 
H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) 
and the combined organic layers were washed with brine (100 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (10% EtOAc/hexane) gave the vinylthiazole 180g (1.40 g, 93%) as a 





H NMR (500 MHz, CDCl3)  7.94-7.89 (2H, m, ArH), 7.46-7.41 (2H, m, 
ArH), 7.40 (1H, s, ArH), 7.37-7.33 (1H, m, ArH), 7.00 (1H, ddd, J = 17.5, 10.9, 0.5 Hz, 
CH=CH2), 6.11 (1H, dd, J =17.5 Hz, CH=CH2), 5.59 (1H, dd, J = 10.9 Hz, CH=CH2); 
13
C NMR (125.8 MHz, CDCl3)  166.9 (C), 156.0 (C), 134.3 (C), 130.6 (CH), 128.7 (2 x 







A solution of 2-bromobenzothiazole (1.00 g, 4.67 mmol), potassium vinyltrifluoroborate 
(0.75 g, 5.61 mmol), PdCl2(dppf)·CH2Cl2 (76 mg, 0.09 mmol), and Et3N (0.65 mL, 4.67 
mmol) in i-PrOH (60 mL) was heated to reflux for 16 h. The mixture was cooled to room 
temperature and partitioned between CH2Cl2 (50 mL) and H2O (20 mL). The aqueous 
layer was separated and extracted with CH2Cl2 (2 x 50 mL) and the combined organic 
layers were washed with brine (50 mL), dried (MgSO4), filtered, and concentrated in 
vacuo. Purification of the residue by column chromatography (5% EtOAc/hexane) gave 
the vinylbenzothiazole 180h (0.530 g, 70%) as a pale yellow solid. IR (film) 3060, 2359, 




H NMR (500 MHz, CDCl3)  8.00 
(1H, m, ArH), 7.86 (1H, ddd, J = 7.9, 1.1, 0.6 Hz, ArH), 7.48 (1H, ddd, J = 8.3, 7.3, 1.2 
Hz, ArH), 7.39 (1H, ddd, J = 8.3, 7.3, 1.2 Hz, ArH), 7.06 (1H, dd, J = 17.5, 10.9 Hz, 
CH=CH2), 6.20 (1H, d, J =17.5 Hz, CH=CH2), 5.78 (1H, d, J =10.9 Hz, CH=CH2); 
13
C 
NMR ((125.8 MHz, CDCl3)  167.2 (C), 153.6 (C), 134.3 (C), 131.4 (CH), 126.3 (CH), 
125.6 (CH), 123.3 (CH), 123.2 (CH2), 121.6 (CH); m/z (ES) 161.1 ([M+H]
+






A solution of 2-chlorobenzoxazole (768 mg, 5.0 mmol),  potassium vinyltrifluoroborate 
(800 mg, 6.0 mmol), PdCl2(dppf)·CH2Cl2 (82 mg, 0.082 mmol), and Et3N (0.7 mL, 5.0 
mmol) in i-PrOH (80 mL) was heated to reflux for 16 h. The mixture was cooled to room 
temperature and partitioned between CH2Cl2 (50 mL) and H2O (20 mL). The aqueous 
layer was separated and extracted with CH2Cl2 (2 x 50 mL) and the combined organic 
layers were washed with brine (50 mL), dried (MgSO4), filtered, and concentrated in 
vacuo. Purification of the residue by column chromatography (5% EtOAc/hexane) gave 
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the vinylbenzoxazole 180i (726 mg, 67%) as a colourless oil that displayed spectroscopic 




Ethyl 6-vinylpyridine-3-carboxylate (180j) 
 
 A solution of ethyl-6-chloronicotinate (1.48 g, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and 
Et3N (1.12 mL, 8.00 mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (100 mL) and 
H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) 
and the combined organic layers were washed with brine (100 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the vinylpyridine 180j (1.30 g, 92%) as a pale 





H NMR (500 MHz, CDCl3)  9.17 (1H, d, J = 1.8 Hz, ArH), 8.25 (1H, dd, J = 8.2, 
2.2 Hz, ArH), 7.40 (1H, d, J = 8.2 Hz, ArH), 6.87 (1H, dd, J = 17.5, 10.8 Hz, CH=CH2), 
6.34 (1H, dd, J = 17.5, 1.0 Hz, CH=CH2), 5.62 (1H, dd, J = 10.8, 1.0 Hz, CH=CH2), 
4.41 (2H, q, J = 7.1 Hz, OCH2CH3), 1.41 (3H, t, J = 7.1 Hz, OCH2CH3); 
13
C NMR 
(125.8 MHz, CDCl3)  165.2 (C), 159.1 (C), 150.8 (CH), 137.6 (CH), 136.2 (CH), 124.8 




2-Vinyl-nicotinitrile (180k)   
 
A solution of 2-chloronicotinonitrile (1.11 g, 8.00 mmol), potassium vinyltrifluoroborate 
(1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and Et3N (1.12 mL, 8.00 
mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The mixture was cooled to 
room temperature and partitioned between CH2Cl2 (100 mL) and H2O (40 mL). The 
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aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) and the combined 
organic layers were washed with brine (100 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. Purification of the residue by column chromatography (5% 
EtOAc/hexane) gave the vinylnicotinitrile 180k (847 mg, 81%) as a pink solid. IR (film) 




H NMR (500 
MHz, CDCl3)  8.77 (1H, dd, J = 4.8, 1.7 Hz, ArH), 7.93 (1H, dd, J =7.9, 1.8 Hz, ArH), 
7.29 (1H, dd, , J =7.9, 4.8 Hz, ArH), 7.20 (1H, dd, J =16.9, 10.7 Hz, ArCH=CH), 6.67 
(1H, dd, J =16.9, 1.9 Hz, ArCH=CH2), 5.76 (1H, dd, J =10.7, 1.5 Hz, ArCH=CH2); 
13
C 
NMR (125.8 MHz, CDCl3)  157.1(C), 152.7 (CH), 140.4 (CH), 132.0 (CH), 123.9 






A solution of ethyl-2-chloronicotinate (928 mg, 5.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and 
Et3N (1.12 mL, 8.00 mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (100 mL) and 
H2O (40 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 50 mL) 
and the combined organic layers were washed with brine (100 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the vinylnicotinate 180l (804 mg, 91%) as a 
dark yellow oil. IR (film) 2982, 1722 (C=O), 1581, 1557, 1437, 1263, 1140, 1073, 990, 




H NMR (500 MHz, CDCl3)  8.69 (1H, dd, J = 4.7, 1.8 Hz, ArH), 
8.15 (1H, dd, J =7.9, 1.8 Hz, ArH), 7.62 (1H, dd, , J =17.0, 10.7 Hz, ArH), 7.23 (1H, dd, 
J =7.9, 4.7 Hz, ArH), 6.49 (1H, dd, J =17.0, 2.2 Hz, ArCH=CH), 5.59(1H, dd, J =10.7, 
2.2 Hz, ArCH=CH), 4.39 (2H, q, J = 7.14, 7.12 Hz, -OCH2CH3), 1.4 (3H, t, J = 7.14 Hz, 
-OCH2CH3) ; 
13
C NMR (125.8 MHz, CDCl3)   166.4(C), 155.0 (C), 151.9 (CH), 138.4 










A solution of 2-bromoacetophenone (0.40 mL, 3.00 mmol), potassium 
vinyltrifluoroborate (482 mg, 3.60 mmol), PdCl2(dppf)·CH2Cl2 (49 mg, 0.06 mmol), and 
Et3N (0.42 mL, 3.00 mmol) in i-PrOH (50 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (50 mL) and 
H2O (20 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 20 mL) 
and the combined organic layers were washed with brine (50 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the vinylacetophenone 190a (847 mg, 81%) as 









A solution of methyl-2-bromobenzoate (1.12 mL, 8.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and 
Et3N (1.12 mL, 8.00 mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (50 mL) and 
H2O (20 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 20 mL) 
and the combined organic layers were washed with brine (50 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the vinylbenzene 190b (1.10 g, 85%) as a clear 










A solution of ethyl-4-bromobenzoate (1.31 mL, 3.00 mmol), potassium 
vinyltrifluoroborate (1.29 g, 9.60 mmol), PdCl2(dppf)·CH2Cl2 (131 mg, 0.16 mmol), and 
Et3N (1.12 mL, 8.00 mmol) in i-PrOH (125 mL) was heated to reflux for 16 h. The 
mixture was cooled to room temperature and partitioned between CH2Cl2 (50 mL) and 
H2O (20 mL). The aqueous layer was separated and extracted with CH2Cl2 (2 x 20 mL) 
and the combined organic layers were washed with brine (50 mL), dried (MgSO4), 
filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (5% EtOAc/hexane) gave the ethenylbenzoate 190c (1.13 g, 80%) as a 





(E)-4,5-Diphenyl-2-(prop-1-enyl)oxazole (183a). Prepared by other 







A solution of 2-bromopyrimidine (477 mg, 3.00 mmol), alkenylboronic ester 85e (588 
μL, 2.77 mmol), Pd(OAc)2 (34 mg, 0.15 mmol), PPh3 (157 mg, 0.60 mmol), and Cs2CO3 
(1.95 g, 6.00 mmol) in MeCN (30 mL) and H2O (8 mL) was heated to reflux for 16 h. 
The mixture was cooled to room temperature, diluted with H2O (30 mL), and extracted 
with CH2Cl2 (2 x 50 mL). The combined organic layers were washed with saturated 
aqueous NH4Cl solution (50 mL), dried (MgSO4), filtered, and concentrated in vacuo. 
Purification of the residue by column chromatography (5% EtOAc/hexane→40% 
EtOAc/hexane) gave the alkenylpyrimidine 183b (303 mg, 75%) as a yellow oil. IR 




H NMR (500 
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MHz, CDCl3) 8.69 (2H, d, J = 4.7 Hz, ArH), 7.19 (1H, dt, J = 15.7, 5.7 Hz, =CHCH2), 
7.12 (1H, t, J = 4.9 Hz, ArH), 6.83-6.76 (1H, m, CH=CHCH2), 4.21 (2H, dd, J = 5.2, 1.7 
Hz, CH2), 3.44 (3H, s, OCH3); 
13
C NMR (125.8 MHz, CDCl3)  164.2 (C), 157.0 (2 x 
CH), 137.1 (CH), 130.4 (CH), 118.8 (CH), 72.1 (CH2), 58.4 (CH3); HRMS (EI) Exact 
mass calcd for C8H10N2O1 [M]
+
: 150.0788, found: 150.0787. 
 
2,4-Dimethoxy-6-[(E)-3-methoxyprop-1-en-1-yl]-1,3,5-triazine (183c)  
 
A solution of 2-chloro-4,6-dimethyl-1,3,5-triazine (1.40 g, 8.00 mmol), boronic ester 
85a
195
 (2.27 g, 8.80 mmol), Pd(OAc)2 (269 mg, 1.20 mmol), PPh3 (630 mg, 2.40 mmol), 
and NaOH (960 mg, 24.0 mmol) in THF (80 mL) was heated to reflux for 2 h. The 
mixture was cooled to room temperature, diluted with H2O (60 mL), and extracted with 
CH2Cl2 (2 x 50 mL). The combined organic layers were washed with brine (50 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. Purification of the residue by column 
chromatography (10% EtOAc/hexane→20% EtOAc/hexane) gave the alkenyltriazine 
183c (1.41g, 65%) as a pale brown solid. m.p. 52-54 C; IR (film) 1654, 1559, 1498, 




H NMR (500 MHz, CDCl3) 7.48 (1H, dt, 
J = 15.6, 6.9 Hz, =CHCH2), 7.33-7.28 (2H, m, ArH), 7.24-7.18 (3H, m, ArCH), 6.39 
(1H, d, J = 15.6 Hz, CH=CHCH2), 4.05 (6H, s, 2 x OCH3), 2.88-2.81 (2H, m, CH2Ph), 
2.68-2.60 (2H, m, CH2CH2Ph); 
13
C NMR (125.8 MHz, CDCl3)  174.6 (C), 172.5 (C), 
146.3 (CH), 141.0 (C), 128.5 (2 x CH), 128.3 (2 x CH), 126.1 (CH), 55.0 (2 x CH3), 34.6 
(CH2), 34.4 (CH2); HRMS (EI) Exact mass calcd for C15H18N3O2 [M]
+
: 272.1394, found: 
272.1391. 
 
Preparation of Alkene 187a 
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(Z)-2-Benzyl-3-pyridin-2-ylpropenal (185). Following a slight 
modification of a literature procedure for a similar compound,
206
 to a 
vigorously stirred suspension of Bu4NPF6 (387 mg, 1.00 mmol) and KOH (84 mg, 1.50 
mmol) in toluene (15 mL) was added 2-pyridinecarboxaldehyde (0.95 mL, 10.0 mmol) 
dropwise over 1 min, followed by hydrocinnamaldehyde (1.76 mL, 12.0 mmol) dropwise 
over 2 min. The reaction was stirred vigorously at room temperature for 5 h, and then 
partitioned between H2O (50 mL) and CH2Cl2 (50 mL). The aqueous layer was separated 
and extracted with CH2Cl2 (2 x 50 mL) and the combined organic layers were dried 
(Na2SO4) and concentrated in vacuo. Purification of the residue by column 
chromatography (20% EtOAc/hexane→60% EtOAc/hexane) gave the enal 185 (819 mg, 
37%) as a red-brown solid. m.p. 46-48 °C; IR (CHCl3) 3059, 2924, 2823, 2717, 2360, 
1684 (C=O), 1631 (C=C), 1579, 1308, 1136, 739; 
1
H NMR (250 MHz, CDCl3)  9.53 
(1H, s, CHO), 8.61-8.59 (1H, m, ArH), 7.57 (1H, dt, J = 7.8, 1.9 Hz, ArH), 7.29 (1H, d, J 
= 7.8 Hz, ArH), 7.21-6.98 (7H, m, ArH and CH=CCH2Ph), 4.24 (2H, s, CH2Ph); 
13
C 
NMR (62.9 MHz, CDCl3)  195.3 (CH), 153.7 (C), 149.8 (CH), 147.6 (CH), 143.7 (C), 
139.0 (C), 136.4 (CH), 128.6 (2 x CH), 128.1 (2 x CH), 126.2 (CH), 125.8 (CH), 123.7 





(Z)-2-Benzyl-3-pyridin-2-ylprop-2-en-1-ol (186). To a solution of 
aldehyde 185 (447 mg, 2.00 mmol) in EtOH (10 mL) at room 
temperature was added NaBH4 (227 mg, 6.00 mmol) portionwise over 5 min. The 
resulting mixture was stirred at room temperature for 1 h and quenched carefully with 
saturated aqueous NH4Cl solution (20 mL). Most of the EtOH was removed in vacuo, and 
the aqueous residue was extracted with EtOAc (3 x 30 mL). The combined organic layers 
were dried (MgSO4) and concentrated in vacuo. Purification of the residue by column 
chromatography (50% EtOAc/hexane) gave the alcohol 186 (451 mg, 99%) as a cream 
solid. m.p. 67-69 C; IR (film) 3273 (OH), 3025, 2906, 1659 (C=C), 1585, 1472, 1151, 




H NMR (360 MHz, CDCl3)  8.46-8.40 (1H, m, ArH), 7.49 (1H, 
dt, J = 7.7, 1.8 Hz, ArH), 7.16-7.03 (6H, m, ArH), 7.00 (1H, ddd, J = 7.5, 4.9, 0.9 Hz, 









C NMR (62.9 MHz, CDCl3)  156.3 (C), 148.8 (CH), 145.0 (C), 139.2 (C), 
136.3 (CH), 128.4 (2 x CH), 128.3 (2 x CH), 125.9 (CH), 124.3 (CH), 123.7 (CH), 121.3 
(CH), 65.2 (CH2), 34.2 (CH2); HRMS (ES) Exact mass calcd for C15H16N1O1 [M+H]
+
: 
226.1226, found: 226.1223. 
The stereochemistry of alcohol 186 was determined using an NOE experiment, which 









pyridine (187a). To a solution of the alcohol 186 (0.50 mmol) and 
imidazole (85 mg, 1.25 mmol) in DMF (2 mL) at room temperature was added TBSCl 
(98 mg, 0.65 mmol) in one portion, and the mixture was stirred at room temperature for 1 
h. The reaction was quenched with saturated aqueous NH4Cl solution (15 mL) and the 
mixture was extracted with Et2O (2 x 20 mL). The combined organic layers were washed 
with brine (15 mL). The brine layer was separated and extracted with Et2O (2 x 20 mL), 
and the combined organic layers were dried (MgSO4), and concentrated in vacuo. 
Purification of the residue by column chromatography (10% EtOAc/hexane) gave the 
alkenylpyridine 187a (134 mg, 79%) as a yellow oil. IR (film) 2927, 2855, 1691 (C=C), 




H NMR (360 MHz, CDCl3) δ 8.62-8.56 
(1H, m, ArH), 7.63-7.55 (1H, m, ArH), 7.29-7.14 (6H, m, ArH), 7.12-7.05 (1H, m, ArH), 
6.79 (1H, s, CCHC), 4.15 (2H, d, J = 1.7 Hz, OCH2), 4.07 (2H, s, PhCH2), 0.93 (9H, s, 
C(CH3)3), 0.04 (6H, s, Si(CH3)2); 
13
C NMR (90.6 MHz, CDCl3)  156.7 (C), 149.2 (CH), 
144.3 (C), 139.7 (C), 136.0 (CH), 128.6 (2 x CH), 128.3 (2 x CH), 125.9 (CH), 124.1 
(CH), 123.9 (CH), 121.1 (CH), 66.0 (CH2), 34.1 (CH2), 25.9 (3 x CH3), 18.3 (C), -5.5 (2 




Acetic acid (E)-2-benzyl-3-pyridin-2-ylallyl ester (187b) 
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To a solution of the alcohol 186 (225 mg, 1.00 mmol), Et3N (697 L, 5.00 mmol), and 
DMAP (31 mg, 0.25 mmol) in CH2Cl2 (5 mL) at room temperature was added acetic 
anhydride (198 L, 2.10 mmol) over 1 min, and the resulting mixture was stirred at room 
temperature for 5 h. The reaction was quenched with saturated aqueous Na2CO3 solution 
(20 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were dried 
(Na2SO4) and concentrated in vacuo. Purification of the residue by column 
chromatography (25% EtOAc/hexane→50% EtOAc/hexane) gave the acetic ester 187b 
(207 mg, 78%) as a pale yellow oil. IR (film) 3026, 1739 (C=O), 1658, 1584, 1494, 1431, 




H NMR (360 MHz, CDCl3) δ 8.72-8.50 (1H, m, ArH), 
7.69-7.57 (1H, m, ArH), 7.33-7.07 (7H, m, ArH), 6.73 (1H, s, CCHC), 4.62 (2H, s, 
OCH2), 4.16 (2H, s, PhCH2), 2.04 (3H, s, CH3); 
13
C NMR (90.6 MHz, CDCl3)  170.4 
(C), 155.5 (C), 149.1 (CH), 139.3 (C), 138.8 (C), 136.0 (CH), 128.6 (2 x CH), 128.3 (2 x 
CH), 127.7 (CH), 126.0 (CH), 124.1 (CH), 121.6 (CH), 67.3 (CH2), 34.5 (CH2), 20.7 




Copper-Catalyzed Reductive Coupling of Alkenylazaarenes with Ketones 
 
General Procedure B: Reductive Coupling of Vinylazaarenes Using Ligand L13 
(0.40 mmol Scale) 
 
A solution of the appropriate vinylazaarene (0.40 mmol), Cu(OAc)2·H2O (4.0 mg, 0.02 
mmol), ligand SL-T001-1 (L13) (13.8 mg, 0.02 mmol), and the appropriate ketone (0.44 
mmol) in toluene (2 mL) was stirred at 0 °C for 15 min. PhSiH3 (59 μL, 0.48 mmol) was 
then added dropwise over 1 min. The mixture was stirred at 0 °C for 30 min, then at room 
temperature for 15 h. The reaction was quenched carefully with silica gel (ca. 250 mg), 
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and the resulting suspension was stirred for 15 min before being filtered through a short 
plug of silica gel using EtOAc (50 mL) as eluent. The filtrate was concentrated in vacuo 
and the residue was purified by column chromatography to give the reductive coupling 
product. 
 
(2S,3R)-2-Phenyl-3-(quinolin-2-yl)butan-2-ol (193a). The title 
compound was prepared according to General Procedure B from 2-
vinylquinoline 180a (62 mg, 0.40 mmol) and acetophenone (51 μL, 
0.44 mmol) and purified by column chromatography (5% EtOAc/hexane) to give a white 
solid (66 mg, 60%). m.p. 108-110 C; [α] +14.2 (c 0.84, CHCl3); IR (film) 3312 (OH), 




H NMR (500 MHz, CDCl3)  
8.17 (1H, d, J = 8.4 Hz, ArH), 8.08 (1H, d, J = 8.5 Hz, ArH), 7.84 (1H, d, J = 8.0 Hz, 
ArH), 7.77-7.73 (1H, m, ArH), 7.62 (2H, d, J = 7.4 Hz, ArH), 7.58-7.53 (1H, m, ArH), 
7.41 (2H, t, J = 7.8 Hz, ArH), 7.36 (1H, d, J = 8.4 Hz, ArH), 7.30-7.26 (1H, m, ArH), 
7.06 (1H, br s, OH), 3.36 (1H, q, J = 7.0 Hz, CHCH3), 1.41 (3H, s, CH3COH), 1.13 (3H, 
d, J = 7.1 Hz, CHCH3); 
13
C NMR (125.8 MHz, CDCl3)  166.1 (C), 147.4 (C), 146.9 (C), 
137.1 (CH), 129.9 (CH), 128.8 (CH), 128.0 (2 x CH), 127.6 (CH), 126.9 (C), 126.22 
(CH), 126.18 (CH), 125.0 (2 x CH), 122.5 (CH), 76.4 (C), 50.7 (CH), 30.8 (CH3), 17.1 
(CH3); HRMS (ESI) Exact mass calcd for C19H20N1O1 [M+H]
+
: 278.1539, found: 
278.1541. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column 
(98:2 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (minor) = 12.6 min, tr (major) = 
20.3 min; 93% ee.  
 
(2S,3R)-1,2-Diphenyl-3-(quinolin-2-yl)butan-2-ol (193b). The title 
compound was prepared according to General Procedure B from 2-
vinylquinoline 180a (62 mg, 0.40 mmol) and 2-phenylacetophenone 
(86 mg, 0.44 mmol) and purified by column chromatography (5% EtOAc/hexane) to give 
a white solid (85 mg, 60%). m.p. 108-110 C; [α] 24D  +55.2 (c 1.05, CHCl3);  IR (film) 




H NMR (500 
MHz, CDCl3)  8.22 (1H, d, J = 8.4 Hz, ArH), 8.13 (1H, d, J = 8.5 Hz, ArH), 7.87 (1H, 









7.47-7.40 (3H, m, ArH), 7.36-7.27 (3H, m, ArH and OH), 7.25-7.20 (1H, m, ArH), 7.02-
6.98 (3H, m, ArH), 6.70 (2H, dd, J =6.4, 3.1 Hz, ArH), 3.60 (1H, q, J = 7.0 Hz, CHCH3), 
3.10 (1H, d, J = 13.4 Hz, CH2Ph), 2.90 (1H, d, J = 13.4 Hz, CH2Ph), 1.17 (3H, d, J = 7.1 
Hz, CHCH3); 
13
C NMR (125.8 MHz, CDCl3)  166.2 (C), 146.8 (C), 144.5 (C), 137.5 
(C), 137.3 (CH), 130.5 (2 x CH), 130.0 (CH), 128.7 (CH), 127.6 (4 x CH), 127.1 (2 x 
CH), 126.8 (C), 126.3 (CH), 126.1 (CH), 125.9 (CH), 125.6 (CH), 122.7 (CH), 79.6 (C), 
49.0 (CH), 48.9 (CH2), 17.5 (CH3); HRMS (ESI) Exact mass calcd for C25H24N1O1 
[M+H]
+
: 354.1852, found: 354.1856. Enantiomeric excess was determined by HPLC with 
a Chiralcel OD-H column (99:1 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) 
= 10.9 min, tr (minor) = 12.4 min; 97% ee. 
Vapor diffusion of hexane into an EtOAc solution of 193b gave crystals suitable for X-
ray diffraction. 
 
2-Phenyl-3-(pyridin-2-yl)butan-2-ol (193ca and 193cb) 
 
General Procedure B was followed using 2-vinylpyridine 180b (43 µL, 0.40 mmol) and 
acetophenone (51 µL, 0.44 mmol). Purification by column chromatography (5% 
EtOAc/hexane) gave the tertiary alcohol 193cb (28 mg, 31%) as a white solid followed 
by the tertiary alcohol 193ca (59 mg, 65%) as a colorless oil. 
Data for 193ca: [α] 24D  +190.2 (c 1.13, CHCl3); IR (film) 3313 (OH), 2982, 1596, 1569, 




H NMR (500 MHz, CDCl3) δ 8.40-8.35 (1H, m, 
ArH), 7.38 (1H, td, J = 7.7, 1.8 Hz, ArH), 7.35-7.30 (2H, m, ArH), 7.17-7.10 (2H, m, 
ArH), 7.04-7.01 (1H, m, ArH), 6.98 (1H, ddd, J = 7.5, 4.9, 1.1 Hz, ArH), 6.79-6.78 (1H, 
m, ArH), 6.61 (1H, br s, OH), 3.29 (1H, q, J = 7.0 Hz, CHCH3), 1.57 (3H, s, CH3COH), 
1.47 (3H, d, J = 7.0 Hz, CHCH3); 
13
C NMR (125.8 MHz, CDCl3) δ 164.8 (C), 149.4 (C), 
147.9 (CH), 136.6 (CH), 127.5 (2 x CH), 125.7 (CH), 124.8 (2 x CH), 123.4 (CH), 121.2 




: 228.1383, found: 228.1385. Enantiomeric excess was determined 
by HPLC with a Chiralpak AD-H column (98:2 hexane:i-PrOH 0.8 mL/min, 280 nm, 25 
°C); tr (major) = 19.7 min, tr (minor) ca. 23 min (not detected); >99% ee. 
Data for 193cb: m.p. 94-95 C; [α] 24
D
 +73.5 (c 1.06, CHCl3); IR (film) 3329 (OH), 2972, 




H NMR (500 MHz, CDCl3) δ 8.56 
(1H, dd, J = 5.2, 2.0 Hz, ArH), 7.68 (1H, td, J = 7.7, 1.9 Hz, ArH), 7.59-7.54 (2H, m, 
ArH), 7.41-7.34 (2H, m, ArH), 7.28-7.19 (3H, m, ArH), 6.53 (1H, br s, OH), 3.16 (1H, q, 
J = 7.0 Hz, CHCH3), 1.33 (3H, s, CH3COH), 1.04 (3H, d, J = 7.1 Hz, CHCH3); 
13
C NMR 
(125.8 MHz, CDCl3) δ 165.1 (C), 148.4 (CH), 147.4 (C), 137.1 (CH), 127.9 (2 x CH), 
126.1 (CH), 125.0 (2 x CH), 123.9 (CH), 121.6 (CH), 76.1 (C), 50.2 (CH), 30.7 (CH3), 
16.9 (CH3); HRMS (ESI) Exact mass calcd for C15H18N1O1 [M+H]
+
: 228.1383, found: 
228.1386. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column 
(98:2 hexane:i-PrOH, 0.8 mL/min, 254 nm, 25 °C); tr (minor) = 13.1 min, tr (major) = 
15.2 min; 92% ee.  
 
(2R,3S)-3-(Isoquinolin-1-yl)-2-phenylbutan-2-ol (193d). The title 
compound was prepared according to General Procedure B from 2-
vinylisoquinoline 180c (62 mg, 0.40 mmol) and acetophenone (51 μL, 
0.44 mmol) and purified by column chromatography (5% EtOAc/hexane) 
to give a white solid (84 mg, 76%). m.p 72-74 C; [α] 24D  −111.9 (c 0.97, CHCl3); IR 





(500 MHz, CDCl3)  8.48 (1H, d, J = 5.7 Hz, ArH), 8.29 (1H, d, J =8.5 Hz, ArH), 7.89 
(1H, d, J = 8.1 Hz, ArH), 7.77-7.65 (4H, m, ArH), 7.61 (1H, d, J = 5.7 Hz, ArH), 7.49 
(1H, br s, OH), 7.44 (2H, t, J = 7.8 Hz, ArH), 7.33-7.28 (1H, m, ArH), 4.12 (1H, q, J = 
7.0 Hz, CHCH3), 1.38 (3H, s, CH3COH), 1.13 (3H, d, J = 7.0 Hz, CHCH3); 
13
C NMR 
(125.8 MHz, CDCl3)  165.8 (C), 147.8 (C), 140.4 (CH), 136.6 (C), 130.3 (CH), 128.0 (2 
x CH), 127.8 (CH), 127.6 (CH), 127.1 (C), 126.2 (CH), 125.1 (2 x CH), 124.5 (CH), 
119.5 (CH), 76.4 (C), 43.8 (CH), 30.5 (CH3), 16.9 (CH3); HRMS (ESI) Exact mass calcd 
for C19H20N1O1 [M+H]
+
: 278.1539, found: 278.1542. Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column (98:2 hexane:i-PrOH, 0.8 mL/min, 






General Procedure C: Reductive Coupling of Vinylazaarenes Using Ligand L13 
(0.30 mmol Scale) 
 
A solution of the appropriate vinylazaarene (0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 0.015 
mmol), ligand SL-T001-1 (L13) (10.3 mg, 0.015 mmol), and the appropriate ketone (0.33 
mmol) in toluene (1.5 mL) was stirred at 0 °C for 15 min. PhSiH3 (44 μL, 0.36 mmol) 
was then added dropwise over 1 min. The mixture was stirred at 0 °C for 30 min, then at 
room temperature for 15 h. The reaction was quenched carefully with silica gel (ca. 250 
mg), and the resulting suspension was stirred for 15 min before being filtered through a 
short plug of silica gel using EtOAc (50 mL) as eluent. The filtrate was concentrated in 




(trifluoromethyl)phenyl]butan-2-ol (193e). The title compound 
was prepared according to General Procedure C from 2-
vinylisoquinoline 180c (47 mg, 0.30 mmol) and 4'-
(trifluoromethyl)acetophenone (62 mg, 0.33 mmol) and purified by column 
chromatography (5% EtOAc/hexane) to give a white solid (85 mg, 82%). m.p. 132-134 
C; [α] 24D  –106.7 (c 1.03, CHCl3); IR (film) 3283 (OH), 2974, 1457, 1330, 1164, 1122, 




H NMR (500 MHz, CDCl3) δ 8.48 (1H, d, J = 5.7 Hz, ArH), 
8.26 (1H, d, J = 8.4 Hz, ArH), 7.90 (1H, d, J = 8.1 Hz, ArH), 7.83 (2H, d, J = 8.1 Hz, 
ArH), 7.76 (1H, ddd, J = 8.1, 6.9, 1.1 Hz, ArH), 7.72-7.67 (3H, m, ArH), 7.66 (1H, br s, 
OH), 7.63 (1H, d, J = 5.7 Hz, ArH), 4.10 (1H, q, J = 7.0 Hz, CHCH3), 1.38 (3H, s, 
CH3COH), 1.11 (3H, d, J = 7.0 Hz, CHCH3); 
13
C NMR (125.8 MHz, CDCl3) δ 165.2 
(C), 151.9 (C), 140.4 (CH), 136.6 (C), 130.5 (CH), 128.5 (C, q, J = 32.3 Hz), 127.9 (CH), 






271.8 Hz), 124.4 (CH), 119.8 (CH), 76.4 (C), 43.6 (CH), 30.4 (CH3), 16.8 (CH3); 
19
F 
NMR (376 MHz, CDCl3) δ –62.2 (3F, s); HRMS (ESI) Exact mass calcd for 
C20H19F3N1O1 [M+H]
+
: 346.1413, found: 346.1417. Enantiomeric excess was determined 
by HPLC with a Chiralcel OD-H column (98:2 hexane:i-PrOH, 0.8 mL/min, 225 nm, 25 
°C); tr (major) = 7.4 min, tr (minor) ca. 10 min (not detected); >99% ee. 




The title compound was prepared according to General Procedure c 
from 2-vinylisoquinoline 180c (47 mg, 0.30 mmol) and 2'-
methoxyacetophenone (46 μL, 0.33 mmol) and purified by column 
chromatography (5% EtOAc/hexane) to give a white solid (72 mg, 78%). m.p. 119-121 
C; [α] 24D  –90.9 (c 1.06, CHCl3); IR (film) 3290 (OH), 2970, 1487, 1388, 1363, 1236, 




H NMR (400 MHz, CDCl3) δ 8.47 (1H, d, J = 5.7 Hz, ArH), 
8.33 (1H, d, J = 8.3 Hz, ArH), 7.97 (1H, dd, J = 7.7, 1.8 Hz, ArH), 7.88 (1H, d, J = 7.7 
Hz, ArH), 7.74 (1H, ddd, J = 8.1, 6.9, 1.2 Hz, ArH), 7.68 (1H, ddd, J = 8.2, 6.9, 1.4 Hz, 
ArH), 7.58 (1H, d, J = 5.7 Hz, ArH), 7.38 (1H, br s, OH), 7.30 (1H, ddd, J = 8.2, 7.5, 1.9 
Hz, ArH), 7.07 (1H, td, J = 7.6, 1.1 Hz, ArH), 6.98 (1H, dd, J = 8.1, 0.9 Hz, ArH), 4.97 
(1H, q, J = 7.1 Hz, CHCH3), 4.00 (3H, s, OCH3), 1.39 (3H, s, CH3COH), 1.10 (3H, d, J = 
7.1 Hz, CHCH3); 
13
C NMR (100.6 MHz, CDCl3) δ 166.3 (C), 155.6 (C), 140.5 (CH), 
136.6 (C), 135.3 (C), 130.2 (CH), 128.2 (CH), 127.7 (2 x CH), 127.6 (C), 127.4 (CH), 
124.9 (CH), 120.8 (CH), 119.3 (CH), 111.1 (CH), 76.2 (C), 55.5 (CH3), 39.0 (CH), 27.9 
(CH3), 17.2 (CH3); HRMS (ESI) Exact mass calcd for C20H22N1O2 [M+H]
+
: 308.1645, 
found: 308.1649. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column (98:2 hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 10.9 min, tr 
(minor) = 30.0 min; 97% ee. 
 
(2R,3S)-2-(Furan-2-yl)-3-(isoquinolin-1-yl)butan-2-ol (193g). The 
title compound was prepared according to General Procedure C from 2-









(36 mg, 0.33 mmol) and purified by column chromatography (5% EtOAc/hexane) to give 
a yellow solid (61 mg, 76%). m.p. 60-62 C; [α] 24
D
 –103.9 (c 1.02, CHCl3); IR (film) 




H NMR (500 
MHz, CDCl3) δ 8.44 (1H, d, J = 5.7 Hz, ArH), 8.28 (1H, d, J = 8.5 Hz, ArH), 7.87 (1H, 
d, J = 8.1 Hz, ArH), 7.74 (1H, ddd, J = 8.1, 6.9, 1.1 Hz, ArH), 7.66 (1H, ddd, J = 8.3, 
6.9, 1.3 Hz, ArH), 7.59 (1H, d, J = 5.7 Hz, ArH), 7.43 (1H, dd, J = 1.8, 0.9 Hz, ArH), 
7.41 (1H, br s, OH), 6.46 (1H, dd, J = 3.2, 0.9 Hz, ArH), 6.41 (1H, dd, J = 3.2, 1.8 Hz, 
ArH), 4.19 (1H, q, J = 7.0 Hz, CHCH3), 1.37 (3H, s, CH3COH), 1.22 (3H, d, J = 7.1 Hz, 
CHCH3); 
13
C NMR (125.8 MHz, CDCl3) δ 165.6 (C), 159.5 (C), 140.7 (CH), 140.4 
(CH), 136.5 (C), 130.4 (CH), 127.7 (CH), 127.6 (CH), 127.1 (C), 124.7 (CH), 119.6 
(CH), 110.3 (CH), 105.0 (CH), 75.2 (C), 41.7 (CH), 28.4 (CH3), 17.2 (CH3); HRMS 
(ESI) Exact mass calcd for C17H18N1O2 [M+H]
+
: 268.1332, found: 268.1335. 
Enantiomeric excess was determined by HPLC with a Chiralcel OD-H column (98:2 
hexane:i-PrOH, 0.8 mL/min, 225 nm, 25 °C); tr (major) = 11.7 min, tr (minor) = 18.6 
min; 89% ee. 
 
(R)-1-[(R)-1-(4,6-Dimethoxypyrimidin-2-yl)ethyl]indan-1-ol 
(193i). The title compound was prepared according to a slight 
modification of General Procedure C from 2-vinylpyrimidine 180e 
(50 mg, 0.30 mmol) and 1-indanone (44 mg, 0.33 mmol) in that the reaction was stirred 
for 4 h at room temperature (rather than 15 h), and purified by column chromatography 
(5% EtOAc/hexane→10% EtOAc/hexane) to give a colorless gum (76 mg, 85%). [α] 24D  –





H NMR (500 MHz, CDCl3) δ 7.25-7.17 (2H, m, ArH), 7.14-7.07 (1H, m, 
ArH), 6.88 (1H, d, J = 7.6 Hz, ArH), 6.14 (1H, br s, OH), 5.99 (1H, s, ArH), 3.94 (6H, s, 
2 x OCH3), 3.32 (1H, q, J = 7.1 Hz, CHCH3), 3.10-3.00 (1H, m, ArCH2), 2.89-2.79 (1H, 
m, ArCH2), 2.39 (1H, ddd, J = 13.2, 8.4, 4.8 Hz, ArCH2CH2), 2.09 (1H, ddd, J = 13.4, 
8.8, 6.5 Hz, ArCH2CH2), 1.33 (3H, d, J = 7.1 Hz, CHCH3); 
13
C NMR (125.8 MHz, 
CDCl3) δ 172.0 (C), 170.8 (2 x C), 146.9 (C), 143.3 (C), 127.8 (CH), 126.4 (CH), 124.8 
(CH), 123.0 (CH), 87.8 (CH), 85.4 (C), 54.1 (2 x CH3), 48.9 (CH), 36.9 (CH2), 29.7 










323.1366, found: 323.1370. Enantiomeric excess was determined by HPLC with a 
Chiralpak AD-H column (95:5 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (minor) = 
12.5 min, tr (major) = 15.4 min; 96% ee. 
 
(R)-1-[(R)-1-(2,6-Dimethoxypyrimidin-4-yl)ethyl]5-fluoro-indan-
1-ol (193j). The title compound was prepared according to a slight 
modification of General Procedure C from 2-vinylpyrimidine 180f 
(50 mg, 0.30 mmol) and 5-fluoro-1-indanone (50 mg, 0.33 mmol) in 
that the reaction was stirred for 3 h at room temperature (rather than 15 h), and purified 
by column chromatography (5% EtOAc/hexane→20% EtOAc/hexane) to give a colorless 
gum (60 mg, 63%). [α] 24D –71.7 (c 0.78, CHCl3); IR (film) 3375 (OH), 2949, 1597, 1462, 




H NMR (500 MHz, CDCl3) δ 6.87 (1H, dd, J = 
8.9, 1.2 Hz, ArH), 6.83-6.73 (2H, m, ArH), 6.16 (1H, s, ArH), 6.05 (1H, br s, OH), 4.03 
(3H, s, OCH3), 3.98 (3H, s, OCH3), 3.08-2.93 (2H, m, CHCH3 and ArCH2), 2.85-2.73 
(1H, m, ArCH2), 2.42-2.33 (1H, m, ArCH2CH2), 2.08 (1H, ddd, J = 13.5, 8.9, 7.3 Hz, 
ArCH2CH2), 1.28 (3H, d, J = 7.1 Hz, CHCH3); 
13
C NMR (125.8 MHz, CDCl3) δ 173.7 
(C), 172.2 (C), 164.5 (C), 162.9 (C, d, J = 244.8 Hz), 145.2 (C, d, J = 8.3 Hz), 142.6 (C, 
d, J = 2.4 Hz), 124.5 (CH, d, J = 9.1 Hz), 113.6 (CH, d, J = 22.7 Hz), 111.5 (CH, d, J = 
21.8 Hz), 100.7 (CH), 84.9 (C), 54.9 (CH3), 53.9 (CH3), 46.9 (CH), 37.5 (CH2), 29.4 
(CH2, d, J = 2.0 Hz), 15.5 (CH3); 
19
F NMR (376 MHz, CDCl3) δ –115.3 (1F, s); HRMS 
(ESI) Exact mass calcd for C17H20F1N2O3 [M+H]
+
: 319.1452, found: 319.1454. 
Enantiomeric excess was determined by HPLC with a Chiralpak AD-H column (95:5 
hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 °C); tr (minor) = 25.4 min, tr (major) = 39.2 
min; 93% ee. 
 
General Procedure D: Reductive Coupling of Vinylazaarenes Using Ligand L11 










A solution of the appropriate vinylazaarene (0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 0.015 
mmol), (R,R)-Quinox-P* (L11) (5.0 mg, 0.015 mmol), and the appropriate ketone (0.33 
mmol) in toluene (1.5 mL) was stirred at 0 °C for 15 min. PhSiH3 (44 μL, 0.36 mmol) 
was then added dropwise over 1 min. The mixture was stirred at 0 °C for 30 min, then at 
room temperature for 15 h. The reaction was quenched carefully with silica gel (ca. 250 
mg), and the resulting suspension was stirred for 15 min before being filtered through a 
short plug of silica gel using EtOAc (50 mL) as eluent. The filtrate was concentrated in 
vacuo and the residue was purified by column chromatography to give the reductive 
coupling product. 
 
(R)-4-[(S)-1-(4-Phenylthiazol-2-yl)ethyl]chroman-4-ol (193k). The 
title compound was prepared according to General Procedure D from 2-
vinylthiazole 180g (56 mg, 0.30 mmol) and 4-chromanone (49 mg, 0.33 
mmol) and purified by column chromatography (5% EtOAc/hexane) to give a white solid 
(69 mg, 68%). m.p. 100-102 C; [α] 24D  +128.7 (c 0.87, CHCl3); IR (film) 3378 (OH), 




H NMR (500 MHz, CDCl3) δ 
7.95-7.89 (2H, m, ArH), 7.51-7.43 (4H, m, ArH), 7.41-7.35 (1H, m, ArH), 7.21 (1H, 
ddd, J = 8.3, 7.2, 1.6 Hz, ArH), 6.99 (1H, td, J = 7.8, 1.3 Hz, ArH), 6.89 (1H, dd, J = 8.2, 
1.2 Hz, ArH), 6.05 (1H, br s, OH), 4.27-4.17 (2H, m, OCH2), 3.99 (1H, q, J = 7.2 Hz, 
CHCH3), 2.18-2.09 (1H, m, OCH2CH2), 1.62-1.54 (1H, m, OCH2CH2), 1.25 (3H, d, J = 
7.2 Hz, CHCH3); 
13
C NMR (125.8 MHz, CDCl3) δ 174.5 (C), 155.7 (C), 155.3 (C), 133.8 
(C), 129.0 (CH), 128.9 (2 x CH), 128.5 (CH), 127.2 (CH), 126.3 (2 x CH), 125.6 (C), 
121.1 (CH), 117.4 (CH), 111.9 (CH), 71.2 (C), 62.8 (CH2), 45.9 (CH), 31.9 (CH2), 15.7 
(CH3); HRMS (ESI) Exact mass calcd for C20H20N1O2S1 [M+H]
+
: 338.1209, found: 








(98:2 hexane:i-PrOH, 0.8 mL/min, 250 nm, 25 °C); tr (minor) = 28.3 min, tr (major) = 
47.3 min; 93% ee. 




3-carboxylate (193l). The title compound was prepared according 
to General Procedure D from 2-vinylpyridine 180j (53 mg, 0.30 
mmol) and thiocroman-4-one (54 mg, 0.33 mmol) and purified by column 
chromatography (5% EtOAc/hexane→10% EtOAc/hexane) to give a white solid (68 mg, 
66%). m.p. 108-110 C; [α] 24D  –217.8 (c 1.01, CHCl3); IR (film) 3433 (OH), 1718, 1646, 




H NMR (500 MHz, CDCl3) δ 9.16 (1H, 
dd, J = 2.1, 0.5 Hz, ArH), 8.02 (1H, dd, J = 8.1, 2.2 Hz, ArH), 7.06 (1H, dd, J = 7.8, 1.1 
Hz, ArH), 6.94 (1H, td, J = 7.6, 1.5 Hz, ArH), 6.86-6.79 (2H, m, ArH), 6.74 (1H, br s, 
OH), 6.73-6.67 (1H, m, ArH), 4.40 (2H, q, J = 7.1 Hz, OCH2), 3.59 (1H, q, J = 7.0 Hz, 
CHCH3), 3.20-3.13 (2H, m, SCH2), 2.52 (1H, dt, J = 13.7, 4.5 Hz, SCH2CH2), 2.03-1.92 
(1H, m, SCH2CH2), 1.46-1.38 (6H, m, CHCH3 and OCH2CH3); 
13
C NMR (125.8 MHz, 
CDCl3) δ 168.0 (C), 165.0 (C), 149.3 (CH), 140.8 (C), 137.9 (CH), 131.6 (C), 126.8 
(CH), 126.1 (CH), 125.5 (CH), 124.5 (C), 123.6 (CH), 123.3 (CH), 73.9 (C), 61.4 (CH2), 
43.3 (CH), 31.9 (CH2), 22.5 (CH2), 14.8 (CH3), 14.2 (CH3); HRMS (ESI) Exact mass 
calcd for C19H22NO3S [M+H]
+
: 344.1315, found: 344.1318. Enantiomeric excess was 
determined by HPLC with a Chiralpak AS-H column (98:2 hexane:i-PrOH, 0.8 mL/min, 
254 nm, 25 °C); tr (minor) = 33.3 min, tr (major) = 38.5 min; 91% ee. 
 
(R)-1-[(R)-1-Quinoxalin-2-ylethyl]-1,2,3,4-tetrahydronaphthalen-1-ol (193m)  
 
A solution of 2-vinylquinoxaline 180d (47 mg, 0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 







mmol) in toluene (1.5 mL) was stirred at 0 °C for 15 min. PhSiH3 (44 μL, 0.36 mmol) 
was then added dropwise. The mixture was stirred at 0 °C for 30 min, then at room 
temperature for 15 h. The reaction was quenched carefully with silica gel (ca. 250 mg), 
and the resulting suspension was stirred for 15 min before being filtered through a short 
plug of silica gel using EtOAc (50 mL) as eluent. The filtrate was concentrated in vacuo 
and the residue was purified by column chromatography (10% EtOAc/hexane→25% 
EtOAc/hexane) to give the tertiary alcohol 193m (65 mg, 71%) as a yellow gum. [α] 24
D
 





H NMR (500 MHz, CDCl3) δ 8.59 (1H, s, ArH), 8.13 (1H, dd, J = 8.3, 
1.3 Hz, ArH), 8.10 (1H, dd, J = 8.2, 1.4 Hz, ArH), 7.81 (1H, ddd, J = 8.4, 7.0, 1.6 Hz, 
ArH), 7.76 (1H, ddd, J = 8.3, 7.0, 1.6 Hz, ArH), 7.14-7.08 (2H, m, ArH), 7.02 (1H, d, J = 
7.8 Hz, ArH), 6.98-6.92 (1H, m, ArH), 4.87 (1H, br s, OH), 3.77 (1H, q, J = 7.2 Hz, 
CHCH3), 2.86 (2H, t, J = 6.7 Hz, ArCH2), 2.26-2.18 (1H, m, ArCH2CH2CH2), 1.98-1.84 
(2H, m, ArCH2CH2CH2), 1.68-1.59 (1H, m, ArCH2CH2CH2), 1.39 (3H, d, J = 7.2 Hz, 
CHCH3); 
13
C NMR (125.8 MHz, CDCl3) δ 158.8 (C), 146.5 (CH), 141.6 (C), 141.5 (C), 
141.0 (C), 136.9 (C), 130.1 (CH), 129.4 (CH), 129.3 (CH), 129.0 (CH), 128.9 (CH), 
127.0 (CH), 126.0 (CH), 125.8 (CH), 75.1 (C), 47.0 (CH), 33.0 (CH2), 29.2 (CH2), 18.8 
(CH2), 14.9 (CH3); HRMS (ESI) Exact mass calcd for C20H21N2O1 [M+H]
+
: 305.1648, 
found: 305.1652. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column (98:2 hexane:i-PrOH, 0.8 mL/min, 230 nm, 25 °C); tr (major) = 33.8 min, tr 
(minor) = 42.1 min; 96% ee. 
 
General Procedure E: Reductive Coupling of Alkenylazaarenes Using Ligand L13 
(0.30 mmol Scale) 
 
A solution of the appropriate alkenylazaarene (0.30 mmol), Cu(OAc)2·H2O (3.0 mg, 
0.015 mmol), ligand SL-T001-1 (L13) (10.3 mg, 0.015 mmol), and the appropriate 
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ketone (0.42 mmol) in toluene (1.5 mL) was stirred at 0 °C for 15 min. PhSiH3 (56 μL, 
0.45 mmol) was then added dropwise over 1 min. The mixture was stirred at 0 °C for 30 
min, then at room temperature for 3−4 h. The reaction was quenched carefully with silica 
gel (ca. 250 mg), and the resulting suspension was stirred for 15 min before being filtered 
through a short plug of silica gel using EtOAc (50 mL) as eluent. The filtrate was 
concentrated in vacuo and the residue was purified by column chromatography to give 
the reductive coupling product. 
 
(R)-1-[(S)-1-(4,5-Diphenyloxazol-2-yl)-propyl]-1,2,3,4-
tetrahydronaphthalen-1-ol (196a). The title compound was prepared 
according to General Procedure E from alkenylazaarene 183a (78 mg, 
0.30 mmol) and α-tetralone (56 μL, 0.42 mmol) for a reaction time of 
3 h at room temperature, and purified by column chromatography (5% 
EtOAc/hexane→15% EtOAc/hexane) to give a colorless gum (77 mg, 63%). [α] 24D  –21.6 





H NMR (500 MHz, CDCl3) δ 7.78-7.71 (2H, m, ArH), 7.64-7.57 (2H, m, ArH), 
7.51-7.45 (1H, m, ArH), 7.45-7.32 (6H, m, ArCH), 7.25-7.18 (2H, m, ArH), 7.17-7.09 
(1H, m, ArH), 3.93 (1H, br s, OH), 3.59 (1H, dd, J = 11.6, 2.7 Hz, CHCH2), 2.90-2.72 
(2H, m, ArCH2), 2.20-2.09 (1H, m, CH2), 2.08-1.79 (4H, m, CH2), 1.48-1.35 (1H, m, 
CH2), 0.94 (3H, t, J = 7.3 Hz, CH3); 
13
C NMR (125.8 MHz, CDCl3) δ 163.8 (C), 145.4 
(C), 139.9 (C), 137.9 (C), 135.0 (C), 132.2 (C), 129.1 (CH), 128.9 (C), 128.6 (2 x CH), 
128.5 (2 x CH), 128.5 (CH), 128.1 (CH), 127.9 (2 x CH), 127.2 (CH), 126.6 (2 x CH), 
126.4 (CH), 125.8 (CH), 74.0 (C), 52.2 (CH), 33.4 (CH2), 30.0 (CH2), 21.9 (CH2), 19.0 
(CH2), 13.0 (CH3); HRMS (ESI) Exact mass calcd for C28H28N1O2 [M+H]
+
: 410.2115, 
found: 410.2114. Enantiomeric excess was determined by HPLC with a Chiralcel OD-H 
column (98:2 hexane:i-PrOH, 0.8 mL/min, 280 nm, 25 °C); tr (major) = 22.2 min, tr 
(minor) = 32.6 min; 93% ee. 
 
(R)-5-Fluoro-1-[(R)-3-methoxy-1-pyrimidin-2-yl-propyl)indan-1-ol 
(196b). The title compound was prepared according to General Procedure 













indanone (52 μL, 0.42 mmol) for a reaction time of 3 h at room temperature, and purified 
by column chromatography (20% EtOAc/hexane→90% EtOAc/hexane) to give a white 
solid 5c (67 mg, 74%). m.p 80-82 C; [α] 24
D
 +61.9 (c 1.07, CHCl3); IR (film) 3395 (OH), 




H NMR (500 MHz, CDCl3) δ 
8.71 (2H, d, J = 3.7 Hz, ArH), 7.31-7.20 (1H, m, ArH), 6.85 (1H, dd, J = 8.9, 2.2 Hz, 
ArH), 6.63 (1H, td, J = 8.9, 2.3 Hz, ArH), 6.38 (1H, dd, J = 5.3, 8.3 Hz, ArH), 5.41 (1H, 
br s, OH), 3.37 (1H, dd, J = 11.1, 1.9 Hz, CHCH2), 3.30-3.23 (1H, m, OCH2), 3.23-3.13 
(4H, m, OCH3 and OCH2), 2.99-2.90 (1H, m, ArCH2), 2.89-2.79 (1H, m, ArCH2), 2.65-
2.50 (1H, m, ArCH2CH2), 2.40-2.28 (1H, m, ArCH2CH2), 2.17-2.06 (2H, m, OCH2CH2); 
13
C NMR (125.8 MHz, CDCl3) δ 171.5 (C), 162.7 (C, d, J = 244.8 Hz), 156.6 (2 x CH), 
145.2 (C, d, J = 8.3 Hz), 142.8 (C), 123.7 (CH, d, J = 9.1 Hz), 119.4 (CH), 113.3 (CH, d, 
J = 22.7 Hz), 111.7 (CH, d, J = 21.8 Hz), 84.7 (C), 70.7 (CH2), 58.4 (CH3), 52.0 (CH), 
37.7 (CH2), 30.5 (CH2), 29.2 (CH2, d, J = 2.0 Hz); 
19
F NMR (376 MHz, CDCl3) δ –115.3 
(1F, s); HRMS (EIS) Exact mass calcd for C17H20F1N2O2 [M+H]
+
: 303.1503, found: 
303.1498. Enantiomeric excess was determined by HPLC with a Chiralpak AS-H column 
(90:10 hexane:i-PrOH, 0.8 mL/min, 254 nm, 25 °C); tr (minor) = ca. 18 min (not 
detected), tr (major) = 23.3 min; >99% ee. 




chroman-4-ol (196c). The title compound was prepared according 
to General Procedure E from alkenylazaarene 183c (77 mg, 0.30 
mmol) and 4-chromanone (62 mg, 0.42 mmol) for a reaction time of 
4 h at room temperature, and purified by column chromatography (10% 
EtOAc/hexane→40% EtOAc/hexane) to give a yellow gum (95 mg, 75%). [α] 24D  +8.6 (c 





H NMR (500 MHz, CDCl3) δ 7.33 (1H, dd, J = 7.9, 1.4 Hz, ArH), 7.25-7.10 (4H, 
m, ArH), 7.05 (2H, d, J = 7.0 Hz, ArH), 6.93-6.88 (1H, m, ArH), 6.86 (1H, dd, J = 8.2, 
1.1 Hz, ArH), 4.39 (1H, br s, OH), 4.26-4.15 (2H, m, OCH2), 4.02 (6H, s, 2 x OCH3), 
3.53 (1H, dd, J = 11.3, 2.1 Hz, CHCH2), 2.55 (1H, ddd, J = 14.8, 9.1, 6.2 Hz, PhCH2), 
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2.50-2.40 (1H, m, PhCH2), 2.32 (1H, ddd, J = 14.5, 10.2, 4.4 Hz, OCH2CH2), 2.18-2.05 
(1H, m, OCH2CH2), 1.83 (1H, ddd, J = 14.3, 4.9, 2.9 Hz, PhCH2CH2CH2), 1.59-1.40 
(2H, m, PhCH2CH2CH2), 1.35-1.24 (1H, m, PhCH2CH2CH2); 
13
C NMR (125.8 MHz, 
CDCl3) δ 182.7 (C), 171.8 (C), 155.1 (C), 141.8 (C), 129.0 (CH), 128.1 (4 x CH), 126.5 
(C), 125.8 (CH), 125.6 (CH), 120.8 (CH), 117.4 (CH), 70.7 (C), 62.6 (CH2), 55.9 (CH), 
55.2 (2 x CH3), 35.4 (CH2), 32.0 (CH2), 29.8 (CH2), 28.0 (CH2); HRMS (ESI) Exact mass 
calcd for C24H27N3O4Na1 [M+Na]
+
: 444.1894, found: 444.1895. Enantiomeric excess was 
determined by HPLC with a Chiralcel OD-H column (95:5 hexane:i-PrOH, 0.8 mL/min, 
280 nm, 25 °C); tr (minor) = 27.4 min, tr (major) = 30.8 min; 96% ee. 
 
4-Benzyl-2-methyl-3-(pyridine-2-yl)tetrahydrofuran-2-ol (198)  
 
A solution of 2-alkenylpyridine 187b (107 mg, 0.40 mmol), Cu(OAc)2·H2O (4.0 mg, 0.02 
mmol) and ligand SL-J001-1 (L14) (12.8 mg, 0.02 mmol) in toluene (2 mL) was stirred 
at 0 °C for 15 min. PhSiH3 (59 μL, 0.48 mmol) was then added dropwise over 1 min. The 
mixture was stirred at 0 °C for 30 min, then at room temperature for 15 h. The reaction 
was quenched carefully with silica gel (ca. 250 mg), and the resulting suspension was 
stirred for 15 min before being filtered through a short plug of silica gel using EtOAc (50 
mL) as eluent. The filtrate was concentrated in vacuo and the residue was purified by 
column chromatography (10% EtOAc/hexane→25% EtOAc/hexane) to give the 
hemiketal 198 (65 mg, 71%) as a pale yellow oil.
 1
H NMR (500 MHz, CDCl3)  8.56-
8.54 (1H, m, ArH), 7.60 (1H, td, J = 7.7, 1.7 Hz, ArH), 7.22-7.17 (3H, m, ArH), 7.16-
7.12 (1H, m, ArH), 7.08-7.02 (3H, m, ArH), 4.25 (1H, t, J = 8.5 Hz, CHCH2O), 3.76 
(1H, dd, J = 8.5, 7.2 Hz, CHCH2O), 3.21-3.15 (1H, m, PhCH2CH), 2.94 (1H, d, J = 10.2 
Hz, N=CCH)), 2.78 (1H, dd, J = 13.8, 6.0 Hz, PhCH2), 2.73 (1H, dd, J = 14.0, 9.2 Hz, 
PhCH2), 1.45 (3H, s, CH3); 
13
C NMR (125.8 MHz, CDCl3)  161.2 (C), 151.3 (CH), 
142.2 (C), 139.7 (CH), 131.23 (CH), 131.0 (CH), 128.9 (CH), 127.9 (CH), 124.8 (CH), 
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The 1,4-addition of a nucleophile to an alkene conjugated to an electron-
withdrawing group is a fundamental reaction in organic chemistry, and
numerous catalytic asymmetric variants (eq 1) of this process are now
routinely employed in the synthesis of molecules of interest.1,2 The most
common functional groups used to activate alkenes toward asymmetric
conjugate additions include carbonyls, nitriles, sulfones, phosphonates, and
nitro groups. We recently questioned whether other rarely considered yet
common functional groups might also be employed in this capacity, and
our attention focused on nitrogen-containing aromatic heterocycles. Given
that heteroarenes such as oxazoles, thiazoles, pyridines, and others are
ubiquitous in biologically active natural products, pharmaceuticals, and
agrochemicals, the ability to functionalize these privileged structures
through a diverse set of asymmetric conjugate additions of 2-alkenyl
derivatives (eq 2) would open up broad-ranging applications.
Although conjugate additions to 2-vinylheteroarenes (R1, R2 ) H in
eq 2) are relatively common,3 the corresponding reactions of substrates
containing a -substituent are much rarer, presumably for steric reasons.4,5
Furthermore, the only report of a catalytic enantioselective variant is limited
to poorly selective (e15% ee) Grignard additions to 4-alkenylpyridines.5
Therefore, we recently initiated a program targeted at addressing these
deficiencies, and in this communication, our preliminary findings involving
highly enantioselective copper-catalyzed reductions6 of ,’-disubstituted
2-alkenylheteroarenes are presented.
The asymmetric copper-catalyzed conjugate reduction of activated
alkenes is a well-established method for the synthesis of various useful
chiral building blocks.6-10 Whether a nitrogen-containing heteroarene
would provide sufficient activation to an adjacent alkene in an analogous
reaction was, however, uncertain. In addition, it seemed likely that
coordination of the Lewis basic nitrogen of the heteroarene to the copper
catalyst would occur in such a process, and whether this interaction would
be beneficial, inconsequential, or detrimental was not easy to predict.
Our investigations began with a survey of chiral bisphosphines L1-L6
using 2-alkenylbenzoxazole 1a as a test substrate (Table 1). Using 10 mol
% of Cu(OAc)2 ·H2O, 10 mol % of ligand, and 4 equiv each of PhSiH3
and t-BuOH in toluene at room temperature, biaryl-based ligands L1-L4
proved competent in promoting conjugate reduction.11 With (R)-BINAP
(L1), both conversion and enantioselectivity were only moderate. However,
improved results were observed using (R)-MeO-BIPHEP (L2) and the
SEGPHOS ligands L3 and L4, with 91% ee obtained using (S)-SEGPHOS
(L3). The Josiphos ligands L5 and L6 were also effective, providing 2a
in 89% and 87% ee, respectively. Of all the ligands, the highest reaction
rates were observed with L4 and L5 (reactions were complete in 2 h).
However, the superior selectivity provided by L5 prompted us to select
this ligand for further optimization and investigation of the reaction scope.
Using 5 mol % each of Cu(OAc)2 ·H2O and L5, PhSiH3 (1.5 equiv),
and t-BuOH (2.0 equiv) at an initial temperature of 0 °C, a range of ,′-
disubstituted 2-alkenylheteroarenes underwent conjugate reduction with
generally excellent levels of enantioselection (Table 2).11 In addition to
benzoxazole (entries 1-4), other effective nitrogen-containing hetero-
arenes in this process included 5-phenyloxazole (entry 5), benzothiazole
(entry 6), pyridine (entries 7-9), quinoline (entry 10), and pyrazine (entry
11). Tolerated functionality at the -positions of the alkene included simple
aliphatic groups, a phenyl group (entry 4), a benzyl group (entry 9), various
oxygenated alkyl groups (entries 2, 3, 7-9, and 11), and a cyclopropane
(entry 10). The process is tolerant of lower loadings of copper and ligand.
For example, reduction of 1g on a 1.0 mmol scale using 2 mol % each of
Cu(OAc)2 ·H2O and L5 provided 2g in 92% yield and 96% ee (entry 7,
values in parentheses).
Experiments to explore the origins of reactivity were then conducted.
Reduction of 4-alkenylpyridine 3 provided 4 in 60% yield and 94% ee,
albeit in a slower reaction that was incomplete even after 4 days (eq 3).
This result suggests that alkene reduction by copper hydride can occur
without assistance of a directing effect from the nitrogen atom. In contrast,
Table 1. Ligand Optimization for the Asymmetric Reduction of 1aa
a Reactions were conducted using 0.20 mmol of 1a in toluene (1 mL).
Conversions were determined by GC analysis. Enantioselectivities were
determined by chiral HPLC analysis. b Reactions complete after 2 h.
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3-alkenylpyridine 5 was unreactive (eq 4), demonstrating the importance
of conjugation of the alkene to a CdN moiety for reactivity.
In summary, copper-catalyzed asymmetric conjugate reductions of ,′-
disubstituted 2-alkenylheteroarenes are reported. In addition to serving as
a further demonstration of the power of chiral copper hydride catalysis,6
this work has shown nitrogen-containing aromatic heterocycles can provide
effective activation of an adjacent alkene for highly enantioselective
catalytic conjugate addition reactions. Extension of the general concept
to other classes of asymmetric reactions should provide a range of useful
tools for chemists working with heteroarenes. Future studies from our
laboratory will be directed toward this goal.
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Table 2. Scope of Cu-Catalyzed Asymmetric Conjugate
Reductiona
a Reactions were conducted using 0.20 mmol of 1a-1k unless
otherwise stated. b Isolated yield. c Determined by chiral HPLC analysis.
d Using 0.155 mmol of 1d. e Values in parentheses refer to a reaction
conducted using 1.0 mmol of 1g, 2 mol % Cu, and 2 mol % L5. f Using 0.10
mmol of 1h and 2.0 equiv of PhSiH3.
J. AM. CHEM. SOC. 9 VOL. 131, NO. 30, 2009 10387
C O M M U N I C A T I O N S
Dynamic Article LinksC<Chemical Science























































View Online / Journal Homepage / Table of Contents for this issueEnantioselective rhodium-catalyzed arylation of electron-deficient
alkenylarenes†‡
Aakarsh Saxena and Hon Wai Lam*
Received 30th July 2011, Accepted 23rd August 2011
DOI: 10.1039/c1sc00521ab-Substituted alkenyl-para-nitroarenes, an unexplored substrate class for catalytic asymmetric addition
reactions, undergo highly enantioselective rhodium-catalyzed arylations with arylboronic acids in the
presence of a dibenzylamide-containing chiral diene ligand. One example of the asymmetric arylation of
an alkenyl-p-cyano-m-(trifluoromethyl)benzene is also presented.Catalytic enantioselective additions of organometallic reagents
to activated alkenes are an important class of reactions for the
production of enantioenriched chiral compounds.1 However,
examples of such processes where alkenes are activated by arenes
or heteroarenes are uncommon, presumably due to the relatively
low levels of activation that (hetero)arenes provide. Given the
ubiquitous nature of (hetero)arenes in compounds for applica-
tions ranging from biology to materials science, the development
of reactions that address this deficiency is highly desirable.
Our group has demonstrated that heteroarenes containing
a suitably placed C]N moiety are able to activate alkenes2
towards enantioselective copper-catalyzed reductions3 and
rhodium-catalyzed arylations,4 while Bernadi, Adamo, and co-
workers have developed asymmetric additions of nitroalkanes to
4-nitro-5-styrylisoxazoles.5 For alkenes conjugated to simple
arenes (which in general provide only minimal activation), highly
reactive organometallic reagents are usually required.6 A number
of groups have reported stoichiometric or catalytic enantiose-
lective carbolithiations7,8 of various alkenylarenes9–11 mediated
by (–)-sparteine9,10 or a (+)-sparteine surrogate.11 Although these
carbolithiations work well, the development of processes that
proceed under milder conditions, employing organometallic
reagents that exhibit greater functional group compatibility,
represents an unmet need. In this paper, the catalytic enantio-
selective addition of arylboronic acids to alkenes conjugated to
electron-deficient arenes is described.
The rhodium-catalyzed asymmetric 1,4-addition of arylboron
compounds to b-substituted electron-deficient alkenes is now
a well-established method for the preparation of chiralEaStCHEM, School of Chemistry, University of Edinburgh, Joseph Black
Building, The King’s Buildings, West Mains Road, Edinburgh, EH9 3JJ,
United Kingdom. E-mail: h.lam@ed.ac.uk; Tel: +44-131-650-4831
† Dedicated to the memory of Hamish McNab.
‡ Electronic supplementary information (ESI) available: Experimental
procedures, spectroscopic data for new compounds, and
crystallographic data. CCDC reference number 809081. For ESI and
crystallographic data in CIF or other electronic format see DOI:
10.1039/c1sc00521a
2326 | Chem. Sci., 2011, 2, 2326–2331compounds.12–14 Since the initial discovery of enones as
substrates for these reactions,12 subsequent efforts have extended
the scope of the acceptor15 to alkenes conjugated to a range of
common electron-withdrawing groups.16–22 More recently, less
common activating groups have been employed. In addition to
our report on asymmetric arylations of alkenylheteroarenes,4
which builds upon work by Lautens and co-workers describing
non-enantioselective additions of boronic acids to vinylazines,23
Sasaki and Hayashi have disclosed the asymmetric arylation of
borylalkenes.24 However, rhodium-catalyzed addition of aryl-
boron compounds to alkenylarenes has not, to our knowledge,
been described. Instead, simple styrenes (where activation of the
alkene is minimal) were shown by the Lautens group to undergo
Heck-type reactions under aqueous conditions using water-
soluble phosphine ligands (eqn (1)).23
(1)
(2)
It occurred to us that placement of the strongly electron-
withdrawing nitro group at the para-position of the arene might
lead to sufficient polarization of the alkene to the point where
addition products 2, rather than Heck-type products, would
form, even for 1,2-disubstituted alkenes (eqn (2)). Although
nitroalkenes have been successfully employed in myriad addi-
tions of carbon nucleophiles,19,25 the analogous reactions of their






















































View Onlineasymmetric reactions have been reported. Therefore, the
successful realization of the reactions depicted in eqn (2) was an
attractive goal and would set the stage for the use of this under-
exploited class of electrophiles in other catalytic enantioselective
addition reactions.
Our initial experiments focused upon alkenyl-p-nitroarene 1a
as a test substrate (Table 1). As a preliminary gauge of reactivity,
the addition of PhB(OH)2 to 1a was performed using [Rh(cod)
Cl]2 (2.5 mol%) and KOH (2.5 equiv.) in dioxane/H2O at 80
C
under microwave (mw) irradiation26 for 30 min. This experiment
resulted in 42% conversion into rac-2a (entry 1). Next, the use of
chiral ligands was evaluated in combination with [Rh(C2H4)2Cl]2
as a precatalyst to assess whether 2a could be obtained with
improved conversions and in high enantioselectivity. Chiral
diene ligands have been shown to provide excellent results in
asymmetric 1,4-arylation reactions27–29 and, in view of the success
obtained with secondary amide-containing ligand L130 in our
study of the asymmetric arylation of alkenylheteroarenes,4 this
diene was evaluated first. Although L1 did lead to 2a in 97% ee,
the conversion was only 35% (entry 2). Increasing the tempera-
ture to 120 C did increase the conversion with only a slight
impact upon enantioselection (95% ee), but appreciable starting
material remained (entry 3). Additional amide-containing chiralTable 1 Ligand optimization for the asymmetric arylation of 1aa
a Reactions were conducted using 0.20 mmol of 1a in dioxane (0.5 mL) and H2
mixtures. c Determined by HPLC analysis on a chiral stationary phase. d [Rh(c
ligand. e Reaction conducted at 120 C for 30 min. f Product 2a was isolated
This journal is ª The Royal Society of Chemistry 2011dienes were then investigated. The enantioselectivity remained
high with ligand L2 that lacks the pyrrole on the cyclohexyl ring,
but the conversion was low (entry 4). Ligand L34 containing
a morpholine amide provided improved conversion (76%) at
80 C, but the product was formed in only 70% ee (entry 5).
Ligands L4 and L5 containing tertiary amides gave improved
results (entries 6 and 7), with dibenzylamide-containing ligand
L5 giving the product in >95% conversion, 92% isolated yield,
and 95% ee (entry 7). In contrast, ligand L6 containing only one
benzyl group on the amide nitrogen atom afforded inferior
results (entry 8), further suggesting that under these conditions,
a tertiary amide in the ligand is beneficial for high conversion.
Finally, (R)-BINAP (L7) was tested for comparison and
although the enantioselectivity was high, the reaction did not go
to completion (entry 9). On the basis of these results, ligand L5
was selected for further study.
Next, the addition of a range of arylboronic acids to various
alkenyl-p-nitroarenes was investigated (Table 2), and the
enantioselectivity of the reaction was, in most cases, high (84–
97% ee). In addition to a p-nitrophenyl group (entries 1–12),
other arenes that provide effective activation in this process
include o-fluoro-p-nitrophenyl (entry 14), m-methyl-p-nitro-
phenyl (entry 15), m-carbomethoxy-p-nitrophenyl (entry 16),O (0.1 mL). b Determined by 1H NMR analysis of the unpurified reaction
od)Cl]2 was used in place of [Rh(C2H4)2Cl]2, without an additional chiral
in 92% yield.
Chem. Sci., 2011, 2, 2326–2331 | 2327
Table 2 Catalytic asymmetric arylation of alkenyl-p-nitroarenesa
a Unless otherwise stated, reactions were conducted using 0.20 mmol of 1a–1k. Cited yields are of isolated material. Enantiomeric excesses were
determined by chiral HPLC analysis. b Values in parentheses refer to a reaction conducted under thermal heating under otherwise identical
conditions. c Reaction performed using 1.0 mmol of 1b at 80 C under thermal heating for 1 h, using 2.5 mol% of Rh and 3 mol% of L5. d Reaction






















































View Onlineand p-nitro-m-(trifluoromethyl)phenyl (entry 17). The reaction
is not limited to alkenyl-p-nitrobenzenes; substrate 1k con-
taining a 4-nitronaphthyl group also underwent arylation to
provide 2r, though the yield and enantioselectivity were some-
what diminished with this sterically more demanding substrate
(entry 18). The range of tolerated substituents at the b-position
of the alkene include simple linear alkyl groups (entries 1–9 and
14–18), a cyclopropyl group (entry 10), an allyl ether (entry 11)
and an allyl amine (entry 12). However, a b-aryl group was
found to inhibit the reaction (entry 13). Regarding the scope of
the nucleophile, arylboronic acids containing methyl, halogen,2328 | Chem. Sci., 2011, 2, 2326–2331or methoxy substituents were competent reaction partners in
this process. The reaction of sterically demanding 2-methyl-
phenylboronic acid with substrate 1b provided 2f in 97% ee,
though in a modest 61% yield (entry 6). Thermal heating is as
effective as microwave heating, as evidenced by a reaction
conducted under otherwise identical conditions (entry 1, values
in parentheses). Furthermore, thermal heating was employed in
the addition of phenylboronic acid to 1b on a 1.0 mmol sca-
le with 1.25 mol% of [Rh(C2H4)2Cl]2 and 3 mol% of L5 at
80 C for 1 h, which provided 2c in 83% yield and 95% ee
(entry 3).This journal is ª The Royal Society of Chemistry 2011
Fig. 1 An ORTEP drawing of 6 with ellipsoids set at 50% probability.






















































View OnlineAn additional demonstration of the reaction scope is provided
in eqn (3), where substrate 3 containing a b-trimethylsilyl
substituent underwent arylation in 57% yield and 91% ee.31
(3)
To further test the utility of this process, a preparative-scale
reaction was performed using substrate 4 (5.0 mmol) containing
an oxygenated alkyl substituent at the b-position (Scheme 1).
This experiment provided 2t in 88% yield and 93% ee. In addi-
tion, reduction of the nitro group of 2t, followed by tosylation of
the resulting amine 5, provided sulfonamide 6 in 91% yield over
two steps, the absolute stereochemistry of which was determined
by single crystal X-ray analysis (Fig. 1).‡32 The sense of enan-
tioinduction observed using ligand L5 is consistent with the
stereochemical model proposed for previously reported examples
of arylation of acyclic electron-deficient alkenes using structur-
ally similar chiral dienes.4,30 In this model, the rhodium–aryl
bond is situated trans to the more electron-deficient alkene, and
binding of the alkenylnitroarene occurs in a manner that mini-
mizes unfavorable steric interactions (Fig. 2).
Nitroarenes are well-known to undergo a range of valuable
reactions, making them versatile intermediates in the preparation
of dyes, pharmaceuticals, and other functional compounds.33 To
demonstrate the synthetic utility of the arylation products
described herein, 2o was smoothly converted into indole 7 in 67%
yield by treatment with vinylmagnesium bromide according to
the method of Bartoli and co-workers (eqn (4)).34,35Scheme 1 Larger-scale arylation of 4 and subsequent elaboration.
This journal is ª The Royal Society of Chemistry 2011(4)
Further experiments provided insights into the structural
features required in the substrate for the reaction to proceed
under the present conditions. Substrates 8 and 9 containing
m-nitrophenyl and o-nitrophenyl groups, respectively, did not
provide the desired arylation products (Fig. 3).
While the lack of reactivity of 8 is not surprising given that the
nitro group is not conjugated with the alkene,6d the failure of 9 to
undergo arylation was somewhat unexpected, given that
o-nitrostyrene has been shown to react smoothly with a variety of
active methylene compounds under basic conditions.6d The
attempted arylation of 9 using a stoichiometric quantity of the
rhodium-ligand complex also provided no evidence of the desired
product, suggesting that the problem is one of reactivity rather
than catalyst turnover. The addition of 10 mol% of substrate 9 to
a repeat of the reaction of Table 2, entry 1 under otherwise
identical conditions led to the formation of 2a in >95% conver-
sion and 94% ee, further suggesting that 9 does not poison the
catalyst. Exactly how the o-nitro group in 9 inhibits the carbo-
rhodation step in the mechanism of rhodium-catalyzed addition
of arylboronic acids to electron-deficient alkenes36 is not known
at this time.Fig. 3 Unreactive substrates.






















































View OnlineNevertheless, the powerful effect of a p-nitro group allowed us
to address a problem discovered during our recent study of
enantioselective rhodium-catalyzed additions of arylboronic
acids to alkenylheteroarenes, which identified a 2-pyridyl group
as providing insufficient activation of an adjacent alkene for
arylation to proceed efficiently.4 Gratifyingly, 2-alkenylpyridine
10 containing a 5-nitro group underwent arylation in high yield
and enantioselectivity (eqn (5)).
(5)
Finally, efforts to employ alkenylbenzene substrates contain-
ing a single para-electron-withdrawing substituent other than
a nitro group, such as acetyl, nitrile, or methanesulfonyl, were
unsuccessful with only low conversions into mixtures of identi-
fied products being observed. However, substrate 12, containing
a p-cyano-m-(trifluoromethyl)phenyl group, did undergo aryla-
tion in 59% yield and 84% ee in the presence of 10 mol% of the
rhodium–chiral diene complex after 1.5 h (eqn (6)).
(6)
In contrast, no reaction was observed using (R)-BINAP (L7)
as the ligand. The result of eqn (6) suggests that there is scope to
increase the range of electron-deficient arenes that can be used as
activating groups and future developments in this area may rest
upon the identification of more active catalysts and/or improved
reaction conditions.Conclusions
In summary, highly enantioselective rhodium-catalyzed addi-
tions of arylboronic acids to alkenyl-p-nitroarenes and an
alkenyl-p-cyano-m-(trifluoromethyl)arene have been developed.
These reactions represent, to the best of our knowledge, the first
examples of catalytic asymmetric additions of air- and moisture-
stable organometallic reagents to alkenes activated by electron-
deficient arenes. Extension of this concept to other classes of
reactions may present exciting new opportunities for asymmetric
catalysis. Studies in this area are under way and will be reported
in due course.2330 | Chem. Sci., 2011, 2, 2326–2331Acknowledgements
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ABSTRACT: Catalytic enantioselective methods for the
preparation of chiral azaarene-containing compounds are
of high value. By combining the utility of copper hydride
catalysis with the ability of CN-containing azaarenes to
activate adjacent alkenes toward nucleophilic additions, the
enantioselective reductive coupling of alkenylazaarenes
with ketones has been developed. The process is tolerant
of a wide variety of azaarenes and ketones, and provides
aromatic heterocycles bearing tertiary-alcohol-containing
side chains with high levels of diastereo- and enantiose-
lection.
The development of new catalytic reactions for thefunctionalization of aromatic heterocycles and their
derivatives continues to be a valuable endeavor due to the
importance of these structures in natural products, pharma-
ceuticals, agrochemicals, and other molecules of interest. In this
regard, recent efforts from our laboratory have targeted the
development of processes that exploit the ability of a suitably
positioned CN moiety within azaarenes to activate adjacent
alkenes toward catalytic enantioselective nucleophilic addi-
tions.1−3 The first of these reports described copper-catalyzed
reductions4 of β,β-disubstituted 2-alkenylazaarenes, which
result in alkylazaarenes with a new stereogenic center at the
β-carbon (representative example in Figure 1A).1 Since these
reactions likely proceed via the intermediacy of organocopper
species that undergo protonation with t-BuOH, we questioned
whether these intermediates could be trapped in situ with an
alternative electrophile such as a ketone (Figure 1B). Such a
reductive coupling process would be synthetically more
valuable, delivering more complex tertiary-alcohol-containing
products with stereochemistry at both α- and β-carbons.
Although the proposed process is related to copper-catalyzed
reductive aldol reactions described previously,5−9 to our
knowledge, there are no reports of alkenylazaarenes being
employed as substrates in these reactions. To date, the only
report of catalytic reductive coupling reactions of alkenylazaar-
enes is that from the Krische group, who described racemic
rhodium-catalyzed hydrogenative coupling of vinylazines with
N-sulfonylaldimines (Figure 1C).10 The realization of enantio-
selective variants of this and related processes would therefore
be of obvious value. Herein, we report highly enantioselective
copper-catalyzed reductive coupling reactions of alkenylazaar-
enes with ketones.
This study began with examination of the enantioselective
reductive coupling of 2-vinylquinoline (1a) with acetophenone
(1.1 equiv) using PhSiH3 (1.2 equiv) as the hydride source, 5
mol % Cu(OAc)2·H2O, and 5 mol % of various chiral
bisphosphines in toluene (Table 1).4 Pleasingly, proof of
concept was quickly established, and all ligands evaluated led to
complete consumption of 1a to provide the coupling product
2a as a mixture of diastereomers, along with traces of the simple
reduction product 3.11 Enantioselectivities were modest using
ligands L1−L3 (entries 1−3), but high using (R,R)-Quinox-P*
(L4) (entry 4), the Josiphos ligand L5 (entry 5), and the
Taniaphos ligand L6 (entry 6). However, no diastereoselectiv-
ity was observed in most cases, with the notable exception
being the reaction using L6 which provided 2a in 5:1 dr and
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Figure 1. Catalytic transformations of alkenylazaarenes.
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93% ee for the major isomer (entry 6). Accordingly, L6 was
selected for further experimentation.
Chart 1 presents results of reductive coupling of various
vinylazaarenes 1a−1h12 with a range of ketones. Gratifyingly,
the scope of the process is broad, and the enantioselectivities of
the products were uniformly high (89−>99% ee).11 Although
L6 provided the best results for products 2a−2i, this ligand
resulted in a low yield in the attempted synthesis of 2j, and
poor diastereo- and enantioselectivities in the attempted
syntheses of 2k and 2l. In these cases, (R,R)-Quinox-P* (L4)
was superior for 2j and 2k, and the Josiphos ligand L5 was
optimal for 2l. In addition to 1a, effective substrates include
those containing azines such as pyridines (products 2c and 2k),
isoquinoline (products 2d−2g), two different isomeric
dimethoxypyrimidines (products 2h and 2i), and quinoxaline
(product 2l). A vinylthiazole also smoothly underwent the
reaction (product 2j). With acyclic ketones, the diastereose-
lectivity of the reaction appears to be dependent on the steric
properties of the azaarene, with diastereoselectivity increasing
from pyridine to quinoline to isoquinoline (compare
diastereomeric ratios for products 2c, 2a, and 2d). In the
coupling of 2-vinylpyridine with acetophenone, the two
diastereomeric products 2ca and 2cb were isolated with high
enantioselectivities (>99% and 92% ee, respectively). Regarding
the electrophile, the process is tolerant of acyclic ketones
containing various alkyl, aryl, or heteroaryl substituents
(products 2a−2g). In addition, cyclic ketones are viable
substrates, as exemplified by the successful use of two
indanones (products 2h and 2i), 4-chromanone (product 2j),
4-thiochromanone (product 2k), and tetralone (product 2l).
Interestingly, the absolute stereochemistries of isoquinoline-
containing products 2d−2g are opposite to those of quinoline-
containing products 2a and 2b, even though the same
enantiomer of ligand L6 was employed throughout.11 In
addition, the diastereochemical outcomes of the reactions
producing 2h−2l are different from those resulting in 2a, 2b,
and 2d−2g.11 Assuming that the reactions proceed via
Zimmerman−Traxler-type transition states where the larger
aryl group of the ketone occupies a pseudoequatorial
position,13 Figure 2 depicts conformations that are consistent
with these observations. The stereochemical outcomes of the
reactions producing 2a, 2b, and 2d−2g are consistent with the
participation of Z-azaallylcopper species14 (TS 1 and TS 2),
though the reasons for the opposite sense of enantioinduction
in TS 2 compared with TS 1 are not clear at this time.
Furthermore, while the preference for the Z-azaallylcopper
species in TS 2 is readily explained by the severe A1,3-strain
15
that would disfavor the corresponding E-azaallylcopper species,
a similar argument cannot be used to explain the same
preference in TS 1. For reactions producing 2h−2l, reaction
Table 1. Evaluation of Chiral Bisphosphinesa
entry bisphosphine 2a:3b drb ee (%)c
1 L1 11:1 1:1 43, 50
2 L2 13:1 1:1 67, 67
3 L3 24:1 1:1 27, 17
4 L4 17:1 1:1 −60, −92
5 L5 12:1 1:1 92, 93
6 L6 7:1 5:1 93, 60
aReactions were conducted using 0.10 mmol of 1a. bDetermined by
1H NMR analysis of the unpurified reaction mixtures. cDetermined by
chiral HPLC analysis.
Chart 1. Reaction Scope with Vinylazaarenesa
aReactions were conducted using 0.30−0.40 mmol of 1a−1h. Cited
yields are of pure isolated major diastereomers. Diastereomeric ratios
were determined by 1H NMR analysis of the unpurified reaction
mixtures. Enantiomeric excesses were determined by chiral HPLC
analysis.
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through the E-azaallylcopper species (or Z-azaallylcopper
species in the case of 2j) appears to be favored, as in TS 3
for the formation of 2i. The interplay between the steric and/or
electronic properties of the alkenylazaarene and the ligand and
the resulting effect on the stereochemical outcome are clearly
complex. In addition, while the preceding discussion has been
based upon the assumption that chairlike transition states are
operative, reaction through boatlike structures cannot be
excluded.
Notably, the process is not limited to vinylazaarenes; β-
substituted alkenylazaarenes are also effective coupling partners
(Chart 2). For example, alkenylazaarenes 4a−4c12 containing
methyl, phenethyl, or allylic ether groups smoothly underwent
reductive coupling to deliver products 5a−5c, respectively, in
high enantioselectivities.11 Furthermore, these products contain
additional examples of azaarenes not utilized in Chart 1, such as
diphenyloxazole (product 5a), a dimethoxytriazine (product
5b), and 1,3-pyrimidine (product 5c).
In summary, we have described the first examples of catalytic
enantioselective reductive couplings of alkenylazaarenes. The
scope of this process is broad, with 11 different types of
azaarenes and a range of acyclic and cyclic ketones having been
shown to be effective coupling partners. β-Substitution on the
alkene is tolerated, and the reactions proceed under mild
conditions to deliver products in good to high levels of
diastereo- and enantioselection. These features should be
advantageous for application of this process in the preparation




Experimental procedures, full spectroscopic data for all new
compounds, and crystallographic data in cif format. This
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